US20190290721A1 - Combination - Google Patents
Combination Download PDFInfo
- Publication number
- US20190290721A1 US20190290721A1 US16/201,703 US201816201703A US2019290721A1 US 20190290721 A1 US20190290721 A1 US 20190290721A1 US 201816201703 A US201816201703 A US 201816201703A US 2019290721 A1 US2019290721 A1 US 2019290721A1
- Authority
- US
- United States
- Prior art keywords
- exenatide
- cyclosporine
- ischemia
- pharmaceutically acceptable
- analogue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims abstract description 306
- 108010011459 Exenatide Proteins 0.000 claims abstract description 296
- 229960001519 exenatide Drugs 0.000 claims abstract description 286
- 150000003839 salts Chemical class 0.000 claims abstract description 134
- 229960000206 potassium canrenoate Drugs 0.000 claims abstract description 128
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 119
- 208000028867 ischemia Diseases 0.000 claims abstract description 113
- 206010063837 Reperfusion injury Diseases 0.000 claims abstract description 81
- 238000000034 method Methods 0.000 claims abstract description 73
- 108090001061 Insulin Proteins 0.000 claims abstract description 59
- 102000004877 Insulin Human genes 0.000 claims abstract description 59
- 229940125396 insulin Drugs 0.000 claims abstract description 59
- 229940083712 aldosterone antagonist Drugs 0.000 claims abstract description 58
- 239000002170 aldosterone antagonist Substances 0.000 claims abstract description 55
- 230000005961 cardioprotection Effects 0.000 claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 23
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 22
- 229940127557 pharmaceutical product Drugs 0.000 claims abstract description 22
- JTZQCHFUGHIPDF-RYVBEKKQSA-M potassium canrenoate Chemical compound [K+].O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)CCC([O-])=O)[C@@H]4[C@@H]3C=CC2=C1 JTZQCHFUGHIPDF-RYVBEKKQSA-M 0.000 claims abstract 5
- 230000010410 reperfusion Effects 0.000 claims description 79
- 210000002216 heart Anatomy 0.000 claims description 57
- 239000003814 drug Substances 0.000 claims description 52
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 44
- 229940079593 drug Drugs 0.000 claims description 40
- 208000010496 Heart Arrest Diseases 0.000 claims description 30
- 206010028923 Neonatal asphyxia Diseases 0.000 claims description 24
- 208000007201 Myocardial reperfusion injury Diseases 0.000 claims description 23
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 22
- 206010007625 cardiogenic shock Diseases 0.000 claims description 22
- 108010005794 dulaglutide Proteins 0.000 claims description 22
- 230000001451 cardiotoxic effect Effects 0.000 claims description 20
- 231100000457 cardiotoxic Toxicity 0.000 claims description 19
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 16
- 238000001990 intravenous administration Methods 0.000 claims description 15
- 210000004556 brain Anatomy 0.000 claims description 14
- 108010019598 Liraglutide Proteins 0.000 claims description 11
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 claims description 11
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical group C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 claims description 11
- OGWAVGNOAMXIIM-UHFFFAOYSA-N albiglutide Chemical compound O=C(O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)CNC(=O)C(N)CC=1(N=CNC=1))CCC(=O)O)C(O)C)CC2(=CC=CC=C2))C(O)C)CO)CC(=O)O)C(C)C)CO)CO)CC3(=CC=C(O)C=C3))CC(C)C)CCC(=O)O)CCC(=O)N)C)C)CCCCN)CCC(=O)O)CC4(=CC=CC=C4))C(CC)C)C)CC=6(C5(=C(C=CC=C5)NC=6)))CC(C)C)C(C)C)CCCCN)CCCNC(=N)N OGWAVGNOAMXIIM-UHFFFAOYSA-N 0.000 claims description 11
- 229960004733 albiglutide Drugs 0.000 claims description 11
- 229960005175 dulaglutide Drugs 0.000 claims description 11
- 239000003112 inhibitor Substances 0.000 claims description 11
- 229960002701 liraglutide Drugs 0.000 claims description 11
- 108010004367 lixisenatide Proteins 0.000 claims description 11
- 229960001093 lixisenatide Drugs 0.000 claims description 11
- 208000031225 myocardial ischemia Diseases 0.000 claims description 11
- 108700027806 rGLP-1 Proteins 0.000 claims description 11
- 108010048573 taspoglutide Proteins 0.000 claims description 11
- WRGVLTAWMNZWGT-VQSPYGJZSA-N taspoglutide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 WRGVLTAWMNZWGT-VQSPYGJZSA-N 0.000 claims description 11
- 229950007151 taspoglutide Drugs 0.000 claims description 11
- 210000004072 lung Anatomy 0.000 claims description 9
- 210000003734 kidney Anatomy 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 5
- 229960002478 aldosterone Drugs 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims description 4
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 229940122434 Calcium sensitizer Drugs 0.000 claims description 3
- 230000002776 aggregation Effects 0.000 claims description 3
- 238000004220 aggregation Methods 0.000 claims description 3
- 239000002876 beta blocker Substances 0.000 claims description 3
- 229940097320 beta blocking agent Drugs 0.000 claims description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 3
- 238000007911 parenteral administration Methods 0.000 claims description 3
- 230000010118 platelet activation Effects 0.000 claims description 3
- 229940123263 Phosphodiesterase 3 inhibitor Drugs 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 claims description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract description 257
- 108010036949 Cyclosporine Proteins 0.000 abstract description 252
- 229960001265 ciclosporin Drugs 0.000 abstract description 163
- 229930182912 cyclosporin Natural products 0.000 abstract description 163
- 238000011282 treatment Methods 0.000 abstract description 80
- 239000003018 immunosuppressive agent Substances 0.000 abstract description 46
- 229940125721 immunosuppressive agent Drugs 0.000 abstract description 45
- PBKZPPIHUVSDNM-WNHSNXHDSA-N canrenoic acid Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)CCC(O)=O)[C@@H]4[C@@H]3C=CC2=C1 PBKZPPIHUVSDNM-WNHSNXHDSA-N 0.000 description 150
- 206010061216 Infarction Diseases 0.000 description 88
- 230000007574 infarction Effects 0.000 description 88
- 229930105110 Cyclosporin A Natural products 0.000 description 86
- 241001465754 Metazoa Species 0.000 description 63
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 43
- 229940086673 canrenoate Drugs 0.000 description 39
- 230000002265 prevention Effects 0.000 description 33
- 230000000302 ischemic effect Effects 0.000 description 32
- 230000000694 effects Effects 0.000 description 31
- 238000009097 single-agent therapy Methods 0.000 description 30
- 239000003795 chemical substances by application Substances 0.000 description 24
- 238000012360 testing method Methods 0.000 description 24
- 210000000056 organ Anatomy 0.000 description 23
- 230000009467 reduction Effects 0.000 description 23
- 238000002648 combination therapy Methods 0.000 description 22
- 208000037891 myocardial injury Diseases 0.000 description 21
- 239000000203 mixture Substances 0.000 description 19
- 238000002560 therapeutic procedure Methods 0.000 description 19
- 230000002861 ventricular Effects 0.000 description 19
- 206010002091 Anaesthesia Diseases 0.000 description 18
- 241000283973 Oryctolagus cuniculus Species 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 230000002107 myocardial effect Effects 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- 230000037005 anaesthesia Effects 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 16
- 238000013461 design Methods 0.000 description 14
- 230000002427 irreversible effect Effects 0.000 description 14
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 13
- 230000006378 damage Effects 0.000 description 13
- 208000010125 myocardial infarction Diseases 0.000 description 13
- 239000011591 potassium Substances 0.000 description 13
- 229910052700 potassium Inorganic materials 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 239000000902 placebo Substances 0.000 description 12
- 229940068196 placebo Drugs 0.000 description 12
- 210000003462 vein Anatomy 0.000 description 12
- ZMKGDQSIRSGUDJ-VSROPUKISA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,1 Chemical compound CCC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-VSROPUKISA-N 0.000 description 11
- ZMKGDQSIRSGUDJ-UHFFFAOYSA-N NVa2 cyclosporine Natural products CCCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-UHFFFAOYSA-N 0.000 description 11
- 238000010171 animal model Methods 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 108010019249 cyclosporin G Proteins 0.000 description 11
- -1 isomers Chemical class 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 238000002054 transplantation Methods 0.000 description 11
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 230000000004 hemodynamic effect Effects 0.000 description 10
- 230000000977 initiatory effect Effects 0.000 description 10
- 229960000310 isoleucine Drugs 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 238000013146 percutaneous coronary intervention Methods 0.000 description 10
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 10
- 206010011086 Coronary artery occlusion Diseases 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 9
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 238000001949 anaesthesia Methods 0.000 description 9
- 208000014674 injury Diseases 0.000 description 9
- 229960003299 ketamine Drugs 0.000 description 9
- 210000004165 myocardium Anatomy 0.000 description 9
- 238000011555 rabbit model Methods 0.000 description 9
- 229960002256 spironolactone Drugs 0.000 description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 8
- 230000000747 cardiac effect Effects 0.000 description 8
- 230000003293 cardioprotective effect Effects 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 229940122739 Calcineurin inhibitor Drugs 0.000 description 7
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 description 7
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 description 7
- 208000006011 Stroke Diseases 0.000 description 7
- 102100036859 Troponin I, cardiac muscle Human genes 0.000 description 7
- 101710128251 Troponin I, cardiac muscle Proteins 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 7
- 230000004872 arterial blood pressure Effects 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 7
- 229940084891 byetta Drugs 0.000 description 7
- 229960005057 canrenone Drugs 0.000 description 7
- UJVLDDZCTMKXJK-WNHSNXHDSA-N canrenone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCC(=O)C=C3C=C2)C)CC[C@@]11C)C[C@@]11CCC(=O)O1 UJVLDDZCTMKXJK-WNHSNXHDSA-N 0.000 description 7
- 230000004087 circulation Effects 0.000 description 7
- 229960001208 eplerenone Drugs 0.000 description 7
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 230000002093 peripheral effect Effects 0.000 description 7
- BTBHLEZXCOBLCY-QGZVFWFLSA-N (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide Chemical compound C1([C@@H]2C(=C(C)NC=3C(C)=CN=C(C2=3)OCC)C(N)=O)=CC=C(C#N)C=C1OC BTBHLEZXCOBLCY-QGZVFWFLSA-N 0.000 description 6
- 108010030583 (melle-4)cyclosporin Proteins 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 208000001778 Coronary Occlusion Diseases 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 231100000517 death Toxicity 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 229950004408 finerenone Drugs 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 6
- RPJPZDVUUKWPGT-FOIHOXPVSA-N nim811 Chemical compound CC[C@H](C)[C@@H]1N(C)C(=O)CN(C)C(=O)[C@H](CC)NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC1=O RPJPZDVUUKWPGT-FOIHOXPVSA-N 0.000 description 6
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 description 6
- 229960005330 pimecrolimus Drugs 0.000 description 6
- RRHHMFQGHCFGMH-LAPLKBAYSA-N prorenone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCC(=O)C=C3[C@H]3C[C@H]32)C)CC[C@@]11C)C[C@@]11CCC(=O)O1 RRHHMFQGHCFGMH-LAPLKBAYSA-N 0.000 description 6
- 229960001967 tacrolimus Drugs 0.000 description 6
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 6
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 6
- 229960001600 xylazine Drugs 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 5
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 5
- 108010067028 Mitochondrial Permeability Transition Pore Proteins 0.000 description 5
- 102100040918 Pro-glucagon Human genes 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 208000006117 ST-elevation myocardial infarction Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000004351 coronary vessel Anatomy 0.000 description 5
- 238000007405 data analysis Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000007613 environmental effect Effects 0.000 description 5
- 230000000155 isotopic effect Effects 0.000 description 5
- 238000001543 one-way ANOVA Methods 0.000 description 5
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 5
- 230000004224 protection Effects 0.000 description 5
- 230000000250 revascularization Effects 0.000 description 5
- 239000011885 synergistic combination Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 206010011703 Cyanosis Diseases 0.000 description 4
- 206010019280 Heart failures Diseases 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 229960004195 carvedilol Drugs 0.000 description 4
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 230000003601 intercostal effect Effects 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- 229960002237 metoprolol Drugs 0.000 description 4
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 4
- 230000003278 mimic effect Effects 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 229960001412 pentobarbital Drugs 0.000 description 4
- 210000003516 pericardium Anatomy 0.000 description 4
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
- 238000011552 rat model Methods 0.000 description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 238000011295 triple combination therapy Methods 0.000 description 4
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 description 3
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 239000002083 C09CA01 - Losartan Substances 0.000 description 3
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 3
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 3
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 3
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 3
- 206010013710 Drug interaction Diseases 0.000 description 3
- 108010061435 Enalapril Proteins 0.000 description 3
- 239000005475 Fimasartan Substances 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 206010020571 Hyperaldosteronism Diseases 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 108010007859 Lisinopril Proteins 0.000 description 3
- 239000005480 Olmesartan Substances 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 229960004601 aliskiren Drugs 0.000 description 3
- 229940035674 anesthetics Drugs 0.000 description 3
- 230000000340 anti-metabolite Effects 0.000 description 3
- 230000001327 anti-mineralocorticoid effect Effects 0.000 description 3
- 229940100197 antimetabolite Drugs 0.000 description 3
- 239000002256 antimetabolite Substances 0.000 description 3
- 210000001008 atrial appendage Anatomy 0.000 description 3
- 230000037424 autonomic function Effects 0.000 description 3
- 238000010009 beating Methods 0.000 description 3
- 229960004530 benazepril Drugs 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 229960000932 candesartan Drugs 0.000 description 3
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 3
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 3
- 229960000830 captopril Drugs 0.000 description 3
- 210000004413 cardiac myocyte Anatomy 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229960005025 cilazapril Drugs 0.000 description 3
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 229960000873 enalapril Drugs 0.000 description 3
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 229960003489 fimasartan Drugs 0.000 description 3
- AMEROGPZOLAFBN-UHFFFAOYSA-N fimasartan Chemical compound CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 AMEROGPZOLAFBN-UHFFFAOYSA-N 0.000 description 3
- 229920001109 fluorescent polymer Polymers 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229960002490 fosinopril Drugs 0.000 description 3
- 238000002695 general anesthesia Methods 0.000 description 3
- 239000003193 general anesthetic agent Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000002008 hemorrhagic effect Effects 0.000 description 3
- KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 description 3
- 229960001195 imidapril Drugs 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 229960002198 irbesartan Drugs 0.000 description 3
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 3
- 210000005240 left ventricle Anatomy 0.000 description 3
- 229960002394 lisinopril Drugs 0.000 description 3
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 3
- 229960004773 losartan Drugs 0.000 description 3
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 238000011587 new zealand white rabbit Methods 0.000 description 3
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 3
- 229960005117 olmesartan Drugs 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 208000033300 perinatal asphyxia Diseases 0.000 description 3
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 3
- 229960002582 perindopril Drugs 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- ZDHURYWHEBEGHO-UHFFFAOYSA-N potassiopotassium Chemical compound [K].[K] ZDHURYWHEBEGHO-UHFFFAOYSA-N 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 229960001455 quinapril Drugs 0.000 description 3
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 3
- 229960003401 ramipril Drugs 0.000 description 3
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 3
- 229960004702 remikiren Drugs 0.000 description 3
- ZHIQVOYGQFSRBZ-VQXQMPIVSA-N remikiren Chemical compound C([C@H](CS(=O)(=O)C(C)(C)C)C(=O)N[C@@H](CC=1[N]C=NC=1)C(=O)N[C@@H](CC1CCCCC1)[C@@H](O)[C@@H](O)C1CC1)C1=CC=CC=C1 ZHIQVOYGQFSRBZ-VQXQMPIVSA-N 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 229960005187 telmisartan Drugs 0.000 description 3
- 229960002051 trandolapril Drugs 0.000 description 3
- 229960004699 valsartan Drugs 0.000 description 3
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 3
- 229960002769 zofenopril Drugs 0.000 description 3
- IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 description 3
- CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 description 2
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 2
- FBMYKMYQHCBIGU-UHFFFAOYSA-N 2-[2-hydroxy-3-[[1-(1h-indol-3-yl)-2-methylpropan-2-yl]amino]propoxy]benzonitrile Chemical compound C=1NC2=CC=CC=C2C=1CC(C)(C)NCC(O)COC1=CC=CC=C1C#N FBMYKMYQHCBIGU-UHFFFAOYSA-N 0.000 description 2
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229930003347 Atropine Natural products 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 206010007558 Cardiac failure chronic Diseases 0.000 description 2
- KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 description 2
- 101001098806 Dictyostelium discoideum cGMP-specific 3',5'-cGMP phosphodiesterase 3 Proteins 0.000 description 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 2
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 2
- DVJAMEIQRSHVKC-BDAKNGLRSA-N Dutogliptin Chemical compound OB(O)[C@@H]1CCCN1C(=O)CN[C@H]1CNCC1 DVJAMEIQRSHVKC-BDAKNGLRSA-N 0.000 description 2
- 108010008165 Etanercept Proteins 0.000 description 2
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 2
- ZWPRRQZNBDYKLH-VIFPVBQESA-N Gemigliptin Chemical compound C([C@@H](N)CC(=O)N1CC2=C(C(=NC(=N2)C(F)(F)F)C(F)(F)F)CC1)N1CC(F)(F)CCC1=O ZWPRRQZNBDYKLH-VIFPVBQESA-N 0.000 description 2
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 2
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000270431 Heloderma suspectum Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
- 206010058558 Hypoperfusion Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108010073961 Insulin Aspart Proteins 0.000 description 2
- 108010089308 Insulin Detemir Proteins 0.000 description 2
- 108010057186 Insulin Glargine Proteins 0.000 description 2
- 108010065920 Insulin Lispro Proteins 0.000 description 2
- FYZPCMFQCNBYCY-WIWKJPBBSA-N Insulin degludec Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC(O)=O)C(O)=O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC FYZPCMFQCNBYCY-WIWKJPBBSA-N 0.000 description 2
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N Lactic Acid Natural products CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 2
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 description 2
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 2
- IRLWJILLXJGJTD-UHFFFAOYSA-N Muraglitazar Chemical compound C1=CC(OC)=CC=C1OC(=O)N(CC(O)=O)CC(C=C1)=CC=C1OCCC1=C(C)OC(C=2C=CC=CC=2)=N1 IRLWJILLXJGJTD-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 239000004792 Prolene Substances 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 238000010162 Tukey test Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229960002964 adalimumab Drugs 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229950010157 aleglitazar Drugs 0.000 description 2
- DAYKLWSKQJBGCS-NRFANRHFSA-N aleglitazar Chemical compound C1=2C=CSC=2C(C[C@H](OC)C(O)=O)=CC=C1OCCC(=C(O1)C)N=C1C1=CC=CC=C1 DAYKLWSKQJBGCS-NRFANRHFSA-N 0.000 description 2
- 229960001667 alogliptin Drugs 0.000 description 2
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- LDXYBEHACFJIEL-HNNXBMFYSA-N anagliptin Chemical compound C=1N2N=C(C)C=C2N=CC=1C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N LDXYBEHACFJIEL-HNNXBMFYSA-N 0.000 description 2
- 229950009977 anagliptin Drugs 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- RCHHVVGSTHAVPF-ZPHPLDECSA-N apidra Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CNC=N1 RCHHVVGSTHAVPF-ZPHPLDECSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 2
- 229960000396 atropine Drugs 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 2
- 229960000516 bezafibrate Drugs 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 229950005341 bucindolol Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- 229940014641 bydureon Drugs 0.000 description 2
- PBKZPPIHUVSDNM-WNHSNXHDSA-M canrenoate Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)CCC([O-])=O)[C@@H]4[C@@H]3C=CC2=C1 PBKZPPIHUVSDNM-WNHSNXHDSA-M 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000002680 cardiopulmonary resuscitation Methods 0.000 description 2
- 230000009084 cardiovascular function Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229960001222 carteolol Drugs 0.000 description 2
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 2
- KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 description 2
- 229960002174 ciprofibrate Drugs 0.000 description 2
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 2
- 229960001214 clofibrate Drugs 0.000 description 2
- 230000002301 combined effect Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 229950003693 dutogliptin Drugs 0.000 description 2
- 229960001123 epoprostenol Drugs 0.000 description 2
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 2
- 229960000403 etanercept Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 2
- 229960002297 fenofibrate Drugs 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 235000020680 filtered tap water Nutrition 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229960003627 gemfibrozil Drugs 0.000 description 2
- 229960002458 gemigliptin Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000002631 hypothermal effect Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 229960000598 infliximab Drugs 0.000 description 2
- 229960004717 insulin aspart Drugs 0.000 description 2
- 108010050259 insulin degludec Proteins 0.000 description 2
- 229960004225 insulin degludec Drugs 0.000 description 2
- 229960003948 insulin detemir Drugs 0.000 description 2
- 229960002869 insulin glargine Drugs 0.000 description 2
- 108700039926 insulin glulisine Proteins 0.000 description 2
- 229960000696 insulin glulisine Drugs 0.000 description 2
- 229960002068 insulin lispro Drugs 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 229960001632 labetalol Drugs 0.000 description 2
- UGOZVNFCFYTPAZ-IOXYNQHNSA-N levemir Chemical compound CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=2C=CC=CC=2)C(C)C)CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 UGOZVNFCFYTPAZ-IOXYNQHNSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229960002397 linagliptin Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000002394 mineralocorticoid antagonist Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 229950001135 muraglitazar Drugs 0.000 description 2
- 229960004255 nadolol Drugs 0.000 description 2
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000002644 neurohormonal effect Effects 0.000 description 2
- VOMXSOIBEJBQNF-UTTRGDHVSA-N novorapid Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 VOMXSOIBEJBQNF-UTTRGDHVSA-N 0.000 description 2
- MKMPWKUAHLTIBJ-ISTRZQFTSA-N omarigliptin Chemical compound C1([C@H]2OC[C@@H](C[C@@H]2N)N2CC3=CN(N=C3C2)S(=O)(=O)C)=CC(F)=CC=C1F MKMPWKUAHLTIBJ-ISTRZQFTSA-N 0.000 description 2
- 229960004570 oxprenolol Drugs 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 229960002035 penbutolol Drugs 0.000 description 2
- KQXKVJAGOJTNJS-HNNXBMFYSA-N penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 description 2
- 239000008024 pharmaceutical diluent Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229960002508 pindolol Drugs 0.000 description 2
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 201000002638 post-cardiac arrest syndrome Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 229960003712 propranolol Drugs 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 239000002461 renin inhibitor Substances 0.000 description 2
- 229940086526 renin-inhibitors Drugs 0.000 description 2
- 229950006544 saroglitazar Drugs 0.000 description 2
- MRWFZSLZNUJVQW-DEOSSOPVSA-N saroglitazar Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCN1C(C=2C=CC(SC)=CC=2)=CC=C1C MRWFZSLZNUJVQW-DEOSSOPVSA-N 0.000 description 2
- 229960004937 saxagliptin Drugs 0.000 description 2
- 108010033693 saxagliptin Proteins 0.000 description 2
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 2
- 229960004034 sitagliptin Drugs 0.000 description 2
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229960002370 sotalol Drugs 0.000 description 2
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000037351 starvation Effects 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- WGRQANOPCQRCME-PMACEKPBSA-N teneligliptin Chemical compound O=C([C@H]1NC[C@H](C1)N1CCN(CC1)C1=CC(=NN1C=1C=CC=CC=1)C)N1CCSC1 WGRQANOPCQRCME-PMACEKPBSA-N 0.000 description 2
- 229950000034 teneligliptin Drugs 0.000 description 2
- 229950004704 tesaglitazar Drugs 0.000 description 2
- CXGTZJYQWSUFET-IBGZPJMESA-N tesaglitazar Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 CXGTZJYQWSUFET-IBGZPJMESA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229960000103 thrombolytic agent Drugs 0.000 description 2
- 229960004605 timolol Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- IWYJYHUNXVAVAA-OAHLLOKOSA-N trelagliptin Chemical compound C=1C(F)=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 IWYJYHUNXVAVAA-OAHLLOKOSA-N 0.000 description 2
- 229950010728 trelagliptin Drugs 0.000 description 2
- 229960001254 vildagliptin Drugs 0.000 description 2
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- QWCKQJZIFLGMSD-UHFFFAOYSA-N 2-Aminobutanoic acid Natural products CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 1
- RMWVZGDJPAKBDE-UHFFFAOYSA-N 2-acetyloxy-4-(trifluoromethyl)benzoic acid Chemical compound CC(=O)OC1=CC(C(F)(F)F)=CC=C1C(O)=O RMWVZGDJPAKBDE-UHFFFAOYSA-N 0.000 description 1
- HWEOXFSBSQIWSY-MRXNPFEDSA-N 3-[(6r)-6-[(4-chlorophenyl)sulfonylamino]-2-methyl-5,6,7,8-tetrahydronaphthalen-1-yl]propanoic acid Chemical compound N([C@H]1CC2=CC=C(C(=C2CC1)CCC(O)=O)C)S(=O)(=O)C1=CC=C(Cl)C=C1 HWEOXFSBSQIWSY-MRXNPFEDSA-N 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 208000002333 Asphyxia Neonatorum Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 206010061666 Autonomic neuropathy Diseases 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 239000005465 B01AC22 - Prasugrel Substances 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 206010049993 Cardiac death Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000016998 Conn syndrome Diseases 0.000 description 1
- 208000022540 Consciousness disease Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 108010056764 Eptifibatide Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 101000886868 Homo sapiens Gastric inhibitory polypeptide Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229940122199 Insulin secretagogue Drugs 0.000 description 1
- 201000006347 Intellectual Disability Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 208000001300 Perinatal Death Diseases 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 229940098892 Protease-activated receptor-1 antagonist Drugs 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 102000003938 Thromboxane Receptors Human genes 0.000 description 1
- 108090000300 Thromboxane Receptors Proteins 0.000 description 1
- 241001149960 Tolypocladium inflatum Species 0.000 description 1
- 208000018452 Torsade de pointes Diseases 0.000 description 1
- 208000002363 Torsades de Pointes Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 229940125669 adenosine diphosphate receptor inhibitor Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960002105 amrinone Drugs 0.000 description 1
- RNLQIBCLLYYYFJ-UHFFFAOYSA-N amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 229940044684 anti-microtubule agent Drugs 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 229960002594 arsenic trioxide Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- QZVNQOLPLYWLHQ-ZEQKJWHPSA-N benidipine Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@H]2CN(CC=3C=CC=CC=3)CCC2)=CC=CC([N+]([O-])=O)=C1 QZVNQOLPLYWLHQ-ZEQKJWHPSA-N 0.000 description 1
- 229960004916 benidipine Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 235000012745 brilliant blue FCF Nutrition 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 229960002823 canrenoic acid Drugs 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 239000008148 cardioplegic solution Substances 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical group C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 208000024376 chronic urticaria Diseases 0.000 description 1
- 229960004588 cilostazol Drugs 0.000 description 1
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 1
- 230000005796 circulatory shock Effects 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 description 1
- 229960004845 drospirenone Drugs 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 201000010048 endomyocardial fibrosis Diseases 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 229960004468 eptifibatide Drugs 0.000 description 1
- GLGOPUHVAZCPRB-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CN=C2[C]1C=CC=C2 GLGOPUHVAZCPRB-LROMGURASA-N 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 description 1
- 229960005352 gestodene Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000002039 glucoregulatory effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940125672 glycoprotein IIb/IIIa inhibitor Drugs 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960002240 iloprost Drugs 0.000 description 1
- HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000002486 insulinomimetic effect Effects 0.000 description 1
- 230000002473 insulinotropic effect Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 230000002530 ischemic preconditioning effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- WHXMKTBCFHIYNQ-SECBINFHSA-N levosimendan Chemical compound C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1 WHXMKTBCFHIYNQ-SECBINFHSA-N 0.000 description 1
- 229960000692 levosimendan Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 201000000083 maturity-onset diabetes of the young type 1 Diseases 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229960003574 milrinone Drugs 0.000 description 1
- PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000013310 pig model Methods 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229930001118 polyketide hybrid Natural products 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 230000010411 postconditioning Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229960004197 prasugrel Drugs 0.000 description 1
- DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 208000013846 primary aldosteronism Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000029054 response to nutrient Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 108010073863 saruplase Proteins 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 108010008962 streptokinase-plasminogen complex Proteins 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229950001286 terutroban Drugs 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 239000003768 thromboxane synthase inhibitor Substances 0.000 description 1
- 229960002528 ticagrelor Drugs 0.000 description 1
- OEKWJQXRCDYSHL-FNOIDJSQSA-N ticagrelor Chemical compound C1([C@@H]2C[C@H]2NC=2N=C(N=C3N([C@H]4[C@@H]([C@H](O)[C@@H](OCCO)C4)O)N=NC3=2)SCCC)=CC=C(F)C(F)=C1 OEKWJQXRCDYSHL-FNOIDJSQSA-N 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960003425 tirofiban Drugs 0.000 description 1
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 229960005032 treprostinil Drugs 0.000 description 1
- PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical compound C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 description 1
- 229960002268 triflusal Drugs 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000000982 vasogenic effect Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 229960005044 vorapaxar Drugs 0.000 description 1
- ZBGXUVOIWDMMJE-QHNZEKIYSA-N vorapaxar Chemical compound C(/[C@@H]1[C@H]2[C@H](C(O[C@@H]2C)=O)C[C@H]2[C@H]1CC[C@H](C2)NC(=O)OCC)=C\C(N=C1)=CC=C1C1=CC=CC(F)=C1 ZBGXUVOIWDMMJE-QHNZEKIYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Definitions
- the present invention provides a new combination comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent, and (iii) an aldosterone antagonist, for instance, a combination comprising at least two of (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof.
- Said combinations are suitable for cardioprotection and/or for treating and/or preventing ischemia and/or reperfusion injury.
- AMI Acute myocardial infarction
- MI chronic heart failure
- myocardial reperfusion injury a phenomenon termed “myocardial reperfusion injury”, the irreversible consequences of which include microvascular obstruction and myocardial infarction (Yellow and Hausenloy, N. Engl. J. Med., 2007, 357: 1121-1135). It is estimated that ischemia-reperfusion injury is responsible for approximately 50% of the final infarct area (Yetgin et al., Neth. Heart J., 2010; 28, 389-392). Previous attempts to translate cardioprotective therapies (i.e.
- MPTP mitochondrial permeability transition pore
- the present invention provides new combinations which are cardioprotective and suitable for prevention and/or treatment of reperfusion injury.
- the combinations and other aspects of the invention provide a treatment which is more efficacious and provides superior clinical outcomes compared to therapies which employ a single active pharmaceutical agent.
- a first aspect relates to a combination comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent, and (iii) an aldosterone antagonist.
- a second aspect relates to a combination comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof.
- a third aspect relates to a pharmaceutical composition
- a pharmaceutical composition comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent, and (iii) an aldosterone antagonist.
- a fourth aspect relates to a pharmaceutical composition
- a pharmaceutical composition comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
- a fifth aspect relates to a pharmaceutical product comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent, and (iii) an aldosterone antagonist.
- a sixth aspect relates to a pharmaceutical product comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof, and (iii) potassium canrenoate, or a functional derivative or analogue thereof.
- a seventh aspect relates to a combination or a pharmaceutical composition as defined above for use in the treatment and/or prevention of one or more of ischemia and/or reperfusion injury, ischemic stroke, cardiac arrest, acute myocardial infarction, neonatal asphyxia and cardiogenic shock, or for use in providing cardioprotection against cardiotoxic drugs.
- An eighth aspect relates to a pharmaceutical product as defined above for use in the treatment and/or prevention of one or more of ischemia and/or reperfusion injury, ischemic stroke, cardiac arrest, acute myocardial infarction, neonatal asphyxia and cardiogenic shock, or for use in providing cardioprotection against cardiotoxic drugs, wherein the components are for administration simultaneously, sequentially or separately.
- a ninth aspect relates to a method of treating and/or preventing one or more of ischemia and/or reperfusion injury, ischemic stroke, cardiac arrest, acute myocardial infarction, neonatal asphyxia and cardiogenic shock, or for providing cardioprotection against cardiotoxic drugs, said method comprising simultaneously, sequentially or separately administering to a subject in need thereof at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent, and (iii) an aldosterone antagonist.
- a tenth aspect relates to a method of treating and/or preventing one or more of ischemia and/or reperfusion injury, ischemic stroke, cardiac arrest, acute myocardial infarction, neonatal asphyxia and cardiogenic shock, or for providing cardioprotection against cardiotoxic drugs, said method comprising simultaneously, sequentially or separately administering to a subject in need thereof at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof, and (iii) potassium canrenoate, or a functional derivative or analogue thereof.
- An eleventh aspect relates to the use of at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent, and (iii) an aldosterone antagonist, in the manufacture of a medicament for the treatment and/or prevention of one or more of ischemia and/or reperfusion injury, ischemic stroke, cardiac arrest, acute myocardial infarction, neonatal asphyxia and cardiogenic shock, or for providing cardioprotection against cardiotoxic drugs.
- a twelfth aspect relates to the use of at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof, and (iii) potassium canrenoate, or a functional derivative or analogue thereof, in the manufacture of a medicament for the treatment and/or prevention of one or more of ischemia and/or reperfusion injury, ischemic stroke, cardiac arrest, acute myocardial infarction, neonatal asphyxia and cardiogenic shock, or for providing cardioprotection against cardiotoxic drugs.
- a thirteenth aspect relates to the use of a combination comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent, and (iii) an aldosterone antagonist, for treating and/or preventing ischemia and/or reperfusion injury in an ex vivo organ prior to or during transplantation.
- a fourteenth aspect relates to the use of a combination comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof, and (iii) potassium canrenoate, or a functional derivative or analogue thereof, for treating and/or preventing ischemia and/or reperfusion injury in an ex vivo organ prior to or during transplantation.
- the combination of the invention comprises an insulin modulator.
- insulin modulator refers to an agent that is capable of directly or indirectly increasing or decreasing the activity of insulin, which in turn may increase or decrease the insulin-mediated physiological response.
- the combination, methods, compositions and uses comprise an an insulin modulator as an essential feature.
- the insulin modulator may be selected from GLP-1 agonists, DPP-4 inhibitors, PPAR agonists, insulin and analogues thereof.
- GLP-1 agonists examples include exenatide, lixisenatide, albiglutide, liraglutide, taspoglutide and dulaglutide (LY2189265) and pharmaceutically acceptable salts thereof.
- DPP-4 inhibitors examples include sitagliptin, vildagliptin, saxagliptin, linagliptin anagliptin, teneligliptin, alogliptin, trelagliptin, gemigliptin, dutogliptin and omarigliptin (MK-3102) and pharmaceutically acceptable salts thereof.
- PPAR agonists examples include clofibrate, gemfibrozil, ciprofibrate, bezafibrate, fenofibrate, saroglitazar, aleglitazar, muraglitazar and tesaglitazar and pharmaceutically acceptable salts thereof.
- insulin analogues examples include insulin lispro, insulin aspart, insulin glulisine, insulin detemir, insulin degludec, insulin glargine and pharmaceutically acceptable salts thereof.
- the insulin modulator may be selected from exenatide, lixisenatide, albiglutide, liraglutide, taspoglutide, dulaglutide (LY2189265), sitagliptin, vildagliptin, saxagliptin, linagliptin anagliptin, teneligliptin, alogliptin, trelagliptin, gemigliptin, dutogliptin, omarigliptin (MK-3102), clofibrate, gemfibrozil, ciprofibrate, bezafibrate, fenofibrate, saroglitazar, aleglitazar, muraglitazar tesaglitazar, insulin lispro, insulin aspart, insulin glulisine, insulin detemir, insulin degludec, insulin glargine and pharmaceutically acceptable salts thereof.
- the insulin modulator is a GLP-1 agonist selected from exenatide, lixisenatide, albiglutide, liraglutide, taspoglutide, dulaglutide (LY2189265) and pharmaceutically acceptable salts thereof.
- the GLP-1 agonist is exenatide.
- the insulin modulator is selected from exenatide and functional derivatives and analogues thereof, and pharmaceutically acceptable salts thereof.
- Exenatide (synonym is exendin 4) is originally isolated from the saliva of the Gila monster, Heloderma suspectum , by Eng in 1992. It is an insulin secretagogue with glucoregulatory effects similar to the human peptide glucagon-like peptide-1 (GLP-1).
- GLP-1 glucagons-like peptide 1
- GLP-1 receptor is widely expressed in many organs, including heart and vascular endothelium (Bullock et al., Endocrinology, 1996, 137: 2968-2978; Nystrom et al., Am J Physiol Endocrinol Metab, 2004, 287: E1209-E1215).
- exenatide is approved as an anti-diabetic drug for the treatment of patients with diabetes mellitus type 2.
- the recommended dose in this indication is initially 5 ⁇ g (mcg) twice daily, increasing to 10 ⁇ g twice daily after 1 month based on clinical response.
- GLP-1 is ineffective as a therapeutic agent as it has a very short circulating half-life (less than 2 minutes) due to rapid degradation by dipeptidyl peptidase-4.
- Exenatide is 50% homologous to GLP-1, but has a 2.4 hours half-life in humans as the dipeptidyl peptidase-4 cleavage site is absent.
- Exenatide enhances glucose-dependent insulin secretion by the pancreatic beta-cell, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying. Exenatide is extremely potent, having a minimum effective concentration of 50 pg/mL (12 pM) in humans. Current therapies with exenatide involve twice-daily injections (Byetta®). Also, a slow-release formulation (Bydureon®) has been approved for once-weekly injection.
- a functional analogue of exenatide may refer to a compound having a similar structure, but differing from it in a respect of certain aspects (e.g. it can differ in one or more atoms, functional groups, amino acids residues, or substructures, which are replaced with others).
- Functional analogues display similar pharmacological properties and may be structurally related.
- the functional derivative or analogue of exenatide is a form of exenatide that is modified so as to extend the half life, for example, conjugates of exenatide.
- the functional derivative or analogue of exenatide is PEGylated exenatide.
- the functional derivative or analogue is exenatide mono-PEGylated with 40 kDa PEG.
- PEGylated exenatide can be prepared by methods known in the art. By way of example, PEGylated forms of exenatide are described in WO 2013/059323 (Prolynx LLC). Exenatide can also be conjugated to other molecules, e.g. proteins.
- the functional derivative or analogue of exenatide is an extended release form, for example, that marketed under the tradename Bydureon®.
- the functional derivative or analogue of exenatide is in the form of multilayer nanoparticles for sustained delivery, for example, as described in Kim J Y et al, Biomaterials, 2013 November; 34(33):8444-9.
- the exenatide is in an injectable form such as that marketed under the tradename Byetta®.
- a functional derivative or analogue of exenatide may refer to GLP receptor agonists.
- Suitable functional derivatives or analogues of exenatide of include lixisenatide, albiglutide, liraglutide, taspoglutide and dulaglutide (LY2189265).
- a functional analogue of exenatide means exenatide modified wherein one or more amino acid residues has been exchanged for another amino acid residue and/or wherein one or more amino acid residues have been deleted and/or wherein one or more amino acid residues have been added and/or inserted.
- a functional exenatide analogue comprises less than 10 amino acid modifications (substitutions, deletions, additions (including insertions) and any combination thereof) relative to exenatide, alternatively less than 9, 8, 7, 6, 5, 4, 3 or 2 modifications relative to exenatide.
- a functional exenatide analogue comprises 10 amino acid modifications (substitutions, deletions, additions (including insertions) and any combination thereof) relative to exenatide, alternatively 9, 8, 7, 6, 5, 4, 3, 2 or 1 modifications relative to exenatide.
- exenatide includes salts, isomers, enantiomers, solvates, polymorphs, prodrugs and metabolites thereof.
- the combination of the invention comprises an immunosuppressive agent.
- immunosuppressive agent refers to an agent capable of partially or fully suppressing the immune response in a subject.
- the immunosuppressive agent is selected from a glucocorticoid, a cytostatic agent, a cytokine (e.g. interferons, interleukins, chemokines), an immunosuppressive antibody, a calcineurin inhibitor and a TNF binding protein.
- a cytostatic agent e.g. interferons, interleukins, chemokines
- an immunosuppressive antibody e.g. interferons, interleukins, chemokines
- a calcineurin inhibitor e.g. interferons, interleukins, chemokines
- the immunosuppressive agent is selected from an antimetabolite, a calcineurin inhibitor and a TNF binding protein.
- antimetabolites include methotrexate, azathioprine, mercaptopurine and fluorouracil, and pharmaceutically acceptable salts thereof.
- calcineurin inhibitors include cyclosporine, cyclosporine G, N-Methyl-4-isoleucine cyclosporine (also known as NIM811), tacrolimus and pimecrolimus, and pharmaceutically acceptable salts thereof.
- TNF binding proteins examples include infliximab, etanercept and adalimumab, and pharmaceutically acceptable salts thereof.
- the immunosuppressive agent is selected from methotrexate, azathioprine, mercaptopurine, fluorouracil, cyclosporine, cyclosporine G, N-Methyl-4-isoleucine cyclosporine (also known as NIM811), tacrolimus, pimecrolimus, infliximab, etanercept and adalimumab, and pharmaceutically acceptable salts thereof.
- the immunosuppressive agent is a calcineurin inhibitor.
- the calcineurin inhibitor is selected from cyclosporine, cyclosporine G, N-Methyl-4-isoleucine cyclosporine (also known as NIM811), tacrolimus and pimecrolimus, and pharmaceutically acceptable salts thereof.
- the calcineurin inhibitor is cyclosporine.
- the calcineurin inhibitor is selected from cyclosporine, cyclosporine G, and N-Methyl-4-isoleucine cyclosporine (also known as NIM811) and pharmaceutically acceptable salts thereof.
- the calcineurin inhibitor is cyclosporine, or a functional derivative or analogue, or a pharmaceutically acceptable salt thereof.
- the invention also encompasses functional derivatives and analogues of the above immunosuppressive agents, particularly those that are modified so as to extend the half life of the agent, for example conjugates of the agent.
- cyclosporine or “cyclosporin” (also known as cyclosporine A) refers to the natural Tolypocladium inflatum cyclic non-ribosomal peptide with the systematic (IUPAC) name of: (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-Ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methyl-4-hexen-1-yl]-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone.
- Cyclosporine is an immunosuppressant agent used extensively to prevent organ rejection following allogenic transplants.
- the recommended IV dose in this indication is 5 to 6 mg/kg/day initially. It remains an important tool for managing organ transplantation despite having deleterious effects on renal structure and function. Cyclosporine has also been shown to be effective in the treatment psoriasis, atopic dermatitis, pyoderma gangrenosum, chronic autoimmune urticaria, and rheumatoid arthritis. In these indications the recommended initial dose orally is 2.5 mg/kg/day divided in two administrations daily. However, because of the high degree of toxicity associated with the drug, cyclosporine is typically indicated for severe cases of these conditions. For transplant patients, cyclosporine is generally administered only intermittently, or cyclically, with close monitoring of renal function.
- the present invention relates to a functional derivative or analogue of cyclosporine.
- the functional derivative or analogue of cyclosporine is a form of cyclosporine that is modified so as to extend the half life, for example, conjugates of cyclosporine.
- cyclosporine As used herein, functional derivatives of cyclosporine include salts, isomers, enantiomers, solvates, polymorphs, prodrugs and metabolites thereof.
- a functional analogue of cyclosporine may refer to a compound having a similar structure, but differing from it in a respect of certain aspects (e.g. it can differ in one or more atoms, functional groups, amino acids residues, or substructures, which are replaced with others).
- Functional analogues display similar pharmacological properties and may be structurally related.
- the functional derivative or analogue of cyclosporine is selected from cyclosporine G, N-Methyl-4-isoleucine Cyclosporine (also known as NIM811) tacrolimus and pimecrolimus, and pharmaceutically acceptable salts thereof.
- the functional derivative or analogue of cyclosporine is selected from cyclosporine G and N-Methyl-4-isoleucine Cyclosporine (also known as NIM811) and pharmaceutically acceptable salts thereof.
- Cyclosporine G differs from cyclosporine A in the amino acid 2 position, where an L-norvaline replaces the ⁇ -aminobutyric acid. (See generally, Wenger, R. M. 1989, Synthesis of cyclosporine and analogues: structural and conformational requirements for immunosuppressive activity. Progress in Allergy, 38: 46-64).
- the combination of the invention comprises an aldosterone antagonist.
- the combination, methods, compositions and uses of the invention comprise an aldosterone antagonist as an essential feature.
- the renin-angiotensin-aldosterone pathway is one corner stone of such neurohormonal activation.
- Aldosterone which is at its highest levels at presentation after acute myocardial infarction, is reported to promote a broad spectrum of deleterious cardiovascular effects including acute endothelial dysfunction, inhibition of NO activity, increased endothelial oxidative stress, increased vascular tone, inhibition of tissue recapture of catecholamines, rapid occurrence of vascular smooth muscle cell and cardiac myocyte necrosis, collagen deposition in blood vessels, myocardial hypertrophy, and fibrosis (Struthers, Am Heart J, 2002, 144: S2-S7; Zannad and Radauceanu, Heart Fail Rev, 2005, 10: 71-78). Furthermore, it has been found to predict poor outcomes (Beygui et al, Circulation, 2006, 114: 2604-2610).
- aldosterone antagonist or an antimineralocorticoid is a diuretic drug which antagonizes the action of aldosterone at mineralocorticoid receptors. This group of drugs is often used for the management of chronic heart failure. Members of this class are also used in the management of hyperaldosteronism (including Conn's syndrome) and female hirsutism (due to additional antiandrogen actions). Most antimineralocorticoids are steroidal spirolactones.
- Antagonism of mineralocorticoid receptors inhibits sodium resorption in the collecting duct of the nephron in the kidneys. This interferes with sodium/potassium exchange, reducing urinary potassium excretion and weakly increasing water excretion (diuresis).
- aldosterone antagonists are used in addition to other drugs for additive diuretic effect, which reduces edema and the cardiac workload.
- aldosterone antagonists examples include spironolactone (the first and most widely used member of this class), eplerenone (much more selective than spironolactone on target, but somewhat less potent and efficacious), canrenone and potassium canrenoate, finerenone (non-steroidal and more potent and selective than either eplerenone or spironolactone) and prorenone.
- the aldosterone antagonist is potassium canrenoate.
- Some drugs also have antimineralocorticoid effects secondary to their main mechanism of actions. Examples include progesterone, drospirenone, gestodene, and benidipine.
- the invention also encompasses functional derivatives and analogues of the aldosterone antagonists, particularly those that are modified so as to extend the half life of the agent, for example, conjugates of aldosterone antagonists.
- Potassium canrenoate or canrenoate potassium also known as the potassium salt of canrenoic acid, is an aldosterone antagonist of the spirolactone group. Like spironolactone, it is a prodrug, which is metabolized to canrenone in the body. Potassium canrenoate is typically given intravenously at doses ranging between 200 mg/day and 600 mg/day for the treatment of hyperaldosteronism or hypokaliaemia.
- Potassium canrenoate has systematic (IUPAC) name potassium 3-[(8R,9S,10R,13S,14S,17R)-17-hydroxy-10,13-dimethyl-3-oxo-2,8,9,11,12,14,15,16 octahydro-1H-cyclopenta[a]phenanthren-17-yl]propanoate, formula C 22 H 29 KO 4 and the following chemical structure:
- the invention also encompasses functional derivatives and analagues of potassium canrenoate, particularly those that are modified so as to extend the half life of the agent, for example, conjugates of potassium canrenoate.
- the present invention relates to a combination comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist.
- the combination comprises an insulin modulator and an aldosterone antagonist.
- the combination comprises an insulin modulator and an immunosuppressive agent.
- the combination comprises an immunosuppressive agent, and an aldosterone antagonist.
- the combination comprises (i) an insulin modulator, (ii) an immunosuppressive agent, and (iii) an aldosterone antagonist.
- the insulin modulator is defined according to any of the above-mentioned embodiments of an insulin modulator.
- the immunosuppressive agent is defined according to any of the above mentioned embodiments of an immunosuppressive agent.
- the aldosterone antagonist is defined according to any of the above mentioned embodiments of an aldosterone antagonist.
- the present invention relates to a combination comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof and (iii) potassium canrenoate, or a functional derivative or analogue.
- the present invention relates to a combination comprising (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof.
- the present invention relates to a combination comprising at least two of the following components: (i) at least one of exenatide, lixisenatide, albiglutide, liraglutide, taspoglutide and dulaglutide (LY2189265), or a pharmaceutically acceptable salt thereof, (ii) at least one of cyclosporine A, cyclosporine G, N-Methyl-4-isoleucine cyclosporine, tacrolimus and pimecrolimus, or a pharmaceutically acceptable salt thereof and (iii) at least one of potassium canrenoate, canrenone, spironolactone, eplerenone, finerenone and prorenone or pharmaceutically acceptable salts thereof, where applicable (e.g. pharmaceutically acceptable salts of canrenone, spironolactone, eplerenone, finerenone and prorenone).
- the present invention relates to a combination comprising (i) at least one of exenatide, lixisenatide, albiglutide, liraglutide, taspoglutide and dulaglutide (LY2189265), or a pharmaceutically acceptable salt thereof, and (iii) at least one of potassium canrenoate, canrenone, spironolactone, eplerenone, finerenone and prorenone or pharmaceutically acceptable salts thereof, where applicable.
- the present invention relates to a combination comprising at least two of the following components: (I) at least one of exenatide, lixisenatide, albiglutide, liraglutide, taspoglutide and dulaglutide (LY2189265), or a pharmaceutically acceptable salt thereof, (ii) at least one of cyclosporine A, cyclosporine G and N-Methyl-4-isoleucine cyclosporine, or a pharmaceutically acceptable salt thereof and (iii) at least one of potassium canrenoate, canrenone, spironolactone, eplerenone, finerenone and prorenone or pharmaceutically acceptable salts thereof, where applicable.
- the present invention relates to a combination of (i) exenatide or a pharmaceutically acceptable salt thereof, and (ii) at least one of cyclosporine A, cyclosporine G, N-Methyl-4-isoleucine cyclosporine, tacrolimus and pimecrolimus, or a pharmaceutically acceptable salt thereof.
- the present invention relates to a combination of (i) exenatide or a pharmaceutically acceptable salt thereof, and (ii) at least one of cyclosporine A, cyclosporine G and N-Methyl-4-isoleucine cyclosporine, or a pharmaceutically acceptable salt thereof.
- the present invention relates to a combination of (i) at least one of exenatide, lixisenatide, albiglutide, liraglutide, taspoglutide and dulaglutide (LY2189265), or a pharmaceutically acceptable salt thereof, and (ii) cyclosporine A or a pharmaceutically acceptable salt thereof.
- the present invention relates to a combination of (i) exenatide or a pharmaceutically acceptable salt thereof, (ii) cyclosporine A or a pharmaceutically acceptable salt thereof, and (iii) potassium canrenoate.
- the effect of drug combinations is inherently unpredictable and there is often a propensity for one drug to partially or completely inhibit the effects of the other.
- the present invention demonstrates that a combination comprising at least two of (i) an insulin modulator, such as exenatide or a functional derivative or analogue or a pharmaceutically acceptable salt thereof, (ii) an immunosuppressive agent, such as cyclosporine or a functional derivative or analogue or a pharmaceutically acceptable salt thereof, and (iii) an aldosterone antagonist, such as potassium canrenoate or a functional derivative or analogue, when administered simultaneously, separately or sequentially, does not lead to any significant or dramatic adverse interaction between the two agents.
- an insulin modulator such as exenatide or a functional derivative or analogue or a pharmaceutically acceptable salt thereof
- an immunosuppressive agent such as cyclosporine or a functional derivative or analogue or a pharmaceutically acceptable salt thereof
- an aldosterone antagonist such as potassium canrenoate or a functional derivative
- preferred combinations according to the invention surprisingly demonstrate a potentiation of the effect of the individual components, such that the optimal doses for the agents is lower than the doses recommended in the approved indications for these agents, and/or also lower (in all cases but potassium canrenoate) than the doses reported in the literature for reperfusion injury.
- the combinations of the active agents of the present invention produce an enhanced effect as compared to each drug administered alone.
- the combinations of the active agents of the present invention produce unexpected synergistic effects, for instance, in the treatment and/or prevention of reperfusion injury, particularly myocardial reperfusion injury.
- a combination of two or more drugs may lead to different types of drug interaction.
- a drug interaction is said to be additive when the combined effect of two drugs equals the sum of the effect of each agent given alone.
- a drug interaction is said to be synergistic if the combined effect of the two drugs exceeds the effects of each drug given alone (Goodman and Gilmans' “The Pharmacological Basis of Therapeutics”, 12 th Edition).
- Combination therapy is an important treatment modality in many disease settings, including cardiovascular disease, cancer and infectious diseases. Recent scientific advances have increased our understanding of the pathophysiological processes that underlie these and other complex diseases. This increased understanding has provided further impetus to develop new therapeutic approaches using combinations of drugs directed at multiple therapeutic targets to improve treatment response, minimize development of resistance, or minimize adverse events. In settings in which combination therapy provides significant therapeutic advantages, there is growing interest in the development of new combinations of two or more drugs.
- a synergistic combination may allow for lower doses of each component to be present, thereby decreasing the toxicity of therapy, whilst producing and/or maintaining the same therapeutic effect or an enhanced therapeutic effect.
- each component is present in a sub-therapeutic amount.
- sub-therapeutically effective amount means an amount that is lower than that typically required to produce a therapeutic effect with respect to treatment with each agent alone.
- the present invention relates to a synergistic combination comprising (i) an insulin modulator, and (iii) an aldosterone antagonist.
- the insulin modulator is defined according to any of the above mentioned embodiments of an insulin modulator.
- the aldosterone antagonist is defined according to any of the above mentioned embodiments of an aldosterone antagonist.
- the present invention relates to a synergistic combination of (i) at least one of exenatide, lixisenatide, albiglutide, liraglutide, taspoglutide and dulaglutide (LY2189265), or a pharmaceutically acceptable salt thereof, and (iii) at least one of potassium canrenoate, canrenone, spironolactone, eplerenone, finerenone and prorenone or pharmaceutically acceptable salts thereof, where applicable.
- the present invention relates to a synergistic combination of (i) exenatide or a pharmaceutically acceptable salt thereof, and (iii) potassium canrenoate.
- the present invention relates to a synergistic combination of (i) at least one of exenatide, lixisenatide, albiglutide, liraglutide, taspoglutide and dulaglutide (LY2189265), or a pharmaceutically acceptable salt thereof, and (iii) potassium canrenoate.
- the above described combinations comprise at least one further active pharmaceutical ingredient (API).
- API active pharmaceutical ingredient
- the above described combinations may further comprise at least one further API selected from a beta blocker, a renin-angiotensin inhibitor, a statin (HMG-CoA reductase inhibitor), an inhibitor of platelet activation or aggregation, a phosphodiesterase-3 inhibitor, a calcium sensitizer, an antioxidant and an anti-inflammatory agent.
- a further API selected from a beta blocker, a renin-angiotensin inhibitor, a statin (HMG-CoA reductase inhibitor), an inhibitor of platelet activation or aggregation, a phosphodiesterase-3 inhibitor, a calcium sensitizer, an antioxidant and an anti-inflammatory agent.
- beta-blockers examples include propranolol, metoprolol, bucindolol, carteolol, carvedilol, labetalol, nadolol, oxprenolol, penbutolol, pindolol, sotalol and timolol.
- Renin-angiotensin inhibitors include angiotensin converting enzyme inhibitors, angiotensin AT 1 receptor inhibitors and renin inhibitors.
- angiotensin converting enzyme inhibitors examples include captopril, zofenopril, enalapril, ramipril, quinapril, perindopril, lisinopril, benazepril, imidapril, trandolapril, cilazapril, and fosinopril.
- angiotension AT 1 receptor antagonists examples include losartan, irbesartan, olmesartan, candesartan, valsartan, fimasartan and telmisartan.
- renin inhibitors examples include remikiren and aliskiren.
- Examples of calcium sensitizers include levosimendan and analogues thereof.
- statins examples include atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin.
- platelet activation or aggregation inhibitors include prostacyclin (epoprostenol) and analogues and derivatives thereof (eg. treprostinil, iloprost), irreversible cyclooxygenase inhibitors (e.g. Aspirin, Triflusal), adenosine diphosphate (ADP) receptor inhibitors (e.g. Clopidogrel, Prasugrel, Ticagrelor, Ticlopidine), phosphodiesterase inhibitors (e.g. Cilostazol), protease-activated receptor-1 (PAR-1) antagonists (e.g. Vorapaxar), glycoprotein IIB/IIIA inhibitors (e.g.
- prostacyclin epoprostenol
- analogues and derivatives thereof eg. treprostinil, iloprost
- irreversible cyclooxygenase inhibitors e.g. Aspirin, Triflusal
- ADP aden
- Abciximab Eptifibatide, Tirofiban
- adenosine reuptake inhibitors e.g. Dipyridamole
- thromboxane inhibitors including thromboxane synthase inhibitors and thromboxane receptor antagonists (e.g. Terutroban).
- PDE-3 inhibitors examples include amrinone, milrinone, and analogues thereof.
- antioxidants examples include ascorbic acid, lipoic acid, glutathione and melatonin.
- anti-inflammatory agents examples include COX-2 inhibitors (e.g. celecoxib), glucocorticoids (e.g. hydrocortisone), and non-steroidal anti-inflammatory drugs (e.g. ibuprofen).
- COX-2 inhibitors e.g. celecoxib
- glucocorticoids e.g. hydrocortisone
- non-steroidal anti-inflammatory drugs e.g. ibuprofen
- the above combinations comprise at least one further API selected from propranolol, metoprolol, bucindolol, carteolol, carvedilol, labetalol, nadolol, oxprenolol, penbutolol, pindolol, sotalol, timolol, captopril, zofenopril, enalapril, ramipril, quinapril, perindopril, lisinopril, benazepril, imidapril, trandolapril, cilazapril, fosinopril, losartan, irbesartan, olmesartan, candesartan, valsartan, fimasartan, telmisartan, remikiren and aliskiren.
- the above combinations comprise at least one further API selected from carvedilol, metoprolol, losartan, irbesartan, olmesartan, candesartan, valsartan, fimasartan telmisartan, captopril, zofenopril, enalapril, ramipril, quinapril, perindopril, lisinopril, benazepril, imidapril, trandolapril, cilazapril, fosinopril, remikiren and aliskiren.
- the above combinations comprise at least one further API selected from carvedilol and metoprolol.
- the active pharmaceutical agents of the present invention can be present as pharmaceutically acceptable salts.
- compositions of the agents of the invention include suitable acid addition or base salts thereof.
- suitable pharmaceutical salts may be found in Berge et al., J Pharm Sci, 66, 1-19 (1977). Salts are formed, for example with strong inorganic acids such as mineral acids, e.g.
- sulphuric acid, phosphoric acid or hydrohalic acids with strong organic carboxylic acids, such as alkanecarboxylic acids of 1 to 4 carbon atoms which are unsubstituted or substituted (e.g., by halogen), such as acetic acid; with saturated or unsaturated dicarboxylic acids, for example oxalic, malonic, succinic, maleic, fumaric, phthalic or tetraphthalic; with hydroxycarboxylic acids, for example ascorbic, glycolic, lactic, malic, tartaric or citric acid; with aminoacids, for example aspartic or glutamic acid; with benzoic acid; or with organic sulfonic acids, such as (C1-C4)-alkyl- or aryl-sulfonic acids which are unsubstituted or substituted (for example, by a halogen) such as methane- or p-toluene sulfonic acid.
- the invention also includes where appropriate all enantiomers and tautomers of the active pharmaceutical agents.
- the man skilled in the art will recognise compounds that possess optical properties (one or more chiral carbon atoms) or tautomeric characteristics.
- the corresponding enantiomers and/or tautomers may be isolated/prepared by methods known in the art.
- Some of the active pharmaceutical agents of the invention may exist as stereoisomers and/or geometric isomers—e.g. they may possess one or more asymmetric and/or geometric centres and so may exist in two or more stereoisomeric and/or geometric forms.
- the present invention contemplates the use of all the individual stereoisomers and geometric isomers of those inhibitor agents, and mixtures thereof.
- the terms used in the claims encompass these forms, provided said forms retain the appropriate functional activity (though not necessarily to the same degree).
- the present invention also includes all suitable isotopic variations of the active pharmaceutical agents or pharmaceutically acceptable salts thereof.
- An isotopic variation of an agent of the present invention or a pharmaceutically acceptable salt thereof is defined as one in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature.
- isotopes that can be incorporated into the agent and pharmaceutically acceptable salts thereof include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulphur, fluorine and chlorine such as 2H, 3H, 13C, 14C, 15N, 170, 180, 31P, 32P, 35S, 18F and 36Cl, respectively.
- isotopic variations of the agent and pharmaceutically acceptable salts thereof are useful in drug and/or substrate tissue distribution studies. Tritiated, i.e., 3H, and carbon-14, i.e., 14C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with isotopes such as deuterium, i.e., 2H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements and hence may be preferred in some circumstances. Isotopic variations of the agent of the present invention and pharmaceutically acceptable salts thereof of this invention can generally be prepared by conventional procedures using appropriate isotopic variations of suitable reagents.
- the present invention also includes solvate forms of the active pharmaceutical agents of the present invention.
- the terms used in the claims encompass these forms.
- the invention furthermore relates to active pharmaceutical agents of the present invention in their various crystalline forms, polymorphic forms and (an)hydrous forms. It is well established within the pharmaceutical industry that chemical compounds may be isolated in any of such forms by slightly varying the method of purification and or isolation from the solvents used in the synthetic preparation of such compounds.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a combination comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist; and a pharmaceutically acceptable carrier, diluent or excipient.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a combination comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or a pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or a pharmaceutically acceptable salt thereof and (iii) potassium canrenoate, or a functional derivative or analogue; and a pharmaceutically acceptable carrier, diluent or excipient.
- the compounds of the present invention can be administered alone, they will generally be administered in admixture with a pharmaceutical carrier, excipient or diluent, particularly for human therapy.
- a pharmaceutical carrier excipient or diluent
- the pharmaceutical compositions may be for human or non-human animal usage in human and veterinary medicine respectively.
- Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro edit. 1985).
- routes of administration can be selected with regard to the intended route of administration and standard pharmaceutical practice.
- routes of administration include parenteral (e.g., intravenous, intramuscular, intradermal, intraperitoneal or subcutaneous), oral, inhalation, transdermal (topical), intraocular, iontophoretic, and transmucosal administration.
- the pharmaceutical composition is for parenteral administration (e.g., intravenous, intraarterial, intrathecal, intramuscular, intradermal, intraperitoneal or subcutaneous).
- parenteral administration e.g., intravenous, intraarterial, intrathecal, intramuscular, intradermal, intraperitoneal or subcutaneous.
- the compositions are prepared from sterile or sterilisable solutions.
- the pharmaceutical composition is for intravenous, intramuscular, or subcutaneous administration.
- the pharmaceutical composition is for intravenous administration.
- Solutions or suspension used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl-alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediamine-tetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
- the pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
- compositions suitable for injectable use can include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
- suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM or phosphate buffered saline (PBS).
- a composition for parenteral administration must be sterile and should be fluid to the extent that easy syringeability exists. It should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
- Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the active compounds into a sterile vehicle, which contains a basic dispersion medium and the required other ingredients from those enumerated above.
- typical methods of preparation include vacuum drying and freeze drying, which can yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- the invention also encompasses liposomal and nanoparticulate formulations comprising the active agents. Such formulations, along with methods for their preparation, will be familiar to a person of ordinary skill in the art.
- the present invention relates to a pharmaceutical product comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist.
- the present invention relates to a pharmaceutical product comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof and (iii) potassium canrenoate, or a functional derivative or analogue.
- the pharmaceutical product is a kit of parts containing all necessary equipment (e.g., vials of drug, vials of diluent, syringes and needles) for a treatment course.
- necessary equipment e.g., vials of drug, vials of diluent, syringes and needles
- the kit comprises separate containers for each active agent.
- Said containers may be ampoules, disposable syringes or multiple dose vials.
- the kit comprises a container which comprises a combined preparation of each active agent.
- the kit may further comprise instructions for the treatment and/or prevention of reperfusion injury.
- the present invention relates to a combination comprising at least two of the following components: (i) an insulin modulator (ii) an immunosuppressive agent, and (iii) an aldosterone antagonist for use in the treatment and/or prevention of one or more of ischemia and/or reperfusion injury, ischemic stroke, cardiac arrest, acute myocardial infarction, neonatal asphyxia and cardiogenic shock, or for use in providing cardioprotection against cardiotoxic drugs.
- an insulin modulator ii) an immunosuppressive agent
- an aldosterone antagonist for use in the treatment and/or prevention of one or more of ischemia and/or reperfusion injury, ischemic stroke, cardiac arrest, acute myocardial infarction, neonatal asphyxia and cardiogenic shock, or for use in providing cardioprotection against cardiotoxic drugs.
- the present invention relates to a combination comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically, acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue, for use in the treatment and/or prevention of one or more of ischemia and/or reperfusion injury, ischemic stroke, cardiac arrest, acute myocardial infarction, neonatal asphyxia and cardiogenic shock, or for use in providing cardioprotection against cardiotoxic drugs.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a combination comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist for use in the treatment and/or prevention of one or more of ischemia and/or reperfusion injury, ischemic stroke, cardiac arrest, acute myocardial infarction, neonatal asphyxia and cardiogenic shock, or for use in providing cardioprotection against cardiotoxic drugs.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a combination comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue, for use in the treatment and/or prevention of one or more of ischemia and/or reperfusion injury, ischemic stroke, cardiac arrest, acute myocardial infarction, neonatal asphyxia and cardiogenic shock, or for use in providing cardioprotection against cardiotoxic drugs.
- the present invention relates to a pharmaceutical product comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist, for use in the treatment and/or prevention of one or more of ischemia and/or reperfusion injury, ischemic stroke, cardiac arrest, acute myocardial infarction, neonatal asphyxia and cardiogenic shock, or for use in providing cardioprotection against cardiotoxic drugs, wherein the components are for administration simultaneously, sequentially or separately.
- the present invention relates to a pharmaceutical product comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof and (iii) potassium canrenoate, or a functional derivative or analogue, for use in the treatment and/or prevention of one or more of ischemia and/or reperfusion injury, ischemic stroke, cardiac arrest, acute myocardial infarction, neonatal asphyxia and cardiogenic shock, or for use in providing cardioprotection against cardiotoxic drugs, wherein the components are for administration simultaneously, sequentially or separately.
- the present invention relates to use of at least two of the following components: (i) an insulin modulator and (ii) an immunosuppressive agent and (iii) an aldosterone antagonist in the manufacture of a medicament for the treatment and/or prevention of one or more of ischemia and/or reperfusion injury, ischemic stroke, cardiac arrest, acute myocardial infarction, neonatal asphyxia and cardiogenic shock or for providing cardioprotection against cardiotoxic drugs.
- the present invention relates to use of at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof and (iii) potassium canrenoate, or a functional derivative or analogue thereof in the manufacture of a medicament for the treatment and/or prevention of one or more of ischemia and/or reperfusion injury, ischemic stroke, cardiac arrest, acute myocardial infarction, neonatal asphyxia and cardiogenic shock, or for providing cardioprotection against cardiotoxic drugs.
- the present invention relates to a combination comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist for use in the treatment and/or prevention of reperfusion injury.
- the present invention relates to a combination comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof and (iii) potassium canrenoate, or a functional derivative or analogue thereof, for use in the treatment and/or prevention of reperfusion injury.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a combination comprising at least two of the following components: (i) an insulin modulator (ii) an immunosuppressive agent and (iii) an aldosterone antagonist for use in the treatment and/or prevention of reperfusion injury.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a combination comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof, for use in the treatment and/or prevention of reperfusion injury.
- the present invention relates to a pharmaceutical product comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist for use in the treatment and/or prevention of reperfusion injury, wherein the components are for administration simultaneously, sequentially or separately.
- the present invention relates to a pharmaceutical product comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof, for use in the treatment and/or prevention of reperfusion injury, wherein the components are for administration simultaneously, sequentially or separately.
- the present invention relates to use of at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist in the manufacture of a medicament for the treatment and/or prevention of reperfusion injury.
- the present invention relates to use of at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof in the manufacture of a medicament for the treatment and/or prevention of reperfusion injury.
- the present invention relates to a combination comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist for use in the treatment and/or prevention of ischemia.
- the present invention relates to a combination comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof, for use in the treatment and/or prevention of ischemia.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a combination comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist for use in the treatment and/or prevention of ischemia.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a combination comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof, for use in the treatment and/or prevention of ischemia.
- the present invention relates to a pharmaceutical product comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist for use in the treatment and/or prevention of ischemia, wherein the components are for administration simultaneously, sequentially or separately.
- the present invention relates to a pharmaceutical product comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof, for use in the treatment and/or prevention of ischemia, wherein the components are for administration simultaneously, sequentially or separately.
- the present invention relates to use of at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist in the manufacture of a medicament for the treatment and/or prevention of ischemia.
- the present invention relates to use of at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof, in the manufacture of a medicament for the treatment and/or prevention of ischemia.
- reperfusion injury refers to the damage to tissue caused when blood supply returns to the tissue after a period of ischemia.
- the absence of oxygen and nutrients from blood creates a condition in which the restoration of circulation results in inflammation, mitochondrial dysfunction and oxidative damage through the induction of oxidative stress rather than restoration of normal function.
- Reperfusion injury can occur after a spontaneously occurring event, e.g., arterial blockage, or a planned event, e.g., any of a number of surgical interventions.
- Myocardial reperfusion injury can occur, for example, after myocardial infarction or as a result of heart transplantation.
- the ischemia and/or reperfusion injury may be ischemia and/or reperfusion injury of the brain, heart, lung, kidney, or other organ/tissue susceptible to ischemia and/or reperfusion injury.
- the ischemia and/or reperfusion injury is ischemia and/or reperfusion injury of the heart, preferably myocardial ischemia and/or myocardial reperfusion injury.
- the insulin modulator, the immunosuppressive agent and aldosterone antagonist may be for administration simultaneously, sequentially or separately (as part of a dosing regimen).
- Exenatide or functional derivatives or analogues or pharmaceutically acceptable salts thereof, cyclosporine or functional derivatives or analogues or pharmaceutically acceptable salts thereof, and potassium canrenoate or functional derivatives or analogues thereof, may be for administration simultaneously, sequentially or separately (as part of a dosing regimen).
- “sequentially” is used to mean that the active agents are not administered concurrently, but one after the other.
- administration “sequentially” may permit one agent to be administered within 5 minutes, 10 minutes or a matter of hours after the other provided the circulatory half-life of the first administered agent is such that they are both concurrently present in therapeutically effective amounts.
- the time delay between administrations of the components will vary depending on the exact nature of the components, the interaction there between, and their respective half-lives.
- “separately” is used herein to mean that the gap between administering one agent and the other is significant i.e. the first administered agent may no longer be present in the bloodstream in a therapeutically effective amount when the second agent is administered.
- the components of the combination are for simultaneous administration.
- the present invention relates to a method of treating and/or preventing ischemia and/or reperfusion injury, said method comprising simultaneously, sequentially or separately administering to a subject at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist.
- the present invention relates to a method of treating and/or preventing ischemia and/or reperfusion injury, said method comprising simultaneously, sequentially or separately administering to a subject in need thereof at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof.
- the present invention relates to a method of treating and/or preventing reperfusion injury, said method comprising simultaneously, sequentially or separately administering to a subject in need thereof at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist.
- the present invention relates to a method of treating and/or preventing reperfusion injury, said method comprising simultaneously, sequentially or separately administering to a subject in need thereof at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof.
- the present invention relates to a method of treating and/or preventing ischemia, said method comprising simultaneously, sequentially or separately administering to a subject in need thereof at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist.
- the present invention relates to a method of treating and/or preventing ischemia, said method comprising simultaneously, sequentially or separately administering to a subject in need thereof at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof.
- the method relates to treating and/or preventing ischemia and/or reperfusion injury of the brain, heart, lung, kidney, or other organ/tissue susceptible to ischemia and/or reperfusion injury.
- the method relates to treating and/or preventing reperfusion injury of the brain, heart, lung, kidney, or other organ/tissue susceptible to reperfusion injury.
- the method relates to treating and/or preventing ischemia of the brain, heart, lung, kidney, or other organ/tissue susceptible to ischemia.
- the method relates to treating and/or preventing ischemia and/or reperfusion injury of the heart, preferably myocardial ischemia and/or myocardial reperfusion injury.
- the method relates to treating and/or preventing reperfusion injury of the heart, preferably myocardial reperfusion injury.
- the method relates to treating and/or preventing acute myocardial infarction.
- Acute myocardial infarction is one of the most common clinical indications of reperfusion injury.
- the method relates to treating and/or preventing neonatal asphyxia.
- Neonatal asphyxia (or perinatal asphyxia) is the medical condition resulting from deprivation of oxygen to a newborn infant that lasts long enough during the birth process to cause physical harm, usually to the brain.
- the most common cause of neonatal asphyxia is a drop in maternal blood pressure or other interference to the blood flow to the infant's brain during delivery, for example, due to inadequate circulation or perfusion, impaired respiratory effort, or inadequate ventilation.
- Neonatal asphyxia can cause hypoxic damage to most of the infant's organs (heart, lungs, liver, gut, kidneys), but brain damage is of most concern and perhaps the least likely to quickly or completely heal. In more pronounced cases, an infant will survive, but with damage to the brain manifested as either mental, such as developmental delay or intellectual disability, or physical, such as spasticity. An infant suffering severe perinatal asphyxia usually has poor color (cyanosis), perfusion, responsiveness, muscle tone, and respiratory effort. Extreme degrees of asphyxia can cause cardiac arrest and death. Neonatal asphyxia occurs in 2 to 10 per 1000 newborns that are born at term, and in higher instances for those that are born prematurely. WHO estimates that 4 million neonatal deaths occur yearly due to birth asphyxia, representing 38% of deaths of children under 5 years of age.
- the method relates to treating and/or preventing ischemia of the heart, preferably myocardial ischemia.
- the subject is a mammal, more preferably a human.
- the method comprises parenterally (e.g., intravenously, intramuscularly, intradermally, intraperitoneally or subcutaneously) administering the components to the subject.
- parenterally e.g., intravenously, intramuscularly, intradermally, intraperitoneally or subcutaneously.
- the method comprises intravenously, intramuscularly, or subcutaneously administering the components to the subject.
- the method comprises intravenously administering (the components to the subject.
- Each component can be administered by the same or different route to the other components.
- the components are administered by the same route.
- the claimed combinations are administered to a donor subject and/or a recipient subject prior to and/or during and/or after heart transplant.
- the combination may be administered to a first subject from which the heart organ will be removed for transplantation into a second subject.
- the combination is administered to the extracted heart organ, prior to introduction into the second subject.
- the combination therapy is administered to the second subject before, during and/or after heart transplant.
- the claimed combinations are for administration to a subject with cardiogenic shock.
- Cardiogenic shock is a life-threatening medical condition resulting from an inadequate circulation of blood due to primary failure of the ventricles of the heart to function effectively. The condition occurs in 2-10% of patients hospitalized due to myocardial infarction and is the main cause of death among these patients (Holmes et al, 1995, J Am Coll Cardiol, 26: 668-674). More specifically, cardiogenic shock is the result of a complex process with failure of oxygen delivery, generalized ATP deficiency, and multi-organ dysfunction initiated by cardiac pump failure (Okuda, 2006, Shock, 25: 557-570).
- Cardiogenic shock is defined by sustained low blood pressure with tissue hypoperfusion despite adequate left ventricular filling pressure. Signs of tissue hypoperfusion include low urine production ( ⁇ 30 mL/hour), cool extremities, and altered level of consciousness.
- the claimed combinations are for administration to a subject with cardiac arrest.
- Cardiac arrest is a sudden stop in effective blood flow due to the failure of the heart to contract effectively.
- the most common cause of cardiac arrest is coronary artery disease.
- Treatment for cardiac arrest is immediate cardiopulmonary resuscitation (CPR) and if a shockable rhythm is present defibrillation.
- CPR cardiopulmonary resuscitation
- optimizing the management for post-cardiac arrest syndrome is critically important for improving the long term outcome for cardiac arrest patients.
- post-cardiac arrest syndrome there are 3 major areas of emphasis: (1) post-cardiac arrest brain injury; (2) post-cardiac arrest myocardial dysfunction and reperfusion injury; and (3) systemic ischemia-reperfusion response.
- post-resuscitation care can affect long-term survival and the myocardial and neurological recovery and function of survivors (Kern, 2015, Circ J, 79: 1156-1163).
- MPTP mitochondrial permeability transition pore
- the claimed combinations are for administration to a subject with stroke.
- Stroke is when poor blood flow to the brain results in cell death.
- Signs and symptoms of a stroke may include an inability to move or feel on one side of the body, problems understanding or speaking, feeling like the world is spinning, or loss of vision to one side among others.
- An ischemic stroke is typically caused by blockage of a blood vessel. Ischemic stroke treatment includes surgery to open up (reperfusion) the arteries to the brain in those with problematic narrowing.
- An ischemic stroke if detected within three to four and half hours, may be treatable with a medication that can break down the clot.
- stroke was the second most frequent cause of death after coronary artery disease, accounting for 6.4 million deaths (12% of the total).
- Intravenous tissue-type plasminogen activator has long been the only reperfusion therapy with proven clinical benefit in patients with acute ischemic stroke.
- endovascular methods restoring reperfusion in acute ischemic stroke may expose patients to increased ischemic/reperfusion injury, thereby hampering the benefit of recanalization by promoting hemorrhagic transformation and severe vasogenic edema both considering as markers of reperfusion injury (Bai and Lyden, 2015, Int J Stroke, 10: 143-152).
- the subject is at risk of (or susceptible to) vessel occlusion injury or cardiac ischemia-reperfusion injury.
- the claimed combinations are for use in, or methods of, providing cardioprotection in a subject against the cardiotoxic effects of drugs (e.g. anthracyclins).
- drugs e.g. anthracyclins. Examples of cardiotoxic drugs are described in Bovelli et al (Annals of Oncology 21 (Supplement 5): v277-v282, 2010).
- cardioprotection refers to protecting the heart, for example, by preventing, reducing or delaying myocardial injury.
- Cardiotoxic drugs include drugs associated with cardiac heart failure, drugs associated with ischaemia or thromboembolism, drugs associated with hypertension, drugs associated with other toxic effects such as tamponade and endomyocardial fibrosis, haemorrhagic myocarditis, bradyarrhythmias, Raynaud's phenomenon, autonomic neuropathy, QT prolongation or torsades de pointes, or pulmonary fibrosis.
- cardiotoxic drugs examples include anthracyclines/anthraquinolones, cyclophosphamide, Trastuzumab and other monoclonal antibody-based tyrosine kinase inhibitors, antimetabolites (fluorouracil, capecitabine), antimicrotubule agents (paclitaxel, docetaxel), cisplatin, thalidomide, bevacizumab, sunitinib, sorafenib, busulfan, paclitaxel, vinblastine, bleomycin, vincristine, arsenic trioxide, bleomycin, methotrexate.
- anthracyclines/anthraquinolones examples include anthracyclines/anthraquinolones, cyclophosphamide, Trastuzumab and other monoclonal antibody-based tyrosine kinase inhibitors, antimetabolites (fluorouracil, capecitabine
- the components are administered simultaneously.
- the (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof, and (iii) potassium canrenoate, or a functional derivative or analogue thereof are administered simultaneously.
- the components are administered sequentially or separately.
- all three components can be administered simultaneously, or any two components can be administered simultaneously, with the third component administered separately or sequentially.
- all three components can be administered in any order separately or sequentially.
- (i) is administered prior to sequentially or separately administering (ii).
- (ii) is administered prior to sequentially or separately administering (i).
- (i) is administered prior to sequentially or separately administering (iii).
- (iii) is administered prior to sequentially or separately administering (i).
- the (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof, and (iii) potassium canrenoate, or a functional derivative or analogue thereof, are administered sequentially or separately.
- the components are each administered in a therapeutically effective amount with respect to the individual components.
- the (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof, and (iii) potassium canrenoate, or a functional derivative or analogue thereof, are each administered in a therapeutically effective amount with respect to the individual components.
- the term “therapeutically effective amount” refers to a quantity sufficient to achieve a desired therapeutic and/or prophylactic effect, e.g., an amount which results in the prevention of, or a decrease in, ischemia and/or reperfusion injury or one or more symptoms associated with ischemia and/or reperfusion injury.
- the amount of a composition administered to the subject will depend on the type and severity of the disease and on the characteristics of the individual, such as general health, age, sex, body, weight and tolerance to drugs. It will also depend on the degree severity and type of disease. The skilled artisan will be able to determine appropriate dosages depending on these and other factors.
- the composition can also be administered in combination with one or more additional therapeutic agents.
- the components are each administered in a sub-therapeutically effective amount with respect to the individual components.
- the (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof, and (iii) potassium canrenoate, or a functional derivative or analogue thereof, are each administered in a sub-therapeutically effective amount with respect to the individual components.
- the components are administered prior to reperfusion the subject.
- the (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof, and (iii) potassium canrenoate, or a functional derivative or analogue thereof, are administered prior to reperfusion the subject.
- the components are administered during reperfusion of the subject.
- the (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof, and (iii) potassium canrenoate, or a functional derivative or analogue thereof, are administered during reperfusion of the subject.
- the components are administered after reperfusion of the subject.
- the (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof, and (iii) potassium canrenoate, or a functional derivative or analogue thereof, are administered after reperfusion of the subject.
- the components are administered prior to and/or during, and/or after reperfusion of the subject.
- the (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof, and (iii) potassium canrenoate, or a functional derivative or analogue thereof, are administered prior to, during and after reperfusion of the subject.
- the subject is administered (i) continuously before, during, and after reperfusion of the subject and is administered (ii) as a bolus dose prior to reperfusion.
- the subject is administered (ii) continuously before, during, and after reperfusion of the subject and is administered (i) as a bolus dose prior to reperfusion.
- the subject is administered (i), (ii) and (iii) continuously before, during, and after reperfusion of the subject.
- additional administration of one or more of the components may occur after reperfusion.
- this repeat administration is carried out at least twice, more preferably from 2 to 100 times, or can be in the form of continuous infusion.
- the subject is administered the components as a bolus dose prior to reperfusion.
- the subject is administered the components as a bolus dose during reperfusion.
- the subject is administered the components as a bolus dose after reperfusion.
- fusion is the restoration of blood flow to any organ or tissue in which the flow of blood is decreased or blocked.
- blood flow can be restored to any organ or tissue affected by ischemia or hypoxia.
- the restoration of blood flow can occur by any method known to those in the art. For instance, reperfusion of ischemic cardiac tissues may arise from revascularization.
- reperfusion is achieved via a revascularization procedure.
- the revascularization procedure is selected from the group consisting of: percutaneous coronary intervention; balloon angioplasty; insertion of a bypass graft; insertion of a stent; directional coronary atherectomy; treatment with a one or more thrombolytic agent(s); and removal of an occlusion.
- the one or more thrombolytic agents are selected from the group consisting of: tissue plasminogen activator; urokinase; prourokinase; streptokinase; acylated form of plasminogen; acylated form of plasmin; and acylated streptokinase-plasminogen complex.
- a person of ordinary skill in the art can easily determine an appropriate dose of one of the instant compositions to administer to a subject without undue experimentation.
- a physician will determine the actual dosage which will be most suitable for an individual patient and it will depend on a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the individual undergoing therapy.
- the dosages disclosed herein are exemplary of the average case. There can of course be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.
- the dose of the insulin modulator (e.g. exenatide) in the combination is generally lower than the dose typically used in monotherapy in the context of its currently approved therapies, and/or lower than the general doses reported in the reperfusion injury literature.
- the insulin modulator e.g. exenatide
- the dose of the immunosuppressive agent (e.g. cyclosporine) in the combination is generally lower than the dose typically used in monotherapy in the context of its currently approved therapies, and/or lower than the general doses reported in the reperfusion injury literature.
- the immunosuppressive agent e.g. cyclosporine
- exenatide is preferably administered in a dose of from about 0.001 to about 1.5 ⁇ g/kg, more preferably from about 0.005 to about 0.15 ⁇ g/kg.
- potassium canrenoate is preferably administered in a dose of from about 0.03 to about 10, preferably from about 1 to about 10 mg/kg, more preferably, from about 1 to about 5 mg/kg, even more preferably, from about 1 to about 3 mg/kg.
- cyclosporine is preferably administered in a dose of from about 0.001 to about 10 mg/kg, more preferably from about 0.01 to about 5 mg/k, even more preferably from about 0.01 to about 2.5 mg/kg.
- the combination is a fixed dose combination comprising predetermined dosages of the respective components (e.g. about 0.005 to about 0.05 ⁇ g/kg exenatide and from about 1 to about 3 mg/kg potassium canrenoate, more preferably, about 0.05 ⁇ g/kg exenatide and 1 mg/kg potassium canrenoate).
- predetermined dosages of the respective components e.g. about 0.005 to about 0.05 ⁇ g/kg exenatide and from about 1 to about 3 mg/kg potassium canrenoate, more preferably, about 0.05 ⁇ g/kg exenatide and 1 mg/kg potassium canrenoate.
- the present invention relates to use of a combination comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist for treating and/or preventing ischemia and/or reperfusion injury in an ex vivo organ prior to or during transplantation.
- the present invention relates to use of a combination comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof for treating and/or preventing ischemia and/or reperfusion injury in an ex vivo organ prior to or during transplantation.
- the present invention relates to use of a combination comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist for treating and/or preventing reperfusion injury in an ex vivo organ prior to or during transplantation.
- the present invention relates to use of a combination comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or a pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or a pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof for treating and/or preventing reperfusion injury in an ex vivo organ prior to or during transplantation.
- the present invention relates to use of a combination comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist for treating and/or preventing ischemia in an ex vivo organ prior to or during transplantation.
- the present invention relates to use of a combination comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof for treating and/or preventing ischemia in an ex vivo organ prior to or during transplantation.
- an ex vivo (removed from the body) organ can be susceptible to reperfusion injury due to lack of blood flow. Therefore, the combination of the present invention can be used to prevent reperfusion injury in the removed organ.
- the organ is a heart, liver or kidney, more preferably, a heart.
- the removed organ is placed in a standard buffered solution, such as those commonly used in the art, containing the combination of the invention.
- a removed heart can be placed in a cardioplegic solution containing exenatide and cyclosporine.
- concentration of exenatide, cyclosporine and potassium canrenoate useful in the standard buffered solution can be easily determined by those skilled in the art. Such concentrations may be, for example, between about 0.1 nM to about 10 ⁇ M, preferably about 1 nM to about 10 ⁇ M.
- exenatide can attenuate/mitigate myocardial injury resulting from an ischemia-reperfusion (I/R) insult as can occur clinically following acute myocardial infarction (AMI) and/or percutaneous coronary intervention/angioplasty (PCI).
- I/R ischemia-reperfusion
- AMI acute myocardial infarction
- PCI percutaneous coronary intervention/angioplasty
- CsA cyclosporine-A
- CsA can attenuate/mitigate myocardial injury resulting from an I/R insult as can occur clinically following AMI and/or PCI.
- CsA (2.5 mg/Kg IV bolus), when given prior to the onset of reperfusion, may have myocardial sparing effects.
- This study was designed to test the combined cardioprotective effects of exenatide and CsA in a setting that mimics the clinical scenario of an acute I/R insult. The study was conducted under the hypothesis that combined treatment with exenatide and CsA after the onset of ischemia (but prior to reperfusion) would provide a more pronounced myocardial protective effect compared to exenatide or cyclosporine treatment alone.
- New Zealand White rabbits were used in this study.
- the rabbits were males, >8 weeks in age and with a weight between 2.9 and 3.8 Kg. Approvals from the Ethical Committees and the veterinary authorities were obtained before the study was started.
- Environmental controls in the animal rooms were set to maintain temperature of 22° to 28° C. and relative humidity between 30% and 70%. Room temperature and humidity were recorded hourly and monitored daily. There were approximately 10-15 air exchanges per hour in the animal rooms. Photoperiod was 12-hours light and 12-hours dark. Routine daily observations were performed. Certified standard rabbit diet was provided, approximately 180 grams per day from arrival to the facility.
- Exenatide peptide [Byetta®, 10 ⁇ g/injected dose (40 ⁇ l), Eli Lilly Nederland B.V.] and, cyclosporine A [CsA, Sandimmun® (50 mg/ml) Novartis Pharma A.G., Switzerland] are used as the test articles, either in monotherapy or in combined therapy.
- Dosing solutions of exenatide (0.15 ⁇ g/Kg in of normal saline) and/or CsA (2.5 mg/Kg in normal saline) were prepared just before the administration to the rabbits. Normal saline (0.9% NaCl) was used as a control.
- test/control articles were given intravenously, under general anaesthesia, in order to mimic the expected route of administration in the clinical setting of acute myocardial infarction and primary percutaneous coronary intervention.
- Intravenous boluses were administered via a peripheral vein (rabbit auricular vein).
- I/R groups arm B, C, D and E
- rabbits were subjected to 40 min regional ischemia of the heart (coronary occlusion), followed by 120 min (2 h) reperfusion.
- treatments intravenous bolus administration of NS or exenatide or CsA or exenatide plus CsA
- ischemia 10 min before the initiation of reperfusion
- cardiovascular function was monitored both prior to and during ischemia, as well as for up to 120 min (2 h) post-reperfusion.
- IM induced intramuscularly
- ketamine ⁇ 35-50 mg/Kg
- xylazine ⁇ 5-10 mg/Kg
- animals received additional anesthesia as required ( ⁇ 10-15 mg ketamine/30 min or ⁇ 15-20 mg/Kg sodium pentobarbital).
- a venous catheter was placed in a peripheral vein (e.g., ear auricular vein) for the administration of additional anesthetics and normal saline/test articles.
- the effect of anesthesia is assessed by (i) the total abolishment of animal's corneal reflex, (ii) the total abolishment of animal's respiratory centre and the total mechanical ventilation without any resistance to airflow caused by animal's spontaneous breathing, and (iii) the stability of the hemodynamic parameters.
- a cuffed tracheal tube was placed via a tracheotomy (ventral midline incision) and used to mechanically ventilate the lungs with a 95% O 2 /5% CO 2 mixture via a volume-cycled animal ventilator ( ⁇ 40 breaths/min with a tidal volume of ⁇ 12.5 ml/Kg) in order to sustain PaCO 2 values broadly within the physiological range.
- Ischemia was induced by pulling the thread through the tubing, which was firmly positioned against the coronary arterial wall with the aid of a small clamp. Ischemia resulted in ST elevation on the electrocardiogram and a change in the color (i.e., cyanotic) of the myocardium.
- IV bolus either vehicle (normal saline) or exenatide or CsA or the combination of exenatide and CsA; ischemia was continued for additional 10 min (i.e., 40 min total ischemia time) after the treatment.
- the coronary snares were released and the previous ischemic myocardium was reperfused for up to 2 hours. It should be noted that in sham-operated animals the vessel snares were manipulated at the time of ischemia-reperfusion onset, but were not either tightened or loosened.
- cTnI Cardiac troponin-I
- Hearts were kept at ⁇ 20° C. for 24 hours and sectioned perpendicular to its long axis (from apex to base) into 3 mm thick slices. Subsequently, the slices were incubated for 20 min in 2% triphenyl-tetrazolium-chloride (TTC, Sigma, St. Louis, Mo., USA) at 37° C., and fixed in a 10% non-buffered formalin solution.
- TTC triphenyl-tetrazolium-chloride
- the total left ventricular area (LV), the area-at-risk (AAR), and the infarct area (IF) were delineated/measured digitally. With a wavelength of 366 nm UV light, it was separated in each slide the ischemic area (AAR) from infarcted zone (IF) and no ischemic area. All areas were traced onto an acetate sheet. The tracings were subsequently imported into an image analysis program (Image J; National Institutes of Health), and computer-assisted planometry was performed to determine the overall size of the left ventricular (LV), the area-at-risk (AAR) and the infarct (IF).
- the AAR was expressed as a percentage of the LV area (AAR/LV), and the IF was expressed as a percentage of the AAR (IF/AAR).
- quantitative histomorphometry was performed by personnel blinded to the treatment assignment/study-design.
- Hemodynamic variables mean arterial pressures and heart rate, are shown in the Table 2. Baseline values were similar in all groups. As we typically see in our rabbit model, arterial pressures decrease after surgery and occlusion and most significantly at the end of reperfusion. There were no significant differences among groups in this pressure variable. All groups followed a similar pattern over time.
- the LV size and AAR size were comparable in all-treated animals, indicating that the initial left ventricular and ischemic area did not differ significantly between the groups.
- exenatide or CsA resulted in decreased infarct size compared to the control
- the administration of the combination of exenatide and CsA resulted in a superior decrease of infarct size.
- exenatide or CsA reduced cTnI release by 48% and 36%, respectively
- the combined therapy of exenatide and cyclosporine reduced cTnI release by 61% (62.6 ⁇ 10.7, P ⁇ 0.001).
- Table 3 presents data showing cardiac troponin I levels, the ratios of area of risk to left ventricular, infarcted area to left ventricular, and infarcted area to area of risk for each of group used in this study.
- Wistar rats were used in this study.
- the rats were males and with a weight between 266 and 370 g.
- Approvals from the Ethical Committees and the veterinary authorities were obtained before the study was started.
- the animals were housed in individually ventilated cages using HEPA-filtered air, which conform to the size recommendations in the most recent Guide for the Care and Use of Laboratory Animals DHEW (NIH) and Directive 2010/63/EU on the protection of animals used for scientific purposes.
- Environmental controls in the animal rooms were set to maintain temperature of 22° to 28° C. and relative humidity between 30% and 70%.
- Litter material placed beneath the cage was changed at least three times a week. There were approximately 10-15 air exchanges per hour in the animal rooms. Photoperiod was 12-hours light and 12-hours dark. Routine daily observations were performed.
- the animals were conditioned to the housing facilities for at least 3 days prior to testing. Standard laboratory rat chow and filtered tap water was available ad libitum.
- Exenatide (Byetta®, Eli Lilly Nederland B.V.) and CsA (Sandimmun®, Novartis Pharma A.G., Switzerland) are used as the test articles, either in monotherapy or in combined therapy. Dosing solutions of exenatide and/or CsA were prepared just before the administration to the rats. Normal saline (0.9% NaCl) was used as a control.
- the rats were weighted and stomach and chest areas shaved. Maintenance of the body temperature was assisted using a constant temperature heating pad.
- the trachea was intubated with a plastic cannula connected to a rodent ventilator. The animals were ventilated with room air (6.2 ml/Kg, 70 ⁇ 5 breath/min). Blood pressure, surface-lead ECG, and body core temperature were monitored throughout the experiments to ensure the stability of the preparation.
- the right carotid artery was cannulated for measurement of blood pressure and the right jugular vein was cannulated for the administration of the test articles.
- a thoracotomy was performed at the 5 th intercostals space and the heart was exposed.
- a 5-0 Prolene suture was placed around the left descending coronary artery.
- the coronary artery was then occluded for 30 min by placing the ligature through a small piece of plastic tubing and pulling the snare tightly in place using a haemostat. After 30 min of coronary occlusion, reperfusion was initiated by releasing the snare and continued for 120 min.
- the heart was taken out and infarct size was determined. Briefly, the left anterior descending coronary artery was re-occluded and the heart was perfused with 4 ml of 0.3% (w/v) Evans-blue dye (Sigma-Aldrich) with a constant 100cmH 2 O pressure into the aorta to delineate the area-at-risk zone. The non-ischemic perfused tissue area was stained blue, while the risk zone remained unstained. Stained hearts were rapidly frozen ( ⁇ 20° C. for at least 2 hours), cut into 2 mm thick slices and each slice was incubated at 37° C. in 1.5 ml of 1% (w/v) TTC (Merck Biosciences) dissolved in 50 mM phosphate buffer (pH 7.4) for 10 min. Slices were then transferred to 10% formalin solution for 5 min.
- TTC 1%
- the total left ventricular area (LV), the area-at-risk (AAR), and the infarct area (IF) were delineated/measured digitally. Slices were placed between glass plates and digital photos were taken from both sides of the heart slices. The differently stained areas of images were quantified by digital planimetry (InfarctsizeTM 2.5, Pharmahungary, Szeged, Hungary). Evaluation of all images was carried out in a blinded manner by an experienced person throughout the study. For each slide, the AAR was expressed as a percentage of the LV area (AAR/LV), and the IF was expressed as a percentage of the AAR (IF/AAR).
- Hemodynamic variables mean arterial pressures and heart rate, are shown in the Table 5. Baseline values were similar in all groups. As we typically see in our rat model, arterial pressures decrease after surgery and occlusion and most significantly at the end of reperfusion. There were no significant differences among groups in this pressure variable. All groups followed a similar pattern over time.
- the LV size and AAR size were comparable in all-treated animals, indicating that the initial left ventricular and ischemic areas did not differ significantly between the groups.
- Administration of exenatide or CsA exhibited a dose-dependent effect.
- treatment of animals with lower doses of exenatide and CsA resulted in significant decreased infarct size compared to the control, whereas higher doses were without effects.
- the administration of the combination of low doses of exenatide and CsA resulted in a superior decrease of infarct size.
- exenatide at dose of 0.03 ⁇ g/Kg reduced infarcted area by 27% (45.9 ⁇ 1.4; P ⁇ 0.05) and CsA at 0.5 mg/Kg by 26.6% (46.2 ⁇ 3.7; P ⁇ 0.05), respectively, the combined therapy of exenatide and CsA reduced infarcted area by 39.1% (38.3 ⁇ 2.7; P ⁇ 0.05), as compared to control (62.9 ⁇ 3.7).
- Table 6 presents data showing the ratios of area of risk to left ventricular, and infarcted area to area of risk for each of group of the study.
- New Zealand White rabbits were used in this study.
- the rabbits were males, >8 week in age and with a weight between 2.6 and 3.8 Kg. All animals were treated according to the Directive 2010/63/UE European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes, and conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1985). Approvals from the Ethical Committees and the veterinary authorities were obtained before the study was started.
- Environmental controls in the animal rooms were set to maintain temperature of 22° to 28° C. and relative humidity between 30% and 70%. Room temperature and humidity were recorded hourly and monitored daily. There were approximately 10-15 air exchanges per hour in the animal rooms. Photoperiod was 12-hours light and 12-hours dark. Routine daily observations were performed. Certified standard rabbit diet was provided, approximately 180 grams per day from arrival to the facility.
- Exenatide (Byetta®; Eli Lilly Nederland B.V.] and potassium canrenoate (Sigma-Aldrich, Germany) are used as the test articles, either in monotherapy or in combined therapy.
- Dosing solutions of exenatide (0.15 ⁇ g/Kg in of normal saline) and/or potassium canrenoate (1 mg/Kg in normal saline) were prepared just before the administration to the rabbits.
- Normal saline (0.9% NaCl) was used as a control.
- test/control articles were given intravenously, under general anaesthesia, in order to mimic the expected route of administration in the clinical setting of acute myocardial infarction and primary percutaneous coronary intervention.
- Intravenous boluses were administered via a peripheral vein (rabbit auricular vein).
- IM induced intramuscularly
- ketamine ⁇ 35-50 mg/Kg
- xylazine ⁇ 5-10 mg/Kg
- animals received additional anesthesia as required ( ⁇ 10-15 mg ketamine/30 min or ⁇ 15-20 mg/Kg sodium pentobarbital).
- a venous catheter was placed in a peripheral vein (e.g., ear auricular vein) for the administration of additional anesthetics and normal saline/test articles.
- a cuffed tracheal tube was placed via a tracheotomy (ventral midline incision) and used to mechanically ventilate the lungs with a 95% O 2 /5% CO 2 mixture via a volume-cycled animal ventilator ( ⁇ 40 breaths/min with a tidal volume of ⁇ 12.5 ml/Kg) in order to sustain PaCO 2 values broadly within the physiological range.
- the animals were placed in left-lateral recumbence and the chest was surgically opened with a left thoracotomy.
- the chest was opened through the left fourth intercostals space.
- the beating heart was exposed and the pericardium was incised.
- the left anterior descending coronary artery (LAD) was circled with a 3-0 silk suture. Coronary artery occlusion in this region normally results in ischemia of a large territory of the anterolateral and apical ventricular wall.
- the ends of the suture were threaded through a small piece of polyethylene tubing, forming a snare.
- Ischemia was induced by pulling the thread through the tubing, which was firmly positioned against the coronary arterial wall with the aid of a small clamp. Ischemia resulted in a change in the color (i.e., cyanotic) of the myocardium.
- the animals administered with IV bolus of either vehicle (normal saline) or indicated test article; ischemia was continued for additional 15 min (i.e., 30 min total ischemia time) after the treatment.
- the coronary snares were released and the previous ischemic myocardium was reperfused for up to 3 hours.
- infarct area were evaluated.
- Hearts were kept at ⁇ 20° C. for 24 hours and sectioned perpendicular to its long axis (from apex to base) into 3 mm thick slices. Subsequently, the slices were incubated for 20 min in 2% (TTC, Sigma) at 37° C., and fixed in a 10% non-buffered formalin solution.
- the total left ventricular area (LV), the area-at-risk (AAR), and the infarct area (IF) were delineated/measured digitally. With a wavelength of 366 nm UV light, it was separated in each slide the ischemic area (AAR) from infarcted zone (IF) and no ischemic area. All areas were traced onto an acetate sheet. The tracings were subsequently imported into an image analysis program (Image J; National Institutes of Health), and computer-assisted planimetry was performed to determine the overall size of the left ventricular (LV), the area-at-risk (AAR) and the infarct (IF).
- the AAR was expressed as a percentage of the LV area (AAR/LV), and the IF was expressed as a percentage of the AAR (IF/AAR).
- quantitative histomorphometry was performed by personnel blinded to the treatment assignment/study-design.
- the area of the left ventricle (LV) and the ischemic area (AAR) were similar in all animals and did not differ statistically between the study groups.
- the induction of ischemia (30 min) and reperfusion (180 min) in the control group resulted in significant injury to the myocardium of experimental animals (49.47 ⁇ 3.97%), indicating the sufficient implementation of the model and the reproducibility of the experimental procedure of the study.
- the exenatide monotherapy (0.150 ⁇ g/Kg) caused a reduction of the extent of infarct by 36.2% (31.55 ⁇ 3.31%; P ⁇ 0.05) compared with the control group.
- Table 8 presents data showing the ratios of area of risk to left ventricular and infarcted area to area of risk for each of group used in this study.
- This study was designed to test the combined cardioprotective effects of exenatide, cyclosporine (CsA) and potassium canrenoate in a setting that mimics the clinical scenario of an acute I/R insult.
- the study was conducted under the hypothesis that triple combined treatment with exenatide, CsA and potassium canrenoate after the onset of ischemia (but prior to reperfusion) would provide a more pronounced myocardial protective effect compared to double treatment with exenatide and cyclosporine.
- New Zealand White rabbits were used in this study.
- the rabbits were males, >8 week in age and with a weight between 2.6 and 3.8 Kg. All animals were treated according to the Directive 2010/63/UE European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes, and conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1985). Approvals from the Ethical Committees and the veterinary authorities were obtained before the study was started.
- Environmental controls in the animal rooms were set to maintain temperature of 22° to 28° C. and relative humidity between 30% and 70%. Room temperature and humidity were recorded hourly and monitored daily. There were approximately 10-15 air exchanges per hour in the animal rooms. Photoperiod was 12-hours light and 12-hours dark. Routine daily observations were performed. Certified standard rabbit diet was provided, approximately 180 grams per day from arrival to the facility.
- Exenatide (Byetta®; Eli Lilly Nederland B.V.], CsA (Sandimmun®, Novartis Pharma A.G., Switzerland) and potassium canrenoate (Sigma-Aldrich, Germany) are used as the test articles, either in double or in triple combined therapy. Dosing solutions of exenatide, CsA and potassium canrenoate were prepared just before the administration to the rabbits. Normal saline (0.9% NaCl) was used as a control.
- test/control articles were given intravenously, under general anaesthesia, in order to mimic the expected route of administration in the clinical setting of acute myocardial infarction and primary percutaneous coronary intervention.
- Intravenous boluses were administered via a peripheral vein (rabbit auricular vein).
- IM induced intramuscularly
- ketamine ⁇ 35-50 mg/Kg
- xylazine ⁇ 5-10 mg/Kg
- animals received additional anesthesia as required ( ⁇ 10-15 mg ketamine/30 min or ⁇ 15-20 mg/Kg sodium pentobarbital).
- a venous catheter was placed in a peripheral vein (e.g., ear auricular vein) for the administration of additional anesthetics and normal saline/test articles.
- a cuffed tracheal tube was placed via a tracheotomy (ventral midline incision) and used to mechanically ventilate the lungs with a 95% O 2 /5% CO 2 mixture via a volume-cycled animal ventilator ( ⁇ 40 breaths/min with a tidal volume of ⁇ 12.5 ml/Kg) in order to sustain PaCO 2 values broadly within the physiological range.
- the animals were placed in left-lateral recumbence and the chest was surgically opened with a left thoracotomy.
- the chest was opened through the left fourth intercostals space.
- the beating heart was exposed and the pericardium was incised.
- the left anterior descending coronary artery (LAD) was circled with a 3-0 silk suture. Coronary artery occlusion in this region normally results in ischemia of a large territory of the anterolateral and apical ventricular wall.
- the ends of the suture were threaded through a small piece of polyethylene tubing, forming a snare.
- Ischemia was induced by pulling the thread through the tubing, which was firmly positioned against the coronary arterial wall with the aid of a small clamp. Ischemia resulted in a change in the color (i.e., cyanotic) of the myocardium.
- the animals administered with IV bolus of either vehicle (normal saline) or indicated test article; ischemia was continued for additional 15 min (i.e., 30 min total ischemia time) after the treatment.
- the coronary snares were released and the previous ischemic myocardium was reperfused for up to 3 hours.
- infarct area was evaluated.
- Hearts were kept at ⁇ 20° C. for 24 hours and sectioned perpendicular to its long axis (from apex to base) into 3 mm thick slices. Subsequently, the slices were incubated for 20 min in 2% (TTC, Sigma) at 37° C., and fixed in a 10% non-buffered formalin solution.
- the total left ventricular area (LV), the area-at-risk (AAR), and the infarct area (IF) were delineated/measured digitally. With a wavelength of 366 nm UV light, it was separated in each slide the ischemic area (AAR) from infarcted zone (IF) and no ischemic area. All areas were traced onto an acetate sheet. The tracings were subsequently imported into an image analysis program (Image J; National Institutes of Health), and computer-assisted planimetry was performed to determine the overall size of the left ventricular (LV), the area-at-risk (AAR) and the infarct (IF).
- the AAR was expressed as a percentage of the LV area (AAR/LV), and the IF was expressed as a percentage of the AAR (IF/AAR).
- quantitative histomorphometry was performed by personnel blinded to the treatment assignment/study-design.
- the area of the left ventricle (LV) and the ischemic area (AAR) were similar in all animals and did not differ statistically between the study groups.
- Treatment of double combination of exenatide and CsA (0.150 mg/Kg and 0.5 mg/Kg, respectively) caused a reduction of the area of infarction by 50% (24.74 ⁇ 3.8%; P ⁇ 0.05) compared with the control group (49.47 ⁇ 4).
- the addition to this treatment of potassium canrenoate (1 mg/Kg) resulted in a further reduction of the area of the infarct by 70.6% (14.56 ⁇ 3%; P ⁇ 0.001) compared to the control group.
- the administration of a triple combinations of exenatide, potassium canrenoate and CsA 1 mg/Kg reduced the area of the infarct by 74.8% (12.49 ⁇ 2.2%; P ⁇ 0.001), compared to the control group.
- the effect of these triple combinations was statistically significant (P ⁇ 0.05) compared with double combination of exenatide and CsA.
- the administration of a triple combination of exenatide, potassium canrenoate and CsA 2.5 mg/Kg caused a reduction of the extent of infarct by 46.5% (26.48 ⁇ 2.93%; P ⁇ 0.05), which was not statistically significant compared to double combination of exenatide and CsA.
- Table 10 presents data showing the ratios of area of risk to left ventricular and infarcted area to area of risk for each of group used in this study.
- C57BL/6 mice were used in this study. Mice were males, 13-15 weeks in age. All animals were treated according to the Directive 2010/63/UE European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes, and conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1985). Approvals from the Ethical Committees and the veterinary authorities were obtained before the study was started. Environmental controls in the animal rooms were set to maintain temperature of 22° to 28° C. and relative humidity between 30% and 70%. Room temperature and humidity were recorded hourly and monitored daily. There were approximately 10-15 air exchanges per hour in the animal rooms. Photoperiod was 12-hours light and 12-hours dark. Routine daily observations were performed. Standard laboratory mouse chow and filtered tap water was available ad libitum.
- Exenatide (Byetta®; Eli Lilly Nederland B.V.], CsA (Sandimmun®, Novartis Pharma A.G., Switzerland) and potassium canrenoate (Sigma-Aldrich, Germany) are used as the test articles, either as monotherapies or in double or in triple combined therapy.
- Dosing solutions of exenatide, CsA and potassium canrenoate were prepared just before the administration to the mice. Normal saline (0.9% NaCl) was used as a control.
- test/control articles were given intravenously, under general anaesthesia, in order to mimic the expected route of administration in the clinical setting of acute myocardial infarction and primary percutaneous coronary intervention.
- mice were randomly assigned to one of twenty (20) study arms. In all groups, mice were subjected to 30 min regional ischemia of the heart (coronary occlusion), followed by 120 min (2 h) reperfusion. In all cases, treatments (intravenous bolus administration of saline or test articles or their combinations) were performed 20 min after the onset of ischemia (10 min before the initiation of reperfusion). The experiments were terminated 2 h post-reperfusion (end of study); irreversible myocardial injury (infarct size by histomorphometry) at this time-point was evaluated, and was the primary-end-point of the study. The study design is summarized in Table 11.
- CANRENOATE 0.03 ⁇ g/Kg 30 min 120 min of potassium (n 8) (Last 10 min with canrenoate potassium canrenoate) P.
- CANRENOATE 0.3 ⁇ g/Kg 30 min 120 min of potassium (n 7) (Last 10 min with canrenoate potassium canrenoate) P.
- CANRENOATE 1 ⁇ g/Kg 30 min 120 min of potassium (n 8) (Last 10 min with canrenoate potassium canrenoate) P.
- CANRENOATE 1 ⁇ g/Kg (Last 10 min with and potassium (n 11) exenatide and canrenoate potassium canrenoate) EXENATIDE 0.05 ⁇ g/Kg + 30 min 120 min of exenatide P.
- CANRENOATE 10 ⁇ g/Kg (Last 10 min with and potassium (n 6) exenatide and canrenoate potassium canrenoate)
- CYCLOSPORINE 0.15 ⁇ g/Kg + 30 min 120 min of cyclosporine P.
- mice were anaesthetized by intraperitoneal injection (0.01 ml/Kg) with a combination of ketamine, xylazine and atropine (final doses of ketamine, xylazine and atropine were 100, 20 and 0.6 mg/Kg, respectively).
- Anaesthetic depth was evaluated by loss of pedal reflex to toe-pinch stimulus and breathing rate.
- a tracheotomy was performed for artificial respiration at 120-150 breaths/min and positive end-expiratory pressure 2.0 (0.2 ml of total tidal volume; Flexivent rodent ventilator, Scireq, Montreal, ON, Canada).
- a thoracotomy was then performed between the fourth and fifth ribs and the pericardium carefully retracted to visualize the left anterior descending (LAD), which was ligated using an 8-0 prolene monofilament polypropylene suture placed 1 mm below the tip of the left auricle.
- the heart was allowed to stabilize for 12 min prior to ligation to induce ischemia. After the ischemic period, the ligature was released allowing reperfusion of myocardium.
- body temperature was maintained at 37 ⁇ 0.5° C. by way of a heating pad and monitored via a thermocouple inserted rectally.
- mice were sacrificed with an intraperitoneal injection of the ketamine (200 mg/Kg) and xylazine (50 mg/Kg) anesthetic mixture (0.02 ml/Kg) hearts were rapidly excided from mice and directly cannulated and washed with 2.5 ml of saline heparin 1% for blood removal.
- Five ml of 1% TTC phosphate buffer 37° C. were infused into the coronary circulation; the tissue was incubated for 5 min in the same buffer. Evans Blue 1% diluted in distilled water (2.5 ml) was the infused into the heart.
- Hearts were kept at ⁇ 20° C.
- AAR was expressed as a percentage of the LV area (AAR/LV), and the IF was expressed as a percentage of the AAR (IF/AAR). In all cases, quantitative histomorphometry was performed by personnel blinded to the treatment assignment/study-design.
- the area of the left ventricle (LV) and the ischemic area (AAR) were similar in all animals and did not differ statistically between the study groups.
- the induction of ischemia (30 min) and reperfusion (120 min) in the control group resulted in significant injury to the myocardium of experimental animals (47.4 ⁇ 1.9%), indicating the sufficient implementation of the model and the reproducibility of the experimental procedure of the study.
- the exenatide monotherapy (0.001 ⁇ g/kg-1.5 ⁇ g/Kg) caused a dose-response effect with the doses of 0.005 ⁇ g/kg and 0.05 ⁇ g/kg to cause a reduction of infarct size by 36.9% (29.9 ⁇ 1.8%; P ⁇ 0.05) and 31.6% (32.4 ⁇ 1.9%; P ⁇ 0.05), respectively, compared with the control group.
- the cyclosporine monotherapy (0.001 mg/kg-2.5 mg/Kg) caused a dose-response effect with the doses of 0.01 mg/kg and 0.15 mg/kg to cause a reduction of infarct size by 43.7% (26.7 ⁇ 2.8%; P ⁇ 0.05) and 49.4% (24 ⁇ 1.9%; P ⁇ 0.05), respectively, compared with the control group.
- the potassium canrenoate monotherapy (0.03 mg/kg-10 mg/Kg) caused a dose-response effect with the doses of 1 mg/kg and 10 mg/kg to cause a reduction of infarct size by 30% (33.2 ⁇ 2.4%; P ⁇ 0.05) and 58.9% (19.5 ⁇ 2.5%; P ⁇ 0.05), respectively, compared with the control group.
- Double combination of exenatide and cyclosporine caused a reduction in the extent of infarct by 52.5% (22.5 ⁇ 2.3%; P ⁇ 0.05) compared to the control group. However, this effect was not statistically significant compared to the respective monotherapy doses of exenatide and cyclosporine.
- the double combination of exenatide and potassium canrenoate caused a reduction in the extent of infarct by 70.9% (13.8 ⁇ 1.3%; P ⁇ 0.01) compared to the control group.
- the effect of the combination was also statistically significant (P ⁇ 0.05) compared to the respective doses of exenatide and potassium canrenoate monotherapies.
- Table 12 presents data showing the ratios of area of risk to left ventricular and infarcted area to area of risk for each of group used in this study.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fats And Perfumes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- The present invention provides a new combination comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent, and (iii) an aldosterone antagonist, for instance, a combination comprising at least two of (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof. Said combinations are suitable for cardioprotection and/or for treating and/or preventing ischemia and/or reperfusion injury.
- Further aspects relate to pharmaceutical products and pharmaceutical compositions comprising said combinations according to the invention, and methods of treatment using the same.
- Acute myocardial infarction (AMI) is a major cause of mortality and morbidity worldwide. Each year, an estimated 785,000 persons (STEMI 500.000) will have a new AMI in the United States alone and approximately every minute an American will succumb to one (Roger et al., Circulation, 2012, 125: e2-e220). Every sixth man and every seventh woman in Europe will die from myocardial infarction (ESC Guidelines for the management of acute MI in patients presenting with ST-elevation, Eur. Heart J., 2012, 33:2569-2619).
- Currently, timely myocardial reperfusion using either thrombolytic therapy or primary percutaneous coronary intervention (PPCI) is the choice therapy for acute ST-segment elevation myocardial infarction (STEMI) patients (Worner et al., Rev Exp Cardiol., 2013, 66: 5-11). These interventions limit myocardial infarct (MI), preserve left-ventricular systolic function and reduce the onset of heart failure.
- However, mortality remains substantial in these patients with in-hospital mortality ranging between 6 and 14% (Mandelzweig et al., Eur. Heart J., 2006, 27: 2285-2293).
- Furthermore, morbidity remains substantial—MI is the leading cause of chronic heart failure—with about 5 to 6% of patients having a subsequent cardiovascular event by 30 days and re-hospitalisation at 1 year about 27%. (Lagerqvist et al., N. Engl. J. Med., 2014, 371:1111-20).
- Paradoxically, although myocardial reperfusion is essential for myocardial salvage, providing oxygen and nutrients to the ischemic area comes at a price, as it can in itself induce myocardial injury and cardiomyocyte death—a phenomenon termed “myocardial reperfusion injury”, the irreversible consequences of which include microvascular obstruction and myocardial infarction (Yellow and Hausenloy, N. Engl. J. Med., 2007, 357: 1121-1135). It is estimated that ischemia-reperfusion injury is responsible for approximately 50% of the final infarct area (Yetgin et al., Neth. Heart J., 2010; 28, 389-392). Previous attempts to translate cardioprotective therapies (i.e. antioxidants, calcium-channel blockers and anti-inflammatory agents) for reducing reperfusion injury into the clinic have been unsuccessful (Frohlich et al., Eur. Heart J., 2013, 34:1714-1724). There is currently no approved effective therapy for preventing myocardial reperfusion injury in reperfused-STEMI patients, making it an important residual target for cardioprotection.
- Pioneering work in the 1990s first implicated the mitochondrial permeability transition pore (MPTP) as a critical mediator of lethal myocardial reperfusion injury. The opening of the MPTP (a non-selective channel of the inner mitochondrial membrane) in the first few minutes of reperfusion leads to mitochondrial Ca2+ overload, oxidative stress, restoration of a physiological pH, and ATP depletion (Heusch et al, Basic Res Cardiol, 2010, 105: 151-154). These events induce cardiomyocytes death by uncoupling oxidative phosphorylation.
- Alterations in membrane proteins by free radicals are among the important factors in the evolution of myocardial reperfusion damage. Large quantities of reactive oxygen species (ROS) lead to overwhelming of the cellular endogenous antioxidant defenses. This causes, among other effects, the peroxidation of lipid membranes and loss of membrane integrity which results in necrosis and cell death (Zweier and Talukder, Cardiovasc Res, 2006, 70: 181-190). Re-introduction of abundant oxygen at the onset of reperfusion evokes a burst of additional toxic oxygen derivatives, including superoxide anion, hydroxyl radical and peroxynitrite, within the first few minutes of reflow. Moreover, oxidative stress also reduces the bioavailability of nitric oxide (vasodilator compound) at reperfusion, and the administration of NO donors is cardioprotective in animal models.
- There is presently a need for an effective treatment of reperfusion injury, particularly myocardial reperfusion injury.
- The present invention provides new combinations which are cardioprotective and suitable for prevention and/or treatment of reperfusion injury. The combinations and other aspects of the invention provide a treatment which is more efficacious and provides superior clinical outcomes compared to therapies which employ a single active pharmaceutical agent.
- A first aspect relates to a combination comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent, and (iii) an aldosterone antagonist.
- A second aspect relates to a combination comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof.
- A third aspect relates to a pharmaceutical composition comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent, and (iii) an aldosterone antagonist.
- A fourth aspect relates to a pharmaceutical composition comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
- A fifth aspect relates to a pharmaceutical product comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent, and (iii) an aldosterone antagonist.
- A sixth aspect relates to a pharmaceutical product comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof, and (iii) potassium canrenoate, or a functional derivative or analogue thereof.
- A seventh aspect relates to a combination or a pharmaceutical composition as defined above for use in the treatment and/or prevention of one or more of ischemia and/or reperfusion injury, ischemic stroke, cardiac arrest, acute myocardial infarction, neonatal asphyxia and cardiogenic shock, or for use in providing cardioprotection against cardiotoxic drugs.
- An eighth aspect relates to a pharmaceutical product as defined above for use in the treatment and/or prevention of one or more of ischemia and/or reperfusion injury, ischemic stroke, cardiac arrest, acute myocardial infarction, neonatal asphyxia and cardiogenic shock, or for use in providing cardioprotection against cardiotoxic drugs, wherein the components are for administration simultaneously, sequentially or separately.
- A ninth aspect relates to a method of treating and/or preventing one or more of ischemia and/or reperfusion injury, ischemic stroke, cardiac arrest, acute myocardial infarction, neonatal asphyxia and cardiogenic shock, or for providing cardioprotection against cardiotoxic drugs, said method comprising simultaneously, sequentially or separately administering to a subject in need thereof at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent, and (iii) an aldosterone antagonist.
- A tenth aspect relates to a method of treating and/or preventing one or more of ischemia and/or reperfusion injury, ischemic stroke, cardiac arrest, acute myocardial infarction, neonatal asphyxia and cardiogenic shock, or for providing cardioprotection against cardiotoxic drugs, said method comprising simultaneously, sequentially or separately administering to a subject in need thereof at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof, and (iii) potassium canrenoate, or a functional derivative or analogue thereof.
- An eleventh aspect relates to the use of at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent, and (iii) an aldosterone antagonist, in the manufacture of a medicament for the treatment and/or prevention of one or more of ischemia and/or reperfusion injury, ischemic stroke, cardiac arrest, acute myocardial infarction, neonatal asphyxia and cardiogenic shock, or for providing cardioprotection against cardiotoxic drugs.
- A twelfth aspect relates to the use of at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof, and (iii) potassium canrenoate, or a functional derivative or analogue thereof, in the manufacture of a medicament for the treatment and/or prevention of one or more of ischemia and/or reperfusion injury, ischemic stroke, cardiac arrest, acute myocardial infarction, neonatal asphyxia and cardiogenic shock, or for providing cardioprotection against cardiotoxic drugs.
- A thirteenth aspect relates to the use of a combination comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent, and (iii) an aldosterone antagonist, for treating and/or preventing ischemia and/or reperfusion injury in an ex vivo organ prior to or during transplantation.
- A fourteenth aspect relates to the use of a combination comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof, and (iii) potassium canrenoate, or a functional derivative or analogue thereof, for treating and/or preventing ischemia and/or reperfusion injury in an ex vivo organ prior to or during transplantation.
- The preferred embodiments set out below are applicable to any of the above-mentioned aspects of the invention as appropriate.
- In one embodiment, the combination of the invention comprises an insulin modulator.
- As used herein the term “insulin modulator” refers to an agent that is capable of directly or indirectly increasing or decreasing the activity of insulin, which in turn may increase or decrease the insulin-mediated physiological response.
- In a preferred aspect, the combination, methods, compositions and uses comprise an an insulin modulator as an essential feature.
- In one embodiment, the insulin modulator may be selected from GLP-1 agonists, DPP-4 inhibitors, PPAR agonists, insulin and analogues thereof.
- Examples of GLP-1 agonists include exenatide, lixisenatide, albiglutide, liraglutide, taspoglutide and dulaglutide (LY2189265) and pharmaceutically acceptable salts thereof.
- Examples of DPP-4 inhibitors include sitagliptin, vildagliptin, saxagliptin, linagliptin anagliptin, teneligliptin, alogliptin, trelagliptin, gemigliptin, dutogliptin and omarigliptin (MK-3102) and pharmaceutically acceptable salts thereof.
- Examples of PPAR agonists include clofibrate, gemfibrozil, ciprofibrate, bezafibrate, fenofibrate, saroglitazar, aleglitazar, muraglitazar and tesaglitazar and pharmaceutically acceptable salts thereof.
- Examples of insulin analogues include insulin lispro, insulin aspart, insulin glulisine, insulin detemir, insulin degludec, insulin glargine and pharmaceutically acceptable salts thereof.
- Accordingly, in one embodiment the insulin modulator may be selected from exenatide, lixisenatide, albiglutide, liraglutide, taspoglutide, dulaglutide (LY2189265), sitagliptin, vildagliptin, saxagliptin, linagliptin anagliptin, teneligliptin, alogliptin, trelagliptin, gemigliptin, dutogliptin, omarigliptin (MK-3102), clofibrate, gemfibrozil, ciprofibrate, bezafibrate, fenofibrate, saroglitazar, aleglitazar, muraglitazar tesaglitazar, insulin lispro, insulin aspart, insulin glulisine, insulin detemir, insulin degludec, insulin glargine and pharmaceutically acceptable salts thereof.
- In one embodiment, the insulin modulator is a GLP-1 agonist selected from exenatide, lixisenatide, albiglutide, liraglutide, taspoglutide, dulaglutide (LY2189265) and pharmaceutically acceptable salts thereof. Preferably, the GLP-1 agonist is exenatide.
- In one preferred embodiment, the insulin modulator is selected from exenatide and functional derivatives and analogues thereof, and pharmaceutically acceptable salts thereof.
- As used herein, the term “exenatide” refers to a 39-mer peptide of the following sequence:
- H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
- Exenatide (synonym is exendin 4) is originally isolated from the saliva of the Gila monster, Heloderma suspectum, by Eng in 1992. It is an insulin secretagogue with glucoregulatory effects similar to the human peptide glucagon-like peptide-1 (GLP-1).
- Exenatide mimics human glucagons-like peptide 1 (GLP-1), a gut incretin hormone that is release in response to nutrient intake (Goke et al., J. Biol. Chem., 1993, 268: 19650-19655). It exerts insulinotropic and insulinomimetic properties via the GLP-1 receptor. GLP-1 receptor is widely expressed in many organs, including heart and vascular endothelium (Bullock et al., Endocrinology, 1996, 137: 2968-2978; Nystrom et al., Am J Physiol Endocrinol Metab, 2004, 287: E1209-E1215). Currently, exenatide is approved as an anti-diabetic drug for the treatment of patients with diabetes mellitus type 2. The recommended dose in this indication is initially 5 μg (mcg) twice daily, increasing to 10 μg twice daily after 1 month based on clinical response.
- GLP-1 is ineffective as a therapeutic agent as it has a very short circulating half-life (less than 2 minutes) due to rapid degradation by dipeptidyl peptidase-4. Exenatide is 50% homologous to GLP-1, but has a 2.4 hours half-life in humans as the dipeptidyl peptidase-4 cleavage site is absent.
- Exenatide enhances glucose-dependent insulin secretion by the pancreatic beta-cell, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying. Exenatide is extremely potent, having a minimum effective concentration of 50 pg/mL (12 pM) in humans. Current therapies with exenatide involve twice-daily injections (Byetta®). Also, a slow-release formulation (Bydureon®) has been approved for once-weekly injection.
- As used herein a functional analogue of exenatide may refer to a compound having a similar structure, but differing from it in a respect of certain aspects (e.g. it can differ in one or more atoms, functional groups, amino acids residues, or substructures, which are replaced with others). Functional analogues display similar pharmacological properties and may be structurally related.
- In one embodiment, the functional derivative or analogue of exenatide is a form of exenatide that is modified so as to extend the half life, for example, conjugates of exenatide.
- In one preferred embodiment, the functional derivative or analogue of exenatide is PEGylated exenatide. For example, in one preferred embodiment, the functional derivative or analogue is exenatide mono-PEGylated with 40 kDa PEG. PEGylated exenatide can be prepared by methods known in the art. By way of example, PEGylated forms of exenatide are described in WO 2013/059323 (Prolynx LLC). Exenatide can also be conjugated to other molecules, e.g. proteins.
- In one particularly preferred embodiment, the functional derivative or analogue of exenatide is an extended release form, for example, that marketed under the tradename Bydureon®. In another preferred embodiment, the functional derivative or analogue of exenatide is in the form of multilayer nanoparticles for sustained delivery, for example, as described in Kim J Y et al, Biomaterials, 2013 November; 34(33):8444-9.
- In another particularly preferred embodiment, the exenatide is in an injectable form such as that marketed under the tradename Byetta®.
- As used herein a functional derivative or analogue of exenatide may refer to GLP receptor agonists. Suitable functional derivatives or analogues of exenatide of include lixisenatide, albiglutide, liraglutide, taspoglutide and dulaglutide (LY2189265).
- In one embodiment, a functional analogue of exenatide means exenatide modified wherein one or more amino acid residues has been exchanged for another amino acid residue and/or wherein one or more amino acid residues have been deleted and/or wherein one or more amino acid residues have been added and/or inserted.
- In one embodiment a functional exenatide analogue comprises less than 10 amino acid modifications (substitutions, deletions, additions (including insertions) and any combination thereof) relative to exenatide, alternatively less than 9, 8, 7, 6, 5, 4, 3 or 2 modifications relative to exenatide.
- In one embodiment a functional exenatide analogue comprises 10 amino acid modifications (substitutions, deletions, additions (including insertions) and any combination thereof) relative to exenatide, alternatively 9, 8, 7, 6, 5, 4, 3, 2 or 1 modifications relative to exenatide.
- As used herein, functional derivatives of exenatide include salts, isomers, enantiomers, solvates, polymorphs, prodrugs and metabolites thereof.
- In one embodiment, the combination of the invention comprises an immunosuppressive agent.
- As used herein, the term “immunosuppressive agent” refers to an agent capable of partially or fully suppressing the immune response in a subject.
- In one embodiment, the immunosuppressive agent is selected from a glucocorticoid, a cytostatic agent, a cytokine (e.g. interferons, interleukins, chemokines), an immunosuppressive antibody, a calcineurin inhibitor and a TNF binding protein.
- In one embodiment, the immunosuppressive agent is selected from an antimetabolite, a calcineurin inhibitor and a TNF binding protein.
- Examples of antimetabolites include methotrexate, azathioprine, mercaptopurine and fluorouracil, and pharmaceutically acceptable salts thereof.
- Examples of calcineurin inhibitors include cyclosporine, cyclosporine G, N-Methyl-4-isoleucine cyclosporine (also known as NIM811), tacrolimus and pimecrolimus, and pharmaceutically acceptable salts thereof.
- Examples of TNF binding proteins include infliximab, etanercept and adalimumab, and pharmaceutically acceptable salts thereof.
- Accordingly, in one embodiment, the immunosuppressive agent is selected from methotrexate, azathioprine, mercaptopurine, fluorouracil, cyclosporine, cyclosporine G, N-Methyl-4-isoleucine cyclosporine (also known as NIM811), tacrolimus, pimecrolimus, infliximab, etanercept and adalimumab, and pharmaceutically acceptable salts thereof.
- In one embodiment, the immunosuppressive agent is a calcineurin inhibitor. In one embodiment, the calcineurin inhibitor is selected from cyclosporine, cyclosporine G, N-Methyl-4-isoleucine cyclosporine (also known as NIM811), tacrolimus and pimecrolimus, and pharmaceutically acceptable salts thereof. Preferably, the calcineurin inhibitor is cyclosporine.
- In another embodiment, the calcineurin inhibitor is selected from cyclosporine, cyclosporine G, and N-Methyl-4-isoleucine cyclosporine (also known as NIM811) and pharmaceutically acceptable salts thereof.
- In another embodiment, the calcineurin inhibitor is cyclosporine, or a functional derivative or analogue, or a pharmaceutically acceptable salt thereof.
- The invention also encompasses functional derivatives and analogues of the above immunosuppressive agents, particularly those that are modified so as to extend the half life of the agent, for example conjugates of the agent.
- As used herein, the term “cyclosporine” or “cyclosporin” (also known as cyclosporine A) refers to the natural Tolypocladium inflatum cyclic non-ribosomal peptide with the systematic (IUPAC) name of: (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-Ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methyl-4-hexen-1-yl]-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone.
- Cyclosporine is an immunosuppressant agent used extensively to prevent organ rejection following allogenic transplants. For this indication, the recommended IV dose in this indication is 5 to 6 mg/kg/day initially. It remains an important tool for managing organ transplantation despite having deleterious effects on renal structure and function. Cyclosporine has also been shown to be effective in the treatment psoriasis, atopic dermatitis, pyoderma gangrenosum, chronic autoimmune urticaria, and rheumatoid arthritis. In these indications the recommended initial dose orally is 2.5 mg/kg/day divided in two administrations daily. However, because of the high degree of toxicity associated with the drug, cyclosporine is typically indicated for severe cases of these conditions. For transplant patients, cyclosporine is generally administered only intermittently, or cyclically, with close monitoring of renal function.
- In one embodiment, the present invention relates to a functional derivative or analogue of cyclosporine. In one embodiment, the functional derivative or analogue of cyclosporine is a form of cyclosporine that is modified so as to extend the half life, for example, conjugates of cyclosporine.
- As used herein, functional derivatives of cyclosporine include salts, isomers, enantiomers, solvates, polymorphs, prodrugs and metabolites thereof.
- As used herein a functional analogue of cyclosporine may refer to a compound having a similar structure, but differing from it in a respect of certain aspects (e.g. it can differ in one or more atoms, functional groups, amino acids residues, or substructures, which are replaced with others). Functional analogues display similar pharmacological properties and may be structurally related.
- In one embodiment, the functional derivative or analogue of cyclosporine is selected from cyclosporine G, N-Methyl-4-isoleucine Cyclosporine (also known as NIM811) tacrolimus and pimecrolimus, and pharmaceutically acceptable salts thereof. In another embodiment, the functional derivative or analogue of cyclosporine is selected from cyclosporine G and N-Methyl-4-isoleucine Cyclosporine (also known as NIM811) and pharmaceutically acceptable salts thereof.
- Cyclosporine G differs from cyclosporine A in the amino acid 2 position, where an L-norvaline replaces the α-aminobutyric acid. (See generally, Wenger, R. M. 1989, Synthesis of cyclosporine and analogues: structural and conformational requirements for immunosuppressive activity. Progress in Allergy, 38: 46-64).
- Aldosterone Antagonist In one embodiment, the combination of the invention comprises an aldosterone antagonist.
- In a preferred aspect, the combination, methods, compositions and uses of the invention comprise an aldosterone antagonist as an essential feature.
- Acute myocardial infarction and its subsequent hemodynamic changes lead to complex neurohormonal activation. The renin-angiotensin-aldosterone pathway is one corner stone of such neurohormonal activation. Aldosterone, which is at its highest levels at presentation after acute myocardial infarction, is reported to promote a broad spectrum of deleterious cardiovascular effects including acute endothelial dysfunction, inhibition of NO activity, increased endothelial oxidative stress, increased vascular tone, inhibition of tissue recapture of catecholamines, rapid occurrence of vascular smooth muscle cell and cardiac myocyte necrosis, collagen deposition in blood vessels, myocardial hypertrophy, and fibrosis (Struthers, Am Heart J, 2002, 144: S2-S7; Zannad and Radauceanu, Heart Fail Rev, 2005, 10: 71-78). Furthermore, it has been found to predict poor outcomes (Beygui et al, Circulation, 2006, 114: 2604-2610).
- An aldosterone antagonist or an antimineralocorticoid, is a diuretic drug which antagonizes the action of aldosterone at mineralocorticoid receptors. This group of drugs is often used for the management of chronic heart failure. Members of this class are also used in the management of hyperaldosteronism (including Conn's syndrome) and female hirsutism (due to additional antiandrogen actions). Most antimineralocorticoids are steroidal spirolactones.
- Antagonism of mineralocorticoid receptors inhibits sodium resorption in the collecting duct of the nephron in the kidneys. This interferes with sodium/potassium exchange, reducing urinary potassium excretion and weakly increasing water excretion (diuresis). In congestive heart failure, aldosterone antagonists are used in addition to other drugs for additive diuretic effect, which reduces edema and the cardiac workload.
- Current guidelines recommend the use of mineralocorticoid receptor antagonists, in patients presenting with heart failure post myocardial infarction, based on the results of the EPHESUS trial.
- Several studies in animal models of acute myocardial infarction and in the clinic have shown the benefit of aldosterone blockade in the prevention of reperfusion injury and improving heart function in STEMI patient.
- Examples of aldosterone antagonists include spironolactone (the first and most widely used member of this class), eplerenone (much more selective than spironolactone on target, but somewhat less potent and efficacious), canrenone and potassium canrenoate, finerenone (non-steroidal and more potent and selective than either eplerenone or spironolactone) and prorenone.
- In one particularly preferred embodiment, the aldosterone antagonist is potassium canrenoate.
- Some drugs also have antimineralocorticoid effects secondary to their main mechanism of actions. Examples include progesterone, drospirenone, gestodene, and benidipine.
- The invention also encompasses functional derivatives and analogues of the aldosterone antagonists, particularly those that are modified so as to extend the half life of the agent, for example, conjugates of aldosterone antagonists.
- Potassium canrenoate or canrenoate potassium also known as the potassium salt of canrenoic acid, is an aldosterone antagonist of the spirolactone group. Like spironolactone, it is a prodrug, which is metabolized to canrenone in the body. Potassium canrenoate is typically given intravenously at doses ranging between 200 mg/day and 600 mg/day for the treatment of hyperaldosteronism or hypokaliaemia.
- Potassium canrenoate has systematic (IUPAC) name potassium 3-[(8R,9S,10R,13S,14S,17R)-17-hydroxy-10,13-dimethyl-3-oxo-2,8,9,11,12,14,15,16 octahydro-1H-cyclopenta[a]phenanthren-17-yl]propanoate, formula C22H29KO4 and the following chemical structure:
- The invention also encompasses functional derivatives and analagues of potassium canrenoate, particularly those that are modified so as to extend the half life of the agent, for example, conjugates of potassium canrenoate.
- In one aspect, the present invention relates to a combination comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist.
- The preferred embodiments described below apply mutatis mutandis to other aspects of the invention, including methods, uses, products and compositions.
- In one highly preferred embodiment, the combination comprises an insulin modulator and an aldosterone antagonist.
- In another preferred embodiment, the combination comprises an insulin modulator and an immunosuppressive agent.
- In another embodiment, the combination comprises an immunosuppressive agent, and an aldosterone antagonist.
- In another preferred embodiment, the combination comprises (i) an insulin modulator, (ii) an immunosuppressive agent, and (iii) an aldosterone antagonist.
- In one embodiment, the insulin modulator is defined according to any of the above-mentioned embodiments of an insulin modulator.
- In one embodiment, the immunosuppressive agent is defined according to any of the above mentioned embodiments of an immunosuppressive agent.
- In one embodiment, the aldosterone antagonist is defined according to any of the above mentioned embodiments of an aldosterone antagonist.
- In another aspect, the present invention relates to a combination comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof and (iii) potassium canrenoate, or a functional derivative or analogue.
- In one embodiment, the present invention relates to a combination comprising (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof.
- In one embodiment, the present invention relates to a combination comprising at least two of the following components: (i) at least one of exenatide, lixisenatide, albiglutide, liraglutide, taspoglutide and dulaglutide (LY2189265), or a pharmaceutically acceptable salt thereof, (ii) at least one of cyclosporine A, cyclosporine G, N-Methyl-4-isoleucine cyclosporine, tacrolimus and pimecrolimus, or a pharmaceutically acceptable salt thereof and (iii) at least one of potassium canrenoate, canrenone, spironolactone, eplerenone, finerenone and prorenone or pharmaceutically acceptable salts thereof, where applicable (e.g. pharmaceutically acceptable salts of canrenone, spironolactone, eplerenone, finerenone and prorenone).
- In one embodiment, the present invention relates to a combination comprising (i) at least one of exenatide, lixisenatide, albiglutide, liraglutide, taspoglutide and dulaglutide (LY2189265), or a pharmaceutically acceptable salt thereof, and (iii) at least one of potassium canrenoate, canrenone, spironolactone, eplerenone, finerenone and prorenone or pharmaceutically acceptable salts thereof, where applicable.
- In one embodiment, the present invention relates to a combination comprising at least two of the following components: (I) at least one of exenatide, lixisenatide, albiglutide, liraglutide, taspoglutide and dulaglutide (LY2189265), or a pharmaceutically acceptable salt thereof, (ii) at least one of cyclosporine A, cyclosporine G and N-Methyl-4-isoleucine cyclosporine, or a pharmaceutically acceptable salt thereof and (iii) at least one of potassium canrenoate, canrenone, spironolactone, eplerenone, finerenone and prorenone or pharmaceutically acceptable salts thereof, where applicable.
- In one embodiment, the present invention relates to a combination of (i) exenatide or a pharmaceutically acceptable salt thereof, and (ii) at least one of cyclosporine A, cyclosporine G, N-Methyl-4-isoleucine cyclosporine, tacrolimus and pimecrolimus, or a pharmaceutically acceptable salt thereof.
- In one embodiment, the present invention relates to a combination of (i) exenatide or a pharmaceutically acceptable salt thereof, and (ii) at least one of cyclosporine A, cyclosporine G and N-Methyl-4-isoleucine cyclosporine, or a pharmaceutically acceptable salt thereof.
- In one embodiment, the present invention relates to a combination of (i) at least one of exenatide, lixisenatide, albiglutide, liraglutide, taspoglutide and dulaglutide (LY2189265), or a pharmaceutically acceptable salt thereof, and (ii) cyclosporine A or a pharmaceutically acceptable salt thereof.
- In one embodiment, the present invention relates to a combination of (i) exenatide or a pharmaceutically acceptable salt thereof, (ii) cyclosporine A or a pharmaceutically acceptable salt thereof, and (iii) potassium canrenoate.
- The effect of drug combinations is inherently unpredictable and there is often a propensity for one drug to partially or completely inhibit the effects of the other. The present invention demonstrates that a combination comprising at least two of (i) an insulin modulator, such as exenatide or a functional derivative or analogue or a pharmaceutically acceptable salt thereof, (ii) an immunosuppressive agent, such as cyclosporine or a functional derivative or analogue or a pharmaceutically acceptable salt thereof, and (iii) an aldosterone antagonist, such as potassium canrenoate or a functional derivative or analogue, when administered simultaneously, separately or sequentially, does not lead to any significant or dramatic adverse interaction between the two agents. The unexpected absence of any such antagonistic interaction is critical for clinical applications of the combination.
- Moreover, preferred combinations according to the invention surprisingly demonstrate a potentiation of the effect of the individual components, such that the optimal doses for the agents is lower than the doses recommended in the approved indications for these agents, and/or also lower (in all cases but potassium canrenoate) than the doses reported in the literature for reperfusion injury.
- In one embodiment, the combinations of the active agents of the present invention (see (i), (ii) and (iii) above) produce an enhanced effect as compared to each drug administered alone.
- Furthermore, in another embodiment, the combinations of the active agents of the present invention (see (i), (ii) and (iii) above) produce unexpected synergistic effects, for instance, in the treatment and/or prevention of reperfusion injury, particularly myocardial reperfusion injury.
- A combination of two or more drugs may lead to different types of drug interaction. A drug interaction is said to be additive when the combined effect of two drugs equals the sum of the effect of each agent given alone. A drug interaction is said to be synergistic if the combined effect of the two drugs exceeds the effects of each drug given alone (Goodman and Gilmans' “The Pharmacological Basis of Therapeutics”, 12th Edition).
- Combination therapy is an important treatment modality in many disease settings, including cardiovascular disease, cancer and infectious diseases. Recent scientific advances have increased our understanding of the pathophysiological processes that underlie these and other complex diseases. This increased understanding has provided further impetus to develop new therapeutic approaches using combinations of drugs directed at multiple therapeutic targets to improve treatment response, minimize development of resistance, or minimize adverse events. In settings in which combination therapy provides significant therapeutic advantages, there is growing interest in the development of new combinations of two or more drugs.
- Advantageously, a synergistic combination may allow for lower doses of each component to be present, thereby decreasing the toxicity of therapy, whilst producing and/or maintaining the same therapeutic effect or an enhanced therapeutic effect. Thus, in a particularly preferred embodiment, each component is present in a sub-therapeutic amount.
- The term “sub-therapeutically effective amount” means an amount that is lower than that typically required to produce a therapeutic effect with respect to treatment with each agent alone.
- In one embodiment, the present invention relates to a synergistic combination comprising (i) an insulin modulator, and (iii) an aldosterone antagonist.
- In one embodiment, the insulin modulator is defined according to any of the above mentioned embodiments of an insulin modulator.
- In one embodiment, the aldosterone antagonist is defined according to any of the above mentioned embodiments of an aldosterone antagonist.
- In one embodiment the present invention relates to a synergistic combination of (i) at least one of exenatide, lixisenatide, albiglutide, liraglutide, taspoglutide and dulaglutide (LY2189265), or a pharmaceutically acceptable salt thereof, and (iii) at least one of potassium canrenoate, canrenone, spironolactone, eplerenone, finerenone and prorenone or pharmaceutically acceptable salts thereof, where applicable.
- In one embodiment, the present invention relates to a synergistic combination of (i) exenatide or a pharmaceutically acceptable salt thereof, and (iii) potassium canrenoate.
- In one embodiment, the present invention relates to a synergistic combination of (i) at least one of exenatide, lixisenatide, albiglutide, liraglutide, taspoglutide and dulaglutide (LY2189265), or a pharmaceutically acceptable salt thereof, and (iii) potassium canrenoate.
- In one embodiment, the above described combinations comprise at least one further active pharmaceutical ingredient (API).
- In one embodiment, the above described combinations may further comprise at least one further API selected from a beta blocker, a renin-angiotensin inhibitor, a statin (HMG-CoA reductase inhibitor), an inhibitor of platelet activation or aggregation, a phosphodiesterase-3 inhibitor, a calcium sensitizer, an antioxidant and an anti-inflammatory agent.
- Examples of beta-blockers include propranolol, metoprolol, bucindolol, carteolol, carvedilol, labetalol, nadolol, oxprenolol, penbutolol, pindolol, sotalol and timolol.
- Renin-angiotensin inhibitors include angiotensin converting enzyme inhibitors, angiotensin AT1 receptor inhibitors and renin inhibitors.
- Examples of angiotensin converting enzyme inhibitors include captopril, zofenopril, enalapril, ramipril, quinapril, perindopril, lisinopril, benazepril, imidapril, trandolapril, cilazapril, and fosinopril.
- Examples of angiotension AT1 receptor antagonists include losartan, irbesartan, olmesartan, candesartan, valsartan, fimasartan and telmisartan.
- Examples of renin inhibitors include remikiren and aliskiren.
- Examples of calcium sensitizers include levosimendan and analogues thereof.
- Examples of statins include atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin.
- Examples of platelet activation or aggregation inhibitors include prostacyclin (epoprostenol) and analogues and derivatives thereof (eg. treprostinil, iloprost), irreversible cyclooxygenase inhibitors (e.g. Aspirin, Triflusal), adenosine diphosphate (ADP) receptor inhibitors (e.g. Clopidogrel, Prasugrel, Ticagrelor, Ticlopidine), phosphodiesterase inhibitors (e.g. Cilostazol), protease-activated receptor-1 (PAR-1) antagonists (e.g. Vorapaxar), glycoprotein IIB/IIIA inhibitors (e.g. Abciximab, Eptifibatide, Tirofiban), adenosine reuptake inhibitors (e.g. Dipyridamole), and thromboxane inhibitors, including thromboxane synthase inhibitors and thromboxane receptor antagonists (e.g. Terutroban).
- Examples of phosphodiesterase-3 (PDE-3) inhibitors include amrinone, milrinone, and analogues thereof.
- Examples of antioxidants include ascorbic acid, lipoic acid, glutathione and melatonin.
- Examples of anti-inflammatory agents include COX-2 inhibitors (e.g. celecoxib), glucocorticoids (e.g. hydrocortisone), and non-steroidal anti-inflammatory drugs (e.g. ibuprofen).
- In one embodiment, the above combinations comprise at least one further API selected from propranolol, metoprolol, bucindolol, carteolol, carvedilol, labetalol, nadolol, oxprenolol, penbutolol, pindolol, sotalol, timolol, captopril, zofenopril, enalapril, ramipril, quinapril, perindopril, lisinopril, benazepril, imidapril, trandolapril, cilazapril, fosinopril, losartan, irbesartan, olmesartan, candesartan, valsartan, fimasartan, telmisartan, remikiren and aliskiren.
- In another embodiment, the above combinations comprise at least one further API selected from carvedilol, metoprolol, losartan, irbesartan, olmesartan, candesartan, valsartan, fimasartan telmisartan, captopril, zofenopril, enalapril, ramipril, quinapril, perindopril, lisinopril, benazepril, imidapril, trandolapril, cilazapril, fosinopril, remikiren and aliskiren.
- In another embodiment, the above combinations comprise at least one further API selected from carvedilol and metoprolol.
- The active pharmaceutical agents of the present invention can be present as pharmaceutically acceptable salts.
- Pharmaceutically acceptable salts of the agents of the invention include suitable acid addition or base salts thereof. A review of suitable pharmaceutical salts may be found in Berge et al., J Pharm Sci, 66, 1-19 (1977). Salts are formed, for example with strong inorganic acids such as mineral acids, e.g. sulphuric acid, phosphoric acid or hydrohalic acids; with strong organic carboxylic acids, such as alkanecarboxylic acids of 1 to 4 carbon atoms which are unsubstituted or substituted (e.g., by halogen), such as acetic acid; with saturated or unsaturated dicarboxylic acids, for example oxalic, malonic, succinic, maleic, fumaric, phthalic or tetraphthalic; with hydroxycarboxylic acids, for example ascorbic, glycolic, lactic, malic, tartaric or citric acid; with aminoacids, for example aspartic or glutamic acid; with benzoic acid; or with organic sulfonic acids, such as (C1-C4)-alkyl- or aryl-sulfonic acids which are unsubstituted or substituted (for example, by a halogen) such as methane- or p-toluene sulfonic acid.
- The invention also includes where appropriate all enantiomers and tautomers of the active pharmaceutical agents. The man skilled in the art will recognise compounds that possess optical properties (one or more chiral carbon atoms) or tautomeric characteristics. The corresponding enantiomers and/or tautomers may be isolated/prepared by methods known in the art.
- Some of the active pharmaceutical agents of the invention may exist as stereoisomers and/or geometric isomers—e.g. they may possess one or more asymmetric and/or geometric centres and so may exist in two or more stereoisomeric and/or geometric forms. The present invention contemplates the use of all the individual stereoisomers and geometric isomers of those inhibitor agents, and mixtures thereof. The terms used in the claims encompass these forms, provided said forms retain the appropriate functional activity (though not necessarily to the same degree).
- The present invention also includes all suitable isotopic variations of the active pharmaceutical agents or pharmaceutically acceptable salts thereof. An isotopic variation of an agent of the present invention or a pharmaceutically acceptable salt thereof is defined as one in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature. Examples of isotopes that can be incorporated into the agent and pharmaceutically acceptable salts thereof include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulphur, fluorine and chlorine such as 2H, 3H, 13C, 14C, 15N, 170, 180, 31P, 32P, 35S, 18F and 36Cl, respectively. Certain isotopic variations of the agent and pharmaceutically acceptable salts thereof, for example, those in which a radioactive isotope such as 3H or 14C is incorporated, are useful in drug and/or substrate tissue distribution studies. Tritiated, i.e., 3H, and carbon-14, i.e., 14C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with isotopes such as deuterium, i.e., 2H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements and hence may be preferred in some circumstances. Isotopic variations of the agent of the present invention and pharmaceutically acceptable salts thereof of this invention can generally be prepared by conventional procedures using appropriate isotopic variations of suitable reagents.
- The present invention also includes solvate forms of the active pharmaceutical agents of the present invention. The terms used in the claims encompass these forms.
- The invention furthermore relates to active pharmaceutical agents of the present invention in their various crystalline forms, polymorphic forms and (an)hydrous forms. It is well established within the pharmaceutical industry that chemical compounds may be isolated in any of such forms by slightly varying the method of purification and or isolation from the solvents used in the synthetic preparation of such compounds.
- In another aspect, the present invention relates to a pharmaceutical composition comprising a combination comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist; and a pharmaceutically acceptable carrier, diluent or excipient.
- In another aspect, the present invention relates to a pharmaceutical composition comprising a combination comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or a pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or a pharmaceutically acceptable salt thereof and (iii) potassium canrenoate, or a functional derivative or analogue; and a pharmaceutically acceptable carrier, diluent or excipient.
- Even though the compounds of the present invention (including their pharmaceutically acceptable salts) can be administered alone, they will generally be administered in admixture with a pharmaceutical carrier, excipient or diluent, particularly for human therapy. The pharmaceutical compositions may be for human or non-human animal usage in human and veterinary medicine respectively.
- Examples of such suitable excipients for the various different forms of pharmaceutical compositions described herein may be found in the “Handbook of Pharmaceutical Excipients”, 2nd Edition, (1994), edited by A Wade and P J Weller.
- Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro edit. 1985).
- The choice of pharmaceutical carrier, excipient or diluent can be selected with regard to the intended route of administration and standard pharmaceutical practice. Examples of routes of administration include parenteral (e.g., intravenous, intramuscular, intradermal, intraperitoneal or subcutaneous), oral, inhalation, transdermal (topical), intraocular, iontophoretic, and transmucosal administration.
- In one embodiment, the pharmaceutical composition is for parenteral administration (e.g., intravenous, intraarterial, intrathecal, intramuscular, intradermal, intraperitoneal or subcutaneous). Preferably, the compositions are prepared from sterile or sterilisable solutions.
- In another embodiment, the pharmaceutical composition is for intravenous, intramuscular, or subcutaneous administration.
- In another embodiment, the pharmaceutical composition is for intravenous administration.
- Solutions or suspension used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl-alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediamine-tetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
- Pharmaceutical compositions suitable for injectable use can include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ or phosphate buffered saline (PBS). In all cases, a composition for parenteral administration must be sterile and should be fluid to the extent that easy syringeability exists. It should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
- Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compounds into a sterile vehicle, which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, typical methods of preparation include vacuum drying and freeze drying, which can yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. The invention also encompasses liposomal and nanoparticulate formulations comprising the active agents. Such formulations, along with methods for their preparation, will be familiar to a person of ordinary skill in the art.
- In another aspect, the present invention relates to a pharmaceutical product comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist.
- In another aspect, the present invention relates to a pharmaceutical product comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof and (iii) potassium canrenoate, or a functional derivative or analogue.
- In one embodiment, the pharmaceutical product is a kit of parts containing all necessary equipment (e.g., vials of drug, vials of diluent, syringes and needles) for a treatment course.
- In one embodiment, the kit comprises separate containers for each active agent. Said containers may be ampoules, disposable syringes or multiple dose vials.
- In another embodiment, the kit comprises a container which comprises a combined preparation of each active agent.
- The kit may further comprise instructions for the treatment and/or prevention of reperfusion injury.
- In one aspect, the present invention relates to a combination comprising at least two of the following components: (i) an insulin modulator (ii) an immunosuppressive agent, and (iii) an aldosterone antagonist for use in the treatment and/or prevention of one or more of ischemia and/or reperfusion injury, ischemic stroke, cardiac arrest, acute myocardial infarction, neonatal asphyxia and cardiogenic shock, or for use in providing cardioprotection against cardiotoxic drugs.
- In one aspect, the present invention relates to a combination comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically, acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue, for use in the treatment and/or prevention of one or more of ischemia and/or reperfusion injury, ischemic stroke, cardiac arrest, acute myocardial infarction, neonatal asphyxia and cardiogenic shock, or for use in providing cardioprotection against cardiotoxic drugs.
- In another aspect, the present invention relates to a pharmaceutical composition comprising a combination comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist for use in the treatment and/or prevention of one or more of ischemia and/or reperfusion injury, ischemic stroke, cardiac arrest, acute myocardial infarction, neonatal asphyxia and cardiogenic shock, or for use in providing cardioprotection against cardiotoxic drugs.
- In another aspect, the present invention relates to a pharmaceutical composition comprising a combination comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue, for use in the treatment and/or prevention of one or more of ischemia and/or reperfusion injury, ischemic stroke, cardiac arrest, acute myocardial infarction, neonatal asphyxia and cardiogenic shock, or for use in providing cardioprotection against cardiotoxic drugs.
- In another aspect, the present invention relates to a pharmaceutical product comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist, for use in the treatment and/or prevention of one or more of ischemia and/or reperfusion injury, ischemic stroke, cardiac arrest, acute myocardial infarction, neonatal asphyxia and cardiogenic shock, or for use in providing cardioprotection against cardiotoxic drugs, wherein the components are for administration simultaneously, sequentially or separately.
- In another aspect, the present invention relates to a pharmaceutical product comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof and (iii) potassium canrenoate, or a functional derivative or analogue, for use in the treatment and/or prevention of one or more of ischemia and/or reperfusion injury, ischemic stroke, cardiac arrest, acute myocardial infarction, neonatal asphyxia and cardiogenic shock, or for use in providing cardioprotection against cardiotoxic drugs, wherein the components are for administration simultaneously, sequentially or separately.
- In another aspect, the present invention relates to use of at least two of the following components: (i) an insulin modulator and (ii) an immunosuppressive agent and (iii) an aldosterone antagonist in the manufacture of a medicament for the treatment and/or prevention of one or more of ischemia and/or reperfusion injury, ischemic stroke, cardiac arrest, acute myocardial infarction, neonatal asphyxia and cardiogenic shock or for providing cardioprotection against cardiotoxic drugs.
- In another aspect, the present invention relates to use of at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof and (iii) potassium canrenoate, or a functional derivative or analogue thereof in the manufacture of a medicament for the treatment and/or prevention of one or more of ischemia and/or reperfusion injury, ischemic stroke, cardiac arrest, acute myocardial infarction, neonatal asphyxia and cardiogenic shock, or for providing cardioprotection against cardiotoxic drugs.
- In one embodiment, the present invention relates to a combination comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist for use in the treatment and/or prevention of reperfusion injury.
- In one embodiment, the present invention relates to a combination comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof and (iii) potassium canrenoate, or a functional derivative or analogue thereof, for use in the treatment and/or prevention of reperfusion injury.
- In another embodiment, the present invention relates to a pharmaceutical composition comprising a combination comprising at least two of the following components: (i) an insulin modulator (ii) an immunosuppressive agent and (iii) an aldosterone antagonist for use in the treatment and/or prevention of reperfusion injury.
- In another embodiment, the present invention relates to a pharmaceutical composition comprising a combination comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof, for use in the treatment and/or prevention of reperfusion injury.
- In another embodiment, the present invention relates to a pharmaceutical product comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist for use in the treatment and/or prevention of reperfusion injury, wherein the components are for administration simultaneously, sequentially or separately.
- In another embodiment, the present invention relates to a pharmaceutical product comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof, for use in the treatment and/or prevention of reperfusion injury, wherein the components are for administration simultaneously, sequentially or separately.
- In another embodiment, the present invention relates to use of at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist in the manufacture of a medicament for the treatment and/or prevention of reperfusion injury.
- In another embodiment, the present invention relates to use of at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof in the manufacture of a medicament for the treatment and/or prevention of reperfusion injury.
- In one embodiment, the present invention relates to a combination comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist for use in the treatment and/or prevention of ischemia.
- In one embodiment, the present invention relates to a combination comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof, for use in the treatment and/or prevention of ischemia.
- In another embodiment, the present invention relates to a pharmaceutical composition comprising a combination comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist for use in the treatment and/or prevention of ischemia.
- In another embodiment, the present invention relates to a pharmaceutical composition comprising a combination comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof, for use in the treatment and/or prevention of ischemia.
- In another embodiment, the present invention relates to a pharmaceutical product comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist for use in the treatment and/or prevention of ischemia, wherein the components are for administration simultaneously, sequentially or separately.
- In another embodiment, the present invention relates to a pharmaceutical product comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof, for use in the treatment and/or prevention of ischemia, wherein the components are for administration simultaneously, sequentially or separately.
- In another embodiment, the present invention relates to use of at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist in the manufacture of a medicament for the treatment and/or prevention of ischemia.
- In another embodiment, the present invention relates to use of at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof, in the manufacture of a medicament for the treatment and/or prevention of ischemia.
- As used herein, the term “reperfusion injury” refers to the damage to tissue caused when blood supply returns to the tissue after a period of ischemia. The absence of oxygen and nutrients from blood creates a condition in which the restoration of circulation results in inflammation, mitochondrial dysfunction and oxidative damage through the induction of oxidative stress rather than restoration of normal function. Reperfusion injury can occur after a spontaneously occurring event, e.g., arterial blockage, or a planned event, e.g., any of a number of surgical interventions. Myocardial reperfusion injury can occur, for example, after myocardial infarction or as a result of heart transplantation.
- In one embodiment, the ischemia and/or reperfusion injury may be ischemia and/or reperfusion injury of the brain, heart, lung, kidney, or other organ/tissue susceptible to ischemia and/or reperfusion injury.
- In one embodiment, the ischemia and/or reperfusion injury is ischemia and/or reperfusion injury of the heart, preferably myocardial ischemia and/or myocardial reperfusion injury.
- The insulin modulator, the immunosuppressive agent and aldosterone antagonist may be for administration simultaneously, sequentially or separately (as part of a dosing regimen).
- Exenatide or functional derivatives or analogues or pharmaceutically acceptable salts thereof, cyclosporine or functional derivatives or analogues or pharmaceutically acceptable salts thereof, and potassium canrenoate or functional derivatives or analogues thereof, may be for administration simultaneously, sequentially or separately (as part of a dosing regimen).
- As used herein, “simultaneously” is used to mean that the two agents are administered concurrently.
- As used herein, “sequentially” is used to mean that the active agents are not administered concurrently, but one after the other. Thus, administration “sequentially” may permit one agent to be administered within 5 minutes, 10 minutes or a matter of hours after the other provided the circulatory half-life of the first administered agent is such that they are both concurrently present in therapeutically effective amounts. The time delay between administrations of the components will vary depending on the exact nature of the components, the interaction there between, and their respective half-lives.
- In contrast to “sequentially”, “separately” is used herein to mean that the gap between administering one agent and the other is significant i.e. the first administered agent may no longer be present in the bloodstream in a therapeutically effective amount when the second agent is administered.
- In one embodiment, the components of the combination are for simultaneous administration.
- In another aspect, the present invention relates to a method of treating and/or preventing ischemia and/or reperfusion injury, said method comprising simultaneously, sequentially or separately administering to a subject at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist.
- In another aspect, the present invention relates to a method of treating and/or preventing ischemia and/or reperfusion injury, said method comprising simultaneously, sequentially or separately administering to a subject in need thereof at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof.
- In one embodiment, the present invention relates to a method of treating and/or preventing reperfusion injury, said method comprising simultaneously, sequentially or separately administering to a subject in need thereof at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist.
- In one embodiment, the present invention relates to a method of treating and/or preventing reperfusion injury, said method comprising simultaneously, sequentially or separately administering to a subject in need thereof at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof.
- In another embodiment, the present invention relates to a method of treating and/or preventing ischemia, said method comprising simultaneously, sequentially or separately administering to a subject in need thereof at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist.
- In another embodiment, the present invention relates to a method of treating and/or preventing ischemia, said method comprising simultaneously, sequentially or separately administering to a subject in need thereof at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof.
- In one embodiment, the method relates to treating and/or preventing ischemia and/or reperfusion injury of the brain, heart, lung, kidney, or other organ/tissue susceptible to ischemia and/or reperfusion injury.
- In one embodiment, the method relates to treating and/or preventing reperfusion injury of the brain, heart, lung, kidney, or other organ/tissue susceptible to reperfusion injury.
- In one embodiment, the method relates to treating and/or preventing ischemia of the brain, heart, lung, kidney, or other organ/tissue susceptible to ischemia.
- In another embodiment, the method relates to treating and/or preventing ischemia and/or reperfusion injury of the heart, preferably myocardial ischemia and/or myocardial reperfusion injury.
- In another embodiment, the method relates to treating and/or preventing reperfusion injury of the heart, preferably myocardial reperfusion injury.
- In one particularly preferred embodiment, the method relates to treating and/or preventing acute myocardial infarction. Acute myocardial infarction is one of the most common clinical indications of reperfusion injury.
- In another embodiment, the method relates to treating and/or preventing neonatal asphyxia.
- Neonatal asphyxia (or perinatal asphyxia) is the medical condition resulting from deprivation of oxygen to a newborn infant that lasts long enough during the birth process to cause physical harm, usually to the brain. The most common cause of neonatal asphyxia is a drop in maternal blood pressure or other interference to the blood flow to the infant's brain during delivery, for example, due to inadequate circulation or perfusion, impaired respiratory effort, or inadequate ventilation.
- Neonatal asphyxia can cause hypoxic damage to most of the infant's organs (heart, lungs, liver, gut, kidneys), but brain damage is of most concern and perhaps the least likely to quickly or completely heal. In more pronounced cases, an infant will survive, but with damage to the brain manifested as either mental, such as developmental delay or intellectual disability, or physical, such as spasticity. An infant suffering severe perinatal asphyxia usually has poor color (cyanosis), perfusion, responsiveness, muscle tone, and respiratory effort. Extreme degrees of asphyxia can cause cardiac arrest and death. Neonatal asphyxia occurs in 2 to 10 per 1000 newborns that are born at term, and in higher instances for those that are born prematurely. WHO estimates that 4 million neonatal deaths occur yearly due to birth asphyxia, representing 38% of deaths of children under 5 years of age.
- In another embodiment, the method relates to treating and/or preventing ischemia of the heart, preferably myocardial ischemia.
- In one embodiment, the subject is a mammal, more preferably a human.
- In one embodiment, the method comprises parenterally (e.g., intravenously, intramuscularly, intradermally, intraperitoneally or subcutaneously) administering the components to the subject.
- In another embodiment, the method comprises intravenously, intramuscularly, or subcutaneously administering the components to the subject.
- In another embodiment, the method comprises intravenously administering (the components to the subject.
- Each component can be administered by the same or different route to the other components. Preferably, the components are administered by the same route.
- In one embodiment, the claimed combinations are administered to a donor subject and/or a recipient subject prior to and/or during and/or after heart transplant. For example, in some embodiments the combination may be administered to a first subject from which the heart organ will be removed for transplantation into a second subject. Additionally or alternatively, in some embodiments, the combination is administered to the extracted heart organ, prior to introduction into the second subject. Additionally or alternatively, in some embodiments, the combination therapy is administered to the second subject before, during and/or after heart transplant.
- In one embodiment, the claimed combinations are for administration to a subject with cardiogenic shock. Cardiogenic shock is a life-threatening medical condition resulting from an inadequate circulation of blood due to primary failure of the ventricles of the heart to function effectively. The condition occurs in 2-10% of patients hospitalized due to myocardial infarction and is the main cause of death among these patients (Holmes et al, 1995, J Am Coll Cardiol, 26: 668-674). More specifically, cardiogenic shock is the result of a complex process with failure of oxygen delivery, generalized ATP deficiency, and multi-organ dysfunction initiated by cardiac pump failure (Okuda, 2006, Shock, 25: 557-570). As this is a type of circulatory shock, there is insufficient perfusion of tissue to meet the demands for oxygen and nutrients. The condition involves increasingly more pervasive cell death from oxygen starvation (hypoxia) and nutrient starvation (e.g. low blood sugar). Because of this, it may lead to cardiac arrest (or circulatory arrest), which is an abrupt stopping of cardiac pump function (as well as stopped respiration and a loss of consciousness). Cardiogenic shock is defined by sustained low blood pressure with tissue hypoperfusion despite adequate left ventricular filling pressure. Signs of tissue hypoperfusion include low urine production (<30 mL/hour), cool extremities, and altered level of consciousness. Several large trials have demonstrated that coronary revascularization is the most important strategy to improve patient survival (Hochman et al, 1999, N Engl J Med, 341: 625-634). However, patients who develop cardiogenic shock despite acute revascularization have a poor prognosis, likely due to reperfusion injury and considered to be associated to the resulted infarct size. Indeed, hypothermia has shown to offer tissue protection in myocardial ischemia, and preclinical studies have shown beneficial results in reducing infarct size in experimentally induced myocardial infarction (Dae et al, 2002, Am J Physiol Heart Circ Physiol, 282: H1584-H1591). Accordingly, in a pig model mild therapeutic hypothermia reduced acute mortality in cardiogenic shock, and improved hemodynamic parameters (Gotberg et al, 2010, Resuscitation, 81: 1190-1196).
- In one embodiment, the claimed combinations are for administration to a subject with cardiac arrest. Cardiac arrest is a sudden stop in effective blood flow due to the failure of the heart to contract effectively. The most common cause of cardiac arrest is coronary artery disease. Treatment for cardiac arrest is immediate cardiopulmonary resuscitation (CPR) and if a shockable rhythm is present defibrillation. In the United States cardiac arrest outside of hospital occurs in about 13 per 10,000 people per year (326,000 cases). In hospital cardiac arrest occurs in an additional 209,000 (Kronic et al, Circulation, 2015, 132: S397-S413). In addition to providing high quality cardiopulmonary resuscitation, optimizing the management for post-cardiac arrest syndrome is critically important for improving the long term outcome for cardiac arrest patients. Within this syndrome (“post-cardiac arrest syndrome”) there are 3 major areas of emphasis: (1) post-cardiac arrest brain injury; (2) post-cardiac arrest myocardial dysfunction and reperfusion injury; and (3) systemic ischemia-reperfusion response. It is now clear that post-resuscitation care can affect long-term survival and the myocardial and neurological recovery and function of survivors (Kern, 2015, Circ J, 79: 1156-1163). The inhibition of mitochondrial permeability transition pore (MPTP) opening during ischemia-reperfusion can ameliorate injuries in heart and other systemic organs. Indeed, it has been shown in an animal model of cardiac arrest that post-cardiac arrest myocardial dysfunction and survival can be improved by cyclosporine treatment (Huang et al, 2011, Resuscitation, 82S: S41-S47).
- In one embodiment, the claimed combinations are for administration to a subject with stroke. Stroke is when poor blood flow to the brain results in cell death. There are two main types of stroke: ischemic, due to lack of blood flow, and hemorrhagic, due to bleeding. They result in part of the brain not functioning properly. Signs and symptoms of a stroke may include an inability to move or feel on one side of the body, problems understanding or speaking, feeling like the world is spinning, or loss of vision to one side among others. An ischemic stroke is typically caused by blockage of a blood vessel. Ischemic stroke treatment includes surgery to open up (reperfusion) the arteries to the brain in those with problematic narrowing. An ischemic stroke, if detected within three to four and half hours, may be treatable with a medication that can break down the clot. In 2013, stroke was the second most frequent cause of death after coronary artery disease, accounting for 6.4 million deaths (12% of the total).
- Ischemic stroke and acute myocardial infarction require emergency reperfusion in order to improve functional outcome (Patel and Saver, 2013, Stroke, 44: 94-98). Intravenous tissue-type plasminogen activator has long been the only reperfusion therapy with proven clinical benefit in patients with acute ischemic stroke. As it happens in acute myocardial infarction, endovascular methods restoring reperfusion in acute ischemic stroke may expose patients to increased ischemic/reperfusion injury, thereby hampering the benefit of recanalization by promoting hemorrhagic transformation and severe vasogenic edema both considering as markers of reperfusion injury (Bai and Lyden, 2015, Int J Stroke, 10: 143-152). Experimental evidence indicates that brain ischemic reperfusion injury (as happens in myocardial reperfusion injury) may be attenuated by ischemic pre- and post-conditioning. In addition, experimental evidence suggests that mitochondrial permeability transition pore (MPTP) plays a critical role both in myocardial and brain ischemic reperfusion injury (Schinzel et al, 2005, Proc Natl Acad Sci USA, 102: 12005-12010) and cyclosporine A, (a MPTP opening inhibitor) may prevent brain ischemic reperfusion injury in animal models (Leger et al, 2011, Exp Neurol, 230: 58-66; Borlongan et al, 2005, Life Sci, 76: 1503-1512).
- In one embodiment the subject is at risk of (or susceptible to) vessel occlusion injury or cardiac ischemia-reperfusion injury.
- In one embodiment, the claimed combinations are for use in, or methods of, providing cardioprotection in a subject against the cardiotoxic effects of drugs (e.g. anthracyclins). Examples of cardiotoxic drugs are described in Bovelli et al (Annals of Oncology 21 (Supplement 5): v277-v282, 2010).
- As used herein, the term “cardioprotection” refers to protecting the heart, for example, by preventing, reducing or delaying myocardial injury. Cardiotoxic drugs include drugs associated with cardiac heart failure, drugs associated with ischaemia or thromboembolism, drugs associated with hypertension, drugs associated with other toxic effects such as tamponade and endomyocardial fibrosis, haemorrhagic myocarditis, bradyarrhythmias, Raynaud's phenomenon, autonomic neuropathy, QT prolongation or torsades de pointes, or pulmonary fibrosis. Examples of cardiotoxic drugs include anthracyclines/anthraquinolones, cyclophosphamide, Trastuzumab and other monoclonal antibody-based tyrosine kinase inhibitors, antimetabolites (fluorouracil, capecitabine), antimicrotubule agents (paclitaxel, docetaxel), cisplatin, thalidomide, bevacizumab, sunitinib, sorafenib, busulfan, paclitaxel, vinblastine, bleomycin, vincristine, arsenic trioxide, bleomycin, methotrexate.
- In one embodiment, the components are administered simultaneously.
- In one embodiment, the (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof, and (iii) potassium canrenoate, or a functional derivative or analogue thereof are administered simultaneously.
- In one embodiment, the components are administered sequentially or separately.
- For a three component combination, all three components can be administered simultaneously, or any two components can be administered simultaneously, with the third component administered separately or sequentially. Alternatively, all three components can be administered in any order separately or sequentially.
- In one embodiment, (i) is administered prior to sequentially or separately administering (ii).
- In another embodiment, (ii) is administered prior to sequentially or separately administering (i).
- In one embodiment, (i) is administered prior to sequentially or separately administering (iii).
- In one embodiment, (iii) is administered prior to sequentially or separately administering (i).
- In one embodiment, the (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof, and (iii) potassium canrenoate, or a functional derivative or analogue thereof, are administered sequentially or separately.
- In one embodiment, the components are each administered in a therapeutically effective amount with respect to the individual components.
- In one embodiment, the (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof, and (iii) potassium canrenoate, or a functional derivative or analogue thereof, are each administered in a therapeutically effective amount with respect to the individual components.
- As used herein, the term “therapeutically effective amount” refers to a quantity sufficient to achieve a desired therapeutic and/or prophylactic effect, e.g., an amount which results in the prevention of, or a decrease in, ischemia and/or reperfusion injury or one or more symptoms associated with ischemia and/or reperfusion injury.
- In the context of therapeutic or prophylactic applications, the amount of a composition administered to the subject will depend on the type and severity of the disease and on the characteristics of the individual, such as general health, age, sex, body, weight and tolerance to drugs. It will also depend on the degree severity and type of disease. The skilled artisan will be able to determine appropriate dosages depending on these and other factors. The composition can also be administered in combination with one or more additional therapeutic agents.
- In one embodiment, the components are each administered in a sub-therapeutically effective amount with respect to the individual components.
- In one embodiment, the (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof, and (iii) potassium canrenoate, or a functional derivative or analogue thereof, are each administered in a sub-therapeutically effective amount with respect to the individual components.
- In one embodiment, the components are administered prior to reperfusion the subject.
- In one embodiment, the (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof, and (iii) potassium canrenoate, or a functional derivative or analogue thereof, are administered prior to reperfusion the subject.
- In one embodiment, the components are administered during reperfusion of the subject.
- In one embodiment, the (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof, and (iii) potassium canrenoate, or a functional derivative or analogue thereof, are administered during reperfusion of the subject.
- In one embodiment, the components are administered after reperfusion of the subject.
- In one embodiment, the (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof, and (iii) potassium canrenoate, or a functional derivative or analogue thereof, are administered after reperfusion of the subject.
- In one embodiment, the components are administered prior to and/or during, and/or after reperfusion of the subject.
- In one embodiment, the (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof, and (iii) potassium canrenoate, or a functional derivative or analogue thereof, are administered prior to, during and after reperfusion of the subject.
- In some embodiments of the method, the subject is administered (i) continuously before, during, and after reperfusion of the subject and is administered (ii) as a bolus dose prior to reperfusion.
- In some embodiments of the method, the subject is administered (ii) continuously before, during, and after reperfusion of the subject and is administered (i) as a bolus dose prior to reperfusion.
- In some embodiments of the method, the subject is administered (i), (ii) and (iii) continuously before, during, and after reperfusion of the subject.
- In some embodiments of the method, additional administration of one or more of the components may occur after reperfusion. Preferably, this repeat administration is carried out at least twice, more preferably from 2 to 100 times, or can be in the form of continuous infusion.
- In some embodiments of the method, the subject is administered the components as a bolus dose prior to reperfusion.
- In some embodiments of the method, the subject is administered the components as a bolus dose during reperfusion.
- In some embodiments of the method, the subject is administered the components as a bolus dose after reperfusion.
- As used herein “reperfusion” is the restoration of blood flow to any organ or tissue in which the flow of blood is decreased or blocked. For example, blood flow can be restored to any organ or tissue affected by ischemia or hypoxia. The restoration of blood flow (reperfusion) can occur by any method known to those in the art. For instance, reperfusion of ischemic cardiac tissues may arise from revascularization.
- In one embodiment, reperfusion is achieved via a revascularization procedure. In one embodiment, the revascularization procedure is selected from the group consisting of: percutaneous coronary intervention; balloon angioplasty; insertion of a bypass graft; insertion of a stent; directional coronary atherectomy; treatment with a one or more thrombolytic agent(s); and removal of an occlusion.
- In one embodiment, the one or more thrombolytic agents are selected from the group consisting of: tissue plasminogen activator; urokinase; prourokinase; streptokinase; acylated form of plasminogen; acylated form of plasmin; and acylated streptokinase-plasminogen complex.
- A person of ordinary skill in the art can easily determine an appropriate dose of one of the instant compositions to administer to a subject without undue experimentation. Typically, a physician will determine the actual dosage which will be most suitable for an individual patient and it will depend on a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the individual undergoing therapy. The dosages disclosed herein are exemplary of the average case. There can of course be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.
- In one highly preferred embodiment of the invention, the dose of the insulin modulator (e.g. exenatide) in the combination is generally lower than the dose typically used in monotherapy in the context of its currently approved therapies, and/or lower than the general doses reported in the reperfusion injury literature.
- In one highly preferred embodiment of the invention, the dose of the immunosuppressive agent (e.g. cyclosporine) in the combination is generally lower than the dose typically used in monotherapy in the context of its currently approved therapies, and/or lower than the general doses reported in the reperfusion injury literature.
- When used in the presently claimed combinations, exenatide is preferably administered in a dose of from about 0.001 to about 1.5 μg/kg, more preferably from about 0.005 to about 0.15 μg/kg.
- When used in the presently claimed combinations, potassium canrenoate is preferably administered in a dose of from about 0.03 to about 10, preferably from about 1 to about 10 mg/kg, more preferably, from about 1 to about 5 mg/kg, even more preferably, from about 1 to about 3 mg/kg.
- When used in the presently claimed combinations, cyclosporine is preferably administered in a dose of from about 0.001 to about 10 mg/kg, more preferably from about 0.01 to about 5 mg/k, even more preferably from about 0.01 to about 2.5 mg/kg.
- In one highly preferred embodiment, the combination is a fixed dose combination comprising predetermined dosages of the respective components (e.g. about 0.005 to about 0.05 μg/kg exenatide and from about 1 to about 3 mg/kg potassium canrenoate, more preferably, about 0.05 μg/kg exenatide and 1 mg/kg potassium canrenoate).
- In another aspect, the present invention relates to use of a combination comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist for treating and/or preventing ischemia and/or reperfusion injury in an ex vivo organ prior to or during transplantation.
- In another aspect, the present invention relates to use of a combination comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof for treating and/or preventing ischemia and/or reperfusion injury in an ex vivo organ prior to or during transplantation.
- In one embodiment, the present invention relates to use of a combination comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist for treating and/or preventing reperfusion injury in an ex vivo organ prior to or during transplantation.
- In one embodiment, the present invention relates to use of a combination comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or a pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or a pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof for treating and/or preventing reperfusion injury in an ex vivo organ prior to or during transplantation.
- In one embodiment, the present invention relates to use of a combination comprising at least two of the following components: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist for treating and/or preventing ischemia in an ex vivo organ prior to or during transplantation.
- In one embodiment, the present invention relates to use of a combination comprising at least two of the following components: (i) exenatide, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue, or pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof for treating and/or preventing ischemia in an ex vivo organ prior to or during transplantation.
- An ex vivo (removed from the body) organ can be susceptible to reperfusion injury due to lack of blood flow. Therefore, the combination of the present invention can be used to prevent reperfusion injury in the removed organ. Preferably, the organ is a heart, liver or kidney, more preferably, a heart.
- In some embodiments, the removed organ is placed in a standard buffered solution, such as those commonly used in the art, containing the combination of the invention. For example, a removed heart can be placed in a cardioplegic solution containing exenatide and cyclosporine. The concentration of exenatide, cyclosporine and potassium canrenoate useful in the standard buffered solution can be easily determined by those skilled in the art. Such concentrations may be, for example, between about 0.1 nM to about 10 μM, preferably about 1 nM to about 10 μM.
- The present invention is further illustrated by the following examples, which should not be construed as limiting in any way.
- Studies suggest that treatment with exenatide can attenuate/mitigate myocardial injury resulting from an ischemia-reperfusion (I/R) insult as can occur clinically following acute myocardial infarction (AMI) and/or percutaneous coronary intervention/angioplasty (PCI). Exenatide (0.150 μg/Kg IV bolus), when given prior to the onset of reperfusion, may have myocardial sparing effects. In addition, studies suggest that treatment with cyclosporine-A (CsA) can attenuate/mitigate myocardial injury resulting from an I/R insult as can occur clinically following AMI and/or PCI. CsA (2.5 mg/Kg IV bolus), when given prior to the onset of reperfusion, may have myocardial sparing effects. This study was designed to test the combined cardioprotective effects of exenatide and CsA in a setting that mimics the clinical scenario of an acute I/R insult. The study was conducted under the hypothesis that combined treatment with exenatide and CsA after the onset of ischemia (but prior to reperfusion) would provide a more pronounced myocardial protective effect compared to exenatide or cyclosporine treatment alone.
- New Zealand White rabbits were used in this study. The rabbits were males, >8 weeks in age and with a weight between 2.9 and 3.8 Kg. Approvals from the Ethical Committees and the veterinary authorities were obtained before the study was started. Environmental controls in the animal rooms were set to maintain temperature of 22° to 28° C. and relative humidity between 30% and 70%. Room temperature and humidity were recorded hourly and monitored daily. There were approximately 10-15 air exchanges per hour in the animal rooms. Photoperiod was 12-hours light and 12-hours dark. Routine daily observations were performed. Certified standard rabbit diet was provided, approximately 180 grams per day from arrival to the facility.
- Exenatide peptide [Byetta®, 10 μg/injected dose (40 μl), Eli Lilly Nederland B.V.] and, cyclosporine A [CsA, Sandimmun® (50 mg/ml) Novartis Pharma A.G., Switzerland] are used as the test articles, either in monotherapy or in combined therapy. Dosing solutions of exenatide (0.15 μg/Kg in of normal saline) and/or CsA (2.5 mg/Kg in normal saline) were prepared just before the administration to the rabbits. Normal saline (0.9% NaCl) was used as a control.
- The test/control articles were given intravenously, under general anaesthesia, in order to mimic the expected route of administration in the clinical setting of acute myocardial infarction and primary percutaneous coronary intervention. Intravenous boluses were administered via a peripheral vein (rabbit auricular vein).
- The study followed a predetermined placebo and sham controlled design. In brief, 80 healthy, acclimatized, male rabbits were randomly assigned to one of three study arms. Arm A (n=4, SHAM) includes sham-operated time-controls treated with normal saline (NS; IV); Arm B (n=18, CONTROL/PLACEBO) includes I/R animals treated with normal saline (NS; IV); Arm C (n=18, EXENATIDE, 0.15 μg/Kg) includes I/R animals treated with exenatide; Arm D (n=18, CYCLOSPORINE, 2.5 mg/Kg, IV) includes I/R animals treated with CsA; Arm E (n=22, EXENATIDE+CYCLOSPORINE, IV) includes I/R animals treated with exenatide and CsA.
- In I/R groups (arm B, C, D and E), rabbits were subjected to 40 min regional ischemia of the heart (coronary occlusion), followed by 120 min (2 h) reperfusion. In all cases, treatments (intravenous bolus administration of NS or exenatide or CsA or exenatide plus CsA) were performed 30 min after the onset of ischemia (10 min before the initiation of reperfusion). In all cases, cardiovascular function was monitored both prior to and during ischemia, as well as for up to 120 min (2 h) post-reperfusion. The experiments were terminated 2 h post-reperfusion (end of study); irreversible myocardial injury (infarct size by histomorphometry) at this time-point was evaluated, and was the primary-end-point of the study. The study design is summarized in Table 1
-
TABLE 1 Experimental protocol Group Study Group (no. of animals) lschemia Time Reperfusion Time A SHAM - for surgery without 0 min 120 min of placebo ischemia (Last 10 min (NS) (n = 4) with NS) B CONTROL/PLACEBO 40 min 120 min of placebo (n = 18) (Last 10 min (NS) with NS) C EXENATIDE 0.15 μg/Kg 40 min 120 min of (n = 18) (Last 10 min exenatide with exenatide) D CYCLOSPORINE 2.5 μg/Kg 40 min 120 min of CsA (n = 18) (Last 10 min with CsA) E EXENATIDE + 40 min 120 min of CYCLOSPORINE (Last 10 min exenatide + CsA (n = 22) with exenatide + CsA) - General anesthesia was induced intramuscularly (IM) with a ketamine (˜35-50 mg/Kg) and xylazine (˜5-10 mg/Kg) mixture. In order to preserve autonomic function and to maintain anesthesia throughout the experimental procedure, animals received additional anesthesia as required (˜10-15 mg ketamine/30 min or ˜15-20 mg/Kg sodium pentobarbital). A venous catheter was placed in a peripheral vein (e.g., ear auricular vein) for the administration of additional anesthetics and normal saline/test articles. The effect of anesthesia is assessed by (i) the total abolishment of animal's corneal reflex, (ii) the total abolishment of animal's respiratory centre and the total mechanical ventilation without any resistance to airflow caused by animal's spontaneous breathing, and (iii) the stability of the hemodynamic parameters. A cuffed tracheal tube was placed via a tracheotomy (ventral midline incision) and used to mechanically ventilate the lungs with a 95% O2/5% CO2 mixture via a volume-cycled animal ventilator (˜40 breaths/min with a tidal volume of ˜12.5 ml/Kg) in order to sustain PaCO2 values broadly within the physiological range. Throughout the experimental procedure, electrocardiogram, arterial pressure, cardiac pulses, and capnogram were continuously monitored. A temperature probe was inserted into the rectum and body temperature was maintained using a heating pad. Finally, an arterial catheter was placed in a peripheral artery (e.g., ear) for blood sampling.
- Subsequently, the animals were placed in left-lateral recumbence and the chest was surgically opened with a left thoracotomy. The chest was opened through the left fourth intercostals space. The beating heart was exposed and the pericardium was incised. Under the atrial appendage, the first large anterolateral branch of the circumflex artery and if necessary, depending on each animal's coronary anatomy, the circumflex artery itself, was circled with a 3-0 silk suture. Coronary artery occlusion in this region normally results in ischemia of a large territory of the anterolateral and apical ventricular wall. The ends of the suture were threaded through a small piece of polyethylene tubing, forming a snare. Ischemia was induced by pulling the thread through the tubing, which was firmly positioned against the coronary arterial wall with the aid of a small clamp. Ischemia resulted in ST elevation on the electrocardiogram and a change in the color (i.e., cyanotic) of the myocardium. After 30 min of ischemia, the animals administered with IV bolus of either vehicle (normal saline) or exenatide or CsA or the combination of exenatide and CsA; ischemia was continued for additional 10 min (i.e., 40 min total ischemia time) after the treatment. At the end of ischemic period, the coronary snares were released and the previous ischemic myocardium was reperfused for up to 2 hours. It should be noted that in sham-operated animals the vessel snares were manipulated at the time of ischemia-reperfusion onset, but were not either tightened or loosened.
- Hemodynamic variables and rectal temperature were monitored and recorded at 6 predetermined time-points: post-anesthesia (baseline), just before ischemia initiation (preocclusion), 30 min (vehicle/test articles administration) of ischemia, as well as at 30, 60, and 120 min post reperfusion. In addition, in order to determine/quantify the degree of irreversible myocardial injury (i.e., infarction) resulting from the I/R insult with and without exenatide or CsA or their combination, infarcted area were evaluated.
- Venous (<3 mL) whole blood samples were collected for the evaluation of myocardial injury via cardiac biomarker analyses at two data-collection time-points: baseline, and 120 min post-reperfusion. Cardiac troponin-I (cTnI), as the most valuable and reliable clinically used biomarker, was measured. cTnI was determined with a biochemical analyzer (Triage® Cardiac Panel, Alere San Diego, Inc. CA, USA).
- At the completion of the protocol, irreversible myocardial injury (i.e., infarction) resulting from the I/R insult was evaluated. In brief, after the end of reperfusion, hearts were excised, mounted on an apparatus, and perfused with normal saline for 2 min for blood removal. Then the coronary ligature was retightened at the same site and 5 mL of green fluorescent polymer microsphere solution (8 mg/ml; diameter 3-8 μm; Fluoro-Max™, Thermo Scientific, CA, USA) was infused for the separation of the normally perfused area (no ischemic area) and to delineate the myocardial area-at-risk (AAR, ischemic area) during ischemia. Hearts were kept at −20° C. for 24 hours and sectioned perpendicular to its long axis (from apex to base) into 3 mm thick slices. Subsequently, the slices were incubated for 20 min in 2% triphenyl-tetrazolium-chloride (TTC, Sigma, St. Louis, Mo., USA) at 37° C., and fixed in a 10% non-buffered formalin solution.
- Following fixation, the total left ventricular area (LV), the area-at-risk (AAR), and the infarct area (IF) were delineated/measured digitally. With a wavelength of 366 nm UV light, it was separated in each slide the ischemic area (AAR) from infarcted zone (IF) and no ischemic area. All areas were traced onto an acetate sheet. The tracings were subsequently imported into an image analysis program (Image J; National Institutes of Health), and computer-assisted planometry was performed to determine the overall size of the left ventricular (LV), the area-at-risk (AAR) and the infarct (IF). For each slide, the AAR was expressed as a percentage of the LV area (AAR/LV), and the IF was expressed as a percentage of the AAR (IF/AAR). In all cases, quantitative histomorphometry was performed by personnel blinded to the treatment assignment/study-design.
- Obtained data from the above experiment procedure were tabulated and calculated using Excel work sheets. Statistical analysis was performed with SPSS version 21.0 (SPSS Inc., IL, USA). Values are presented as mean±standard error (SEM). Statistical comparisons of numeric variables among the three groups were analyzed using the one-way analysis of variance (ANOVA) model with Bonferroni correction analysis. A calculated P-value of less than 0.05 was considered to be statistically significant.
- Hemodynamic variables, mean arterial pressures and heart rate, are shown in the Table 2. Baseline values were similar in all groups. As we typically see in our rabbit model, arterial pressures decrease after surgery and occlusion and most significantly at the end of reperfusion. There were no significant differences among groups in this pressure variable. All groups followed a similar pattern over time.
-
TABLE 2 Hemodynamic parametersa Baseline Pre- 30 min of 30 min of 60 min of 120 min of HR occlusion Ischemia Reperfusion Reperfusion Reperfusion Group MAP HR MAP HR MAP HR MAP HR MAP HR MAP SHAM 221 ± 5 225 ± 7 228 ± 7 227 ± 5 229 ± 4 231 ± 3 89 ± 6 71 ± 5 73 ± 6 69 ± 3 68 ± 3 70 ± 4 CONTROL 208 ± 6 215 ± 7 218 ± 7 217 ± 5 219 ± 6 221 ± 8 83 ± 2 68 ± 3 70 ± 4 62 ± 4 56 ± 2 44 ± 3 EXENATIDE 217 ± 11 220 ± 3 219 ± 5 221 ± 3 224 ± 6 226 ± 2 86 ± 3 59 ± 4 64 ± 4 58 ± 3 54 ± 2 50 ± 3 CYCLOSPORINE 215 ± 2 218 ± 6 220 ± 4 218 ± 3 224 ± 8 225 ± 2 81 ± 3 70 ± 2 67 ± 3 66 ± 3 57 ± 2 47 ± 2 EXENATIDE + 219 ± 3 223 ± 9 224 ± 5 221 ± 7 226 ± 3 228 ± 3 CYCLOSPORINE 83 ± 2 64 ± 2 69 ± 4 66 ± 2 66 ± 2 51 ± 3 aValues are mean ± SEM; HR: mean heart rate in beats/min; MAP: mean arterial blood pressure; - The LV size and AAR size were comparable in all-treated animals, indicating that the initial left ventricular and ischemic area did not differ significantly between the groups.
- Although the administration of exenatide or CsA resulted in decreased infarct size compared to the control, the administration of the combination of exenatide and CsA resulted in a superior decrease of infarct size. Similarly, whereas exenatide or CsA reduced cTnI release by 48% and 36%, respectively, the combined therapy of exenatide and cyclosporine reduced cTnI release by 61% (62.6±10.7, P<0.001).
- Table 3 presents data showing cardiac troponin I levels, the ratios of area of risk to left ventricular, infarcted area to left ventricular, and infarcted area to area of risk for each of group used in this study.
-
TABLE 3 Study biochemical and histopathology Results cTnI Different (%) Significance (ng/mL AAR/LV (% IF/LV (% IF/AAR (% in IF/AAR in IF/AAR Group mean ± SEM) mean ± SEM) mean ± SEM) mean ± SEM) from Control versus Control SHAM n = 4 10.5 ± 3.5 56.5 ± 7 1.21 ± 0.2 2.3 ± 0.4 −94 P < 0.001 CONTROL n = 18 159 ± 10.4 58 ± 2.4 21.9 ± 7.8 37.7 ± 2.1 EXENATIDE n = 18 82.6 ± 7 55.3 ± 2.2 12.8 ± 4.9 23.5 ± 2 −38 P < 0.001 (0.15 μg/Kg) CYCLOSPORINE n = 18 101.7 ± 10 63.2 ± 2.5 14.28 ± 6.5 22.7 ± 2.3 −40 P < 0.01 (2.5 mg/Kg) EXENATIDE + 62.6 ± 10.7 61.5 ± 3.4 10.09 ± 5.1 16.8 ± 1.7 −55 P < 0.001 CYCLOSPORINE n = 22 - These results show that in a standardized rabbit model of acute myocardial ischemia and reperfusion injury, the combined therapy of exenatide and CsA when administrated as an IV bolus (0.15 μg/Kg and 2.5 mg/Kg, respectively) at 10 min before the initiation of reperfusion was able to produce a greater reduction in the myocardial infarct size compared to exenatide or CsA monotherapy groups. Accordingly, these results demonstrate for first time that in therapy of myocardial reperfusion injury the combined administration of cyclosporine and exenatide is more beneficial and advantageous and provides superior clinical outcome against therapies either with cyclosporine or exenatide alone. As such, combined exenatide and CsA is exceptionally useful in methods at preventing and treating ischemia-reperfusion injury in mammalian subjects.
- This study was designed to investigate the cardioprotective effects of exenatide, CsA and their combinations in a variety of doses and in a rat model of myocardial reperfusion injury. The study was conducted under the hypothesis that combination therapy with exenatide and CsA, after the onset of ischemia and prior to reperfusion, would also result in enhanced reduction of infarct size in an additional animal model.
- Wistar rats were used in this study. The rats were males and with a weight between 266 and 370 g. Approvals from the Ethical Committees and the veterinary authorities were obtained before the study was started. The animals were housed in individually ventilated cages using HEPA-filtered air, which conform to the size recommendations in the most recent Guide for the Care and Use of Laboratory Animals DHEW (NIH) and Directive 2010/63/EU on the protection of animals used for scientific purposes. Environmental controls in the animal rooms were set to maintain temperature of 22° to 28° C. and relative humidity between 30% and 70%. Litter material placed beneath the cage was changed at least three times a week. There were approximately 10-15 air exchanges per hour in the animal rooms. Photoperiod was 12-hours light and 12-hours dark. Routine daily observations were performed. The animals were conditioned to the housing facilities for at least 3 days prior to testing. Standard laboratory rat chow and filtered tap water was available ad libitum.
- Exenatide (Byetta®, Eli Lilly Nederland B.V.) and CsA (Sandimmun®, Novartis Pharma A.G., Switzerland) are used as the test articles, either in monotherapy or in combined therapy. Dosing solutions of exenatide and/or CsA were prepared just before the administration to the rats. Normal saline (0.9% NaCl) was used as a control.
- The study followed a predetermined placebo controlled design. In brief, 130 healthy, acclimatized, male rats were randomly assigned to one of ten study arms. All animals were subjected to 30 min regional ischemia of the heart (coronary occlusion), followed by 120 min (2 h) reperfusion. In all cases, treatments (intravenous bolus administration of NS or exenatide or CsA or their combinations) were performed 20 min after the onset of ischemia (10 min before the initiation of reperfusion). In all cases, cardiovascular function was monitored both prior to and during ischemia, as well as for up to 120 min (2 h) post-reperfusion. The experiments were terminated 2 h post-reperfusion (end of study); irreversible myocardial injury (infarct size by histomorphometry) at this time-point was evaluated, and was the primary-end-point of the study. The study design is summarized in Table 4.
-
TABLE 4 Experimental protocol Study Group (no. of animals) lschemia Time Reperfusion Time CONTROL (saline) 30 min 120 min of saline (n = 11) (Last 10 min with saline) EXENATIDE 0.03 μg/Kg 30 min 120 min of exenatide (n = 11) (Last 10 min with exenatide) CYCLOSPORINE 0.5 mg/Kg 30 min 120 min of CsA (n = 12) (Last 10 min with CsA) EXENATIDE 0.03 μg/Kg + 30 min 120 min of exenatide CYCLOSPORINE 0.5 mg/Kg (Last 10 min with and CsA (n= 12) exenatide and CsA) EXENATIDE 0.15 μg/Kg 30 min 120 min of exenatide (n = 12) (Last 10 min with exenatide) CYCLOSPORINE 2.5 mg/Kg 30 min 120 min of CsA (n = 12) (Last 10 min with CsA) EXENATIDE 0.15 μg/Kg + 30 min 120 min of exenatide CYCLOSPORINE 2.5 mg/Kg (Last 10 min with and CsA (n = 11) exenatide and CsA) EXENATIDE 1 μg/Kg 30 min 120 min of exenatide (n = 12) (Last 10 min with exenatide) CYCLOSPORINE 10 mg/Kg 30 min 120 min of CsA (n = 14) (Last 10 min with CsA) EXENATIDE 1 μg/Kg + 30 min 120 min of exenatide CYCLOSPORINE 10 mg/Kg (Last 10 min with and CsA (n = 11) exenatide and CsA) - Male Wistar rats were anaesthetized by intraperitoneal (IP) injection of pentobarbital (Euthazol, Produlab Pharma b.v., Raamsdonksveer, The Netherlands; 60 mg/Kg bolus dose followed by 15-20 mg/Kg when required during the experiment). The rats were weighted and stomach and chest areas shaved. Maintenance of the body temperature was assisted using a constant temperature heating pad. The trachea was intubated with a plastic cannula connected to a rodent ventilator. The animals were ventilated with room air (6.2 ml/Kg, 70±5 breath/min). Blood pressure, surface-lead ECG, and body core temperature were monitored throughout the experiments to ensure the stability of the preparation. The right carotid artery was cannulated for measurement of blood pressure and the right jugular vein was cannulated for the administration of the test articles. A thoracotomy was performed at the 5th intercostals space and the heart was exposed. A 5-0 Prolene suture was placed around the left descending coronary artery. The coronary artery was then occluded for 30 min by placing the ligature through a small piece of plastic tubing and pulling the snare tightly in place using a haemostat. After 30 min of coronary occlusion, reperfusion was initiated by releasing the snare and continued for 120 min.
- Hemodynamic variables were monitored and recorded at 6 predetermined time-points: post-anesthesia (baseline), just before ischemia initiation (preocclusion), 20 min (vehicle/test articles administration) of ischemia, as well as at 30, 60, and 120 min post reperfusion. In addition, in order to determine/quantify the degree of irreversible myocardial injury (i.e., infarction) resulting from the I/R insult with and without exenatide or CsA or the exenatide and Csa treatment, cardiac biomarkers as well as infarct area were evaluated.
- At the end of the 120 min reperfusion period, the heart was taken out and infarct size was determined. Briefly, the left anterior descending coronary artery was re-occluded and the heart was perfused with 4 ml of 0.3% (w/v) Evans-blue dye (Sigma-Aldrich) with a constant 100cmH2O pressure into the aorta to delineate the area-at-risk zone. The non-ischemic perfused tissue area was stained blue, while the risk zone remained unstained. Stained hearts were rapidly frozen (−20° C. for at least 2 hours), cut into 2 mm thick slices and each slice was incubated at 37° C. in 1.5 ml of 1% (w/v) TTC (Merck Biosciences) dissolved in 50 mM phosphate buffer (pH 7.4) for 10 min. Slices were then transferred to 10% formalin solution for 5 min.
- Following fixation, the total left ventricular area (LV), the area-at-risk (AAR), and the infarct area (IF) were delineated/measured digitally. Slices were placed between glass plates and digital photos were taken from both sides of the heart slices. The differently stained areas of images were quantified by digital planimetry (Infarctsize™ 2.5, Pharmahungary, Szeged, Hungary). Evaluation of all images was carried out in a blinded manner by an experienced person throughout the study. For each slide, the AAR was expressed as a percentage of the LV area (AAR/LV), and the IF was expressed as a percentage of the AAR (IF/AAR).
- Obtained data from the above experiment procedure were tabulated and calculated using Excel work sheets. Statistical analysis was performed with SPSS version 21.0 (SPSS Inc., IL, USA). Values are presented as mean±standard error (SEM). Differences among means of endpoint measurements (i.e. infarct size, AAR) were analyzed by using one-way-ANOVA followed by Tukey post hoc test to make comparisons of each group to the control when appropriate. Differences among means of continuous variables (i.e. hemodynamic data) were analyzed by repeated measures two-way-ANOVA followed by Tukey posthoc test. A calculated P-value of less than 0.05 was considered to be statistically significant.
- Hemodynamic variables, mean arterial pressures and heart rate, are shown in the Table 5. Baseline values were similar in all groups. As we typically see in our rat model, arterial pressures decrease after surgery and occlusion and most significantly at the end of reperfusion. There were no significant differences among groups in this pressure variable. All groups followed a similar pattern over time.
-
TABLE 5 Hemodynamic parameters Pre- 20 min of 30 min of 60 min of 120 min of Baseline occlusion Ischemia Reperfusion Reperfusion Reperfusion Group HR MAP HR MAP HR MAP HR MAP HR MAP HR MAP CONTROL (saline) (n = 11) 427 455 434 434 421 441 112 114 102 88 82 87 EXENATIDE 0.03 μg/Kg 449 439 404 426 404 388 (n = 11) 108 93 71 69 72 71 CYCLOSPORINE 0.5 mg/Kg 421 444 419 419 421 412 (n = 12) 115 110 89 95 80 72 EXENATIDE 0.03 μg/Kg + 430 444 413 410 402 416 CYCLOSPORINE 0.5 mg/Kg 111 95 65 73 72 67 (n = 12) EXENATIDE 0.15 μg/Kg 426 455 439 407 435 435 (n = 12) 119 107 88 75 82 77 CYCLOSPORINE 2.5 mg/Kg 425 468 411 408 438 374 (n = 12) 109 92 72 81 84 67 EXENATIDE 0.15 μg/Kg + 432 460 415 438 388 404 CYCLOSPORINE 2.5 mg/Kg 109 109 81 87 81 68 (n = 11) EXENATIDE 1 μg/Kg 418 449 439 455 469 404 (n = 12) 111 111 92 93 94 86 CYCLOSPORINE 10 mg/Kg 424 445 411 400 425 404 (n = 14) 114 105 93 89 90 86 EXENATIDE 1 μg/Kg + 425 447 441 439 454 469 CYCLOSPORINE 10 mg/Kg 115 107 85 89 90 87 (n = 11) HR: mean heart rate in beats/min; MAP: mean arterial blood pressure in mmHg.. - The LV size and AAR size were comparable in all-treated animals, indicating that the initial left ventricular and ischemic areas did not differ significantly between the groups. Administration of exenatide or CsA exhibited a dose-dependent effect. In particular, treatment of animals with lower doses of exenatide and CsA resulted in significant decreased infarct size compared to the control, whereas higher doses were without effects. Interestingly, the administration of the combination of low doses of exenatide and CsA resulted in a superior decrease of infarct size. Whereas, exenatide at dose of 0.03 μg/Kg reduced infarcted area by 27% (45.9±1.4; P<0.05) and CsA at 0.5 mg/Kg by 26.6% (46.2±3.7; P<0.05), respectively, the combined therapy of exenatide and CsA reduced infarcted area by 39.1% (38.3±2.7; P<0.05), as compared to control (62.9±3.7).
- Table 6 presents data showing the ratios of area of risk to left ventricular, and infarcted area to area of risk for each of group of the study.
-
TABLE 6 Study histopathology results AARILV IF/AAR Different (%) in Significance in (% (% IF/AAR from IF/AAR versus Group Control mean ± SEM) mean ± SEM) Control CONTROL (saline) 47.7 ± 2.9 62.9 ± 3.7 — (n = 11) EXENATIDE 0.03 μg/Kg 44.1 ± 3 45.9 ± 1.4 −27 P < 0.05 (n = 11) CYCLOSPORINE 42.6 ± 2.2 46.2 ± 3.7 −26.6 P < 0.05 0.5 mg/Kg (n= 12) EXENATIDE 0.03 μg/Kg + 42.1 ± 3.5 38.3 ± 2.7 −39.1 P < 0.05 CYCLOSPORINE 0.5 μg/Kg (n = 12) EXENATIDE 0.15 μg/Kg 49.8 ± 3.5 61.5 ± 4.1 −2.2 Non (n= 12) significant CYCLOSPORINE 47.3 ± 2.6 61 ± 4.1 −3 Non 2.5 μg/Kg significant (n = 12) EXENATIDE 0.15 μg/Kg + 44.7 ± 3.5 58.8 ± 5.1 −6.5 Non CYCLOSPORINE significant 2.5μg/Kg (n= 11) EXENATIDE 1 μg/Kg 38.9 ± 2.4 52.6 ± 2.9 16.4 Non (n= 12) significant CYCLOSPORINE 38.7 ± 3.1 54.3 ± 3.5 −13.7 Non 10μg/Kg significant (n= 14) EXENATIDE 1 μg/Kg + 46.2 ± 4.1 51.5 ± 2.5 −18.1 Non CYCLOSPORINE significant 10 mg/Kg (n= 11) - These results show that in an additional standardized animal (rat) model of acute myocardial ischemia and reperfusion injury, the combined therapy of exenatide and CsA was also able to produce a greater reduction in the myocardial infarct size compared to exenatide or CsA monotherapies. However, in the present rat model the cardioprotective effect was evident in lower doses compared to rabbit model of Example 1, indicating that different species may respond differently to exenatide or CsA or to their combination. The fact that the duration of the ischemia was longer in the rabbit model may also be accountable for the difference of the effects seen in the two species. Nevertheless, these results again demonstrate that in therapy of myocardial reperfusion injury the combined administration of CsA and exenatide is more beneficial and advantageous and provides superior clinical outcome against therapies either with cyclosporine or exenatide alone. As such, combined exenatide and CsA is exceptionally useful in methods at preventing and treating ischemia-reperfusion injury in mammalian subjects.
- Studies suggest that treatment with potassium canrenoate can attenuate/mitigate myocardial injury resulting from an I/R insult as can occur clinically following AMI and/or PCI. This study was designed to test the combined cardioprotective effects of exenatide and potassium canrenoate in a setting that mimics the clinical scenario of an acute I/R insult. The study was conducted under the hypothesis that combined treatment with exenatide and potassium canrenoate after the onset of ischemia (but prior to reperfusion) would provide a more pronounced myocardial protective effect compared to exenatide or potassium canrenoate treatment alone.
- New Zealand White rabbits were used in this study. The rabbits were males, >8 week in age and with a weight between 2.6 and 3.8 Kg. All animals were treated according to the Directive 2010/63/UE European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes, and conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1985). Approvals from the Ethical Committees and the veterinary authorities were obtained before the study was started. Environmental controls in the animal rooms were set to maintain temperature of 22° to 28° C. and relative humidity between 30% and 70%. Room temperature and humidity were recorded hourly and monitored daily. There were approximately 10-15 air exchanges per hour in the animal rooms. Photoperiod was 12-hours light and 12-hours dark. Routine daily observations were performed. Certified standard rabbit diet was provided, approximately 180 grams per day from arrival to the facility.
- Exenatide (Byetta®; Eli Lilly Nederland B.V.] and potassium canrenoate (Sigma-Aldrich, Germany) are used as the test articles, either in monotherapy or in combined therapy. Dosing solutions of exenatide (0.15 μg/Kg in of normal saline) and/or potassium canrenoate (1 mg/Kg in normal saline) were prepared just before the administration to the rabbits. Normal saline (0.9% NaCl) was used as a control.
- The test/control articles were given intravenously, under general anaesthesia, in order to mimic the expected route of administration in the clinical setting of acute myocardial infarction and primary percutaneous coronary intervention. Intravenous boluses were administered via a peripheral vein (rabbit auricular vein).
- The study followed a predetermined placebo controlled design. In brief, 52 healthy, acclimatized, male rabbits were randomly assigned to one of four study arms. In all groups, rabbits were subjected to 30 min regional ischemia of the heart (coronary occlusion), followed by 180 min (3 h) reperfusion. In all cases, treatments (intravenous bolus administration of saline or exenatide or potassium canrenoate or their combination) were performed 15 min after the onset of ischemia (15 min before the initiation of reperfusion). The experiments were terminated 3 h post-reperfusion (end of study); irreversible myocardial injury (infarct size by histomorphometry) at this time-point was evaluated, and was the primary-end-point of the study. The study design is summarized in Table 7.
-
TABLE 7 Experimental protocol Study Group (no. of animals) Ischemia Time Reperfusion Time CONTROL 30 min 180 min of placebo (n = 12) (Last 15 min with (saline) saline) EXENATIDE 0.15 μg/Kg 30 min 180 min of exenatide (n = 11) (Last 15 min with exenatide) P. CANRENOATE 1 mg/Kg 30 min 180 min of potassium (n = 12) (Last 15 min with canrenoate potassium canrenoate) EXENATIDE + P. CANRENOATE 30 min 180 min of exenatide (n = 17) (Last 15 min with and potassium exenatide and canrenoate potassium canrenoate) - General anesthesia was induced intramuscularly (IM) with a ketamine (˜35-50 mg/Kg) and xylazine (˜5-10 mg/Kg) mixture. In order to preserve autonomic function and to maintain anesthesia throughout the experimental procedure, animals received additional anesthesia as required (˜10-15 mg ketamine/30 min or ˜15-20 mg/Kg sodium pentobarbital). A venous catheter was placed in a peripheral vein (e.g., ear auricular vein) for the administration of additional anesthetics and normal saline/test articles. A cuffed tracheal tube was placed via a tracheotomy (ventral midline incision) and used to mechanically ventilate the lungs with a 95% O2/5% CO2 mixture via a volume-cycled animal ventilator (˜40 breaths/min with a tidal volume of ˜12.5 ml/Kg) in order to sustain PaCO2 values broadly within the physiological range.
- Subsequently, the animals were placed in left-lateral recumbence and the chest was surgically opened with a left thoracotomy. The chest was opened through the left fourth intercostals space. The beating heart was exposed and the pericardium was incised. Under the atrial appendage, the left anterior descending coronary artery (LAD) was circled with a 3-0 silk suture. Coronary artery occlusion in this region normally results in ischemia of a large territory of the anterolateral and apical ventricular wall. The ends of the suture were threaded through a small piece of polyethylene tubing, forming a snare. Ischemia was induced by pulling the thread through the tubing, which was firmly positioned against the coronary arterial wall with the aid of a small clamp. Ischemia resulted in a change in the color (i.e., cyanotic) of the myocardium. After 15 min of ischemia, the animals administered with IV bolus of either vehicle (normal saline) or indicated test article; ischemia was continued for additional 15 min (i.e., 30 min total ischemia time) after the treatment. At the end of ischemic period, the coronary snares were released and the previous ischemic myocardium was reperfused for up to 3 hours. In order to determine/quantify the degree of irreversible myocardial injury (i.e., infarction) resulting from the ischemia and reperfusion insult with and without indicated treatment, infarct area were evaluated.
- At the completion of the protocol, irreversible myocardial injury (i.e., infarction) resulting from the I/R insult was evaluated. In brief, after the end of reperfusion, hearts were excised, mounted on an apparatus, and perfused with normal saline for 2 min for blood removal. Then the coronary ligature was retightened at the same site and 5 mL of green fluorescent polymer microsphere solution (8 mg/ml; diameter 3-8 μm; Fluoro-Max™, Thermo Scientific, CA, USA) was infused for the separation of the normally perfused area (no ischemic area) and to delineate the myocardial area-at-risk (AAR, ischemic area) during ischemia. Hearts were kept at −20° C. for 24 hours and sectioned perpendicular to its long axis (from apex to base) into 3 mm thick slices. Subsequently, the slices were incubated for 20 min in 2% (TTC, Sigma) at 37° C., and fixed in a 10% non-buffered formalin solution.
- Following fixation, the total left ventricular area (LV), the area-at-risk (AAR), and the infarct area (IF) were delineated/measured digitally. With a wavelength of 366 nm UV light, it was separated in each slide the ischemic area (AAR) from infarcted zone (IF) and no ischemic area. All areas were traced onto an acetate sheet. The tracings were subsequently imported into an image analysis program (Image J; National Institutes of Health), and computer-assisted planimetry was performed to determine the overall size of the left ventricular (LV), the area-at-risk (AAR) and the infarct (IF). For each slide, the AAR was expressed as a percentage of the LV area (AAR/LV), and the IF was expressed as a percentage of the AAR (IF/AAR). In all cases, quantitative histomorphometry was performed by personnel blinded to the treatment assignment/study-design.
- Statistical analysis was performed with SPSS version 21.0 (SPSS Inc., IL, USA). Values are presented as mean±error (SEM). Statistical comparisons of numeric variables among the three groups were analyzed using the one-way ANOVA model with Bonferroni correction analysis. A calculated P-value of less than 0.05 was considered to be statistically significant.
- The area of the left ventricle (LV) and the ischemic area (AAR) were similar in all animals and did not differ statistically between the study groups. The induction of ischemia (30 min) and reperfusion (180 min) in the control group resulted in significant injury to the myocardium of experimental animals (49.47±3.97%), indicating the sufficient implementation of the model and the reproducibility of the experimental procedure of the study. The exenatide monotherapy (0.150 μg/Kg) caused a reduction of the extent of infarct by 36.2% (31.55±3.31%; P<0.05) compared with the control group. Administration of potassium canrenoate monotherapy (1 mg/Kg) reduced the area of the infarct by 30.5% (34.36±2.83%; P<0.05) compared with the control group. Treatment of combination of exenatide and potassium canrenoate caused a dramatic reduction in the extent of infarct by 73.1% (13.31±2.14%; P<0.001) compared to the control group. Interestingly, the effect of the combination was also statistically significant (P<0.01) compared to the respective exenatide and potassium canrenoate monotherapies.
- Table 8 presents data showing the ratios of area of risk to left ventricular and infarcted area to area of risk for each of group used in this study.
-
TABLE 8 Study histopathology results AAR/LV IF/AAR Different (%) in Significance in Significance in (% (% IF/AAR from IF/AAR versus IF/AAR versus Group mean ± SEM) mean ± SEM) Control Control monotherapies CONTROL 55.46 ± 2.84 49.47 ± 3.97 — — (n = 12) EXENATIDE 55.01 ± 2.42 31.55 ± 3.31 −36.2 P < 0.05 — 0.15 μg/Kg (n = 11) P. CANRENOATE 57.67 ± 1.73 34.36 ± 2.83 −30.5 P < 0.05 — 1 mg/Kg (n = 12) EXENATIDE + 56.74 ± 3.46 13.31 ± 2.14 −73.1 P < 0.001 P < 0.01 P. CANRENOATE (n = 17) - These results show that in a standardized rabbit model of acute myocardial ischemia and reperfusion injury, the combined therapy of exenatide and potassium canrenoate when administrated as an IV bolus (0.15 μg/Kg and 1 mg/Kg, respectively) at 15 min before the initiation of reperfusion was able to produce a significantly greater reduction in the myocardial infarct size compared to exenatide or potassium canrenoate monotherapy groups. Furthermore, it is of great interest that the present results provide for first time strong evidence that the combination therapy of potassium canrenoate with exenatide reduced the extent of myocardial injury also in a synergistic manner, since the obtained combination reduction exceeds the sum of the respective monotherapies' reductions. Accordingly, these results demonstrate for first time that in therapy of myocardial reperfusion injury the combined administration of potassium canrenoate and exenatide is more beneficial and advantageous and provides superior clinical outcome against therapies either with potassium canrenoate or exenatide alone. As such, combined exenatide and potassium canrenoate is exceptionally useful in methods at preventing and treating ischemia-reperfusion injury in mammalian subjects.
- This study was designed to test the combined cardioprotective effects of exenatide, cyclosporine (CsA) and potassium canrenoate in a setting that mimics the clinical scenario of an acute I/R insult. The study was conducted under the hypothesis that triple combined treatment with exenatide, CsA and potassium canrenoate after the onset of ischemia (but prior to reperfusion) would provide a more pronounced myocardial protective effect compared to double treatment with exenatide and cyclosporine.
- New Zealand White rabbits were used in this study. The rabbits were males, >8 week in age and with a weight between 2.6 and 3.8 Kg. All animals were treated according to the Directive 2010/63/UE European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes, and conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1985). Approvals from the Ethical Committees and the veterinary authorities were obtained before the study was started. Environmental controls in the animal rooms were set to maintain temperature of 22° to 28° C. and relative humidity between 30% and 70%. Room temperature and humidity were recorded hourly and monitored daily. There were approximately 10-15 air exchanges per hour in the animal rooms. Photoperiod was 12-hours light and 12-hours dark. Routine daily observations were performed. Certified standard rabbit diet was provided, approximately 180 grams per day from arrival to the facility.
- Exenatide (Byetta®; Eli Lilly Nederland B.V.], CsA (Sandimmun®, Novartis Pharma A.G., Switzerland) and potassium canrenoate (Sigma-Aldrich, Germany) are used as the test articles, either in double or in triple combined therapy. Dosing solutions of exenatide, CsA and potassium canrenoate were prepared just before the administration to the rabbits. Normal saline (0.9% NaCl) was used as a control.
- The test/control articles were given intravenously, under general anaesthesia, in order to mimic the expected route of administration in the clinical setting of acute myocardial infarction and primary percutaneous coronary intervention. Intravenous boluses were administered via a peripheral vein (rabbit auricular vein).
- The study followed a predetermined placebo controlled design. In brief, 55 healthy, acclimatized, male rabbits were randomly assigned to one of four study arms. In all groups, rabbits were subjected to 30 min regional ischemia of the heart (coronary occlusion), followed by 180 min (3 h) reperfusion. In all cases, treatments (intravenous bolus administration of saline or test articles combination) were performed 15 min after the onset of ischemia (15 min before the initiation of reperfusion). The experiments were terminated 3 h post-reperfusion (end of study); irreversible myocardial injury (infarct size by histomorphometry) at this time-point was evaluated, and was the primary-end-point of the study. The study design is summarized in Table 9.
-
TABLE 9 Experimental protocol Study Group (no. of animals) Ischemia Time Reperfusion Time CONTROL 30 min 180 min of placebo (n = 12) (Last 15 min with (saline) saline) EXENATIDE 0.15 μg/Kg + 30 min 180 min of exenatide CYCLOSPORINE 0.5 μg/Kg (Last 15 min with and cyclosporine (n = 8) exenatide and cyclosporine) EXENATIDE 0.15 μg/Kg + 30 min 180 min of CYCLOSPORINE 0.5 μg/Kg + (Last 15 min with exenatide and P. CANRENOATE 1 μg/Kg exenatide and cyclosporine and (n = 10) cyclosporine and potassium potassium canrenoate canrenoate) EXENATIDE 0.15 μg/Kg + 30 min 180 min of CYCLOSPORINE 1 μg/Kg + (Last 15 min with exenatide and P. CANRENOATE 1 μg/Kg exenatide and cyclosporine and (n = 9) cyclosporine and potassium potassium canrenoate canrenoate) EXENATIDE 0.15 μg/Kg + 30 min 180 min of CYCLOSPORINE 2.5 mg/Kg + (Last 15 min with exenatide and P. CANRENOATE 1 μg/Kg exenatide and cyclosporine and (n = 16) cyclosporine and potassium potassium canrenoate canrenoate) - General anesthesia was induced intramuscularly (IM) with a ketamine (˜35-50 mg/Kg) and xylazine (˜5-10 mg/Kg) mixture. In order to preserve autonomic function and to maintain anesthesia throughout the experimental procedure, animals received additional anesthesia as required (˜10-15 mg ketamine/30 min or ˜15-20 mg/Kg sodium pentobarbital). A venous catheter was placed in a peripheral vein (e.g., ear auricular vein) for the administration of additional anesthetics and normal saline/test articles. A cuffed tracheal tube was placed via a tracheotomy (ventral midline incision) and used to mechanically ventilate the lungs with a 95% O2/5% CO2 mixture via a volume-cycled animal ventilator (˜40 breaths/min with a tidal volume of ˜12.5 ml/Kg) in order to sustain PaCO2 values broadly within the physiological range.
- Subsequently, the animals were placed in left-lateral recumbence and the chest was surgically opened with a left thoracotomy. The chest was opened through the left fourth intercostals space. The beating heart was exposed and the pericardium was incised. Under the atrial appendage, the left anterior descending coronary artery (LAD) was circled with a 3-0 silk suture. Coronary artery occlusion in this region normally results in ischemia of a large territory of the anterolateral and apical ventricular wall. The ends of the suture were threaded through a small piece of polyethylene tubing, forming a snare. Ischemia was induced by pulling the thread through the tubing, which was firmly positioned against the coronary arterial wall with the aid of a small clamp. Ischemia resulted in a change in the color (i.e., cyanotic) of the myocardium. After 15 min of ischemia, the animals administered with IV bolus of either vehicle (normal saline) or indicated test article; ischemia was continued for additional 15 min (i.e., 30 min total ischemia time) after the treatment. At the end of ischemic period, the coronary snares were released and the previous ischemic myocardium was reperfused for up to 3 hours. In order to determine/quantify the degree of irreversible myocardial injury (i.e., infarction) resulting from the ischemia and reperfusion insult with and without indicated treatment, infarct area was evaluated.
- Histopathology/Histomorphometry.
- At the completion of the protocol, irreversible myocardial injury (i.e., infarction) resulting from the I/R insult was evaluated. In brief, after the end of reperfusion, hearts were excised, mounted on an apparatus, and perfused with normal saline for 2 min for blood removal. Then the coronary ligature was retightened at the same site and 5 mL of green fluorescent polymer microsphere solution (8 mg/ml; diameter 3-8 μm; Fluoro-Max™, Thermo Scientific, CA, USA) was infused for the separation of the normally perfused area (no ischemic area) and to delineate the myocardial area-at-risk (AAR, ischemic area) during ischemia. Hearts were kept at −20° C. for 24 hours and sectioned perpendicular to its long axis (from apex to base) into 3 mm thick slices. Subsequently, the slices were incubated for 20 min in 2% (TTC, Sigma) at 37° C., and fixed in a 10% non-buffered formalin solution.
- Following fixation, the total left ventricular area (LV), the area-at-risk (AAR), and the infarct area (IF) were delineated/measured digitally. With a wavelength of 366 nm UV light, it was separated in each slide the ischemic area (AAR) from infarcted zone (IF) and no ischemic area. All areas were traced onto an acetate sheet. The tracings were subsequently imported into an image analysis program (Image J; National Institutes of Health), and computer-assisted planimetry was performed to determine the overall size of the left ventricular (LV), the area-at-risk (AAR) and the infarct (IF). For each slide, the AAR was expressed as a percentage of the LV area (AAR/LV), and the IF was expressed as a percentage of the AAR (IF/AAR). In all cases, quantitative histomorphometry was performed by personnel blinded to the treatment assignment/study-design.
- Statistical analysis was performed with SPSS version 21.0 (SPSS Inc., IL, USA). Values are presented as mean±error (SEM). Statistical comparisons of numeric variables among the three groups were analyzed using the one-way ANOVA model followed by Fisher LSD post hoc test. A calculated P-value of less than 0.05 was considered to be statistically significant.
- The area of the left ventricle (LV) and the ischemic area (AAR) were similar in all animals and did not differ statistically between the study groups. Treatment of double combination of exenatide and CsA (0.150 mg/Kg and 0.5 mg/Kg, respectively) caused a reduction of the area of infarction by 50% (24.74±3.8%; P<0.05) compared with the control group (49.47±4). The addition to this treatment of potassium canrenoate (1 mg/Kg) resulted in a further reduction of the area of the infarct by 70.6% (14.56±3%; P<0.001) compared to the control group. Similarly, the administration of a triple combinations of exenatide, potassium canrenoate and CsA 1 mg/Kg reduced the area of the infarct by 74.8% (12.49±2.2%; P<0.001), compared to the control group. Interestingly, the effect of these triple combinations was statistically significant (P<0.05) compared with double combination of exenatide and CsA. However, the administration of a triple combination of exenatide, potassium canrenoate and CsA 2.5 mg/Kg caused a reduction of the extent of infarct by 46.5% (26.48±2.93%; P<0.05), which was not statistically significant compared to double combination of exenatide and CsA.
- Table 10 presents data showing the ratios of area of risk to left ventricular and infarcted area to area of risk for each of group used in this study.
-
TABLE 10 Study histopathology results Different Significance Significance in AAR/LV IF/AAR (%) in in IF/AAR IF/AAR versus (% (% IF/AAR from versus double Group mean ± SEM) mean ± SEM) Control Control combination CONTROL 55.46 ± 2.8 49.47 ± 4 — — — (n= 12) EXENATIDE 0.15 μg/Kg + 61.11 ± 5.6 24.74 ± 3.8 −50 P < 0.05 — CYCLOSPORINE 0.5 μg/Kg (n = 8) EXENATIDE 0.15 μg/Kg + 60.52 ± 4.4 14.56 ± 3 −70.6 P < 0.001 P < 0.05 CYCLOSPORINE 0.5 μg/Kg + P. CANRENOATE 1 μg/Kg (n= 10) EXENATIDE 0.15 μg/Kg + 54.5 ± 3.7 12.49 ± 2.2 −74.8 P < 0.001 P < 0.05 CYCLOSPORINE 1 μg/Kg + P. CANRENOATE 1 μg/Kg (n = 9) EXENATIDE 0.15 +82 g/Kg + 53.8 ± 2.6 26.48 ± 2.9 −46.5 P < 0.05 Non CYCLOSPORINE significant 2.5 μg/Kg + P. CANRENOATE 1μg/Kg (n = 16) - These results show that in a standardized rabbit model of acute myocardial ischemia and reperfusion injury, the combined administration of exenatide and CsA provides beneficial effect, while the addition of potassium canrenoate to the treatment demonstrated a significant further potentiation of the cardioprotection of the combination. It is of great interest that the present Example provides for first time strong evidence that triple combination therapy of exenatide, CsA and potassium canrenoate produced a greater reduction in the extent of myocardial injury compared to exenatide and CsA combined treatment. Accordingly, these results demonstrate for first time that in therapy of myocardial reperfusion injury the triple combined administration of exenatide, CsA and potassium canrenoate is more beneficial and advantageous and provides superior clinical outcome against either monotherapies or CsA and exenatide administered as combined therapies. As such, combined exenatide, CsA (at least in low doses) and potassium canrenoate is exceptionally useful in methods at preventing and treating ischemia-reperfusion injury in mammalian subjects.
- This study was designed to test the following:
-
- i) The dose-dependent effects of exenatide, CsA and potassium canrenoate as monotherapy in an additional animal (murine) model of myocardial reperfusion injury.
- ii) The effects of exenatide, CsA and potassium canrenoate double combination therapies at doses that are lower than the optimal monotherapy doses.
- iii) The effect of exenatide, CsA and potassium canrenoate triple combination therapy at the same dose of each component used in the double combination.
- The study was conducted to further demonstrate in a mouse model that double combination therapies with exenatide, CsA and potassium canrenoate, after the onset of ischemia and prior to reperfusion, result in enhanced reduction of infarct size compared to respective monotherapies, and that triple combination therapy with exenatide, CsA and potassium canrenoate is more beneficial and advantageous compared to double combination therapies.
- C57BL/6 mice were used in this study. Mice were males, 13-15 weeks in age. All animals were treated according to the Directive 2010/63/UE European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes, and conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1985). Approvals from the Ethical Committees and the veterinary authorities were obtained before the study was started. Environmental controls in the animal rooms were set to maintain temperature of 22° to 28° C. and relative humidity between 30% and 70%. Room temperature and humidity were recorded hourly and monitored daily. There were approximately 10-15 air exchanges per hour in the animal rooms. Photoperiod was 12-hours light and 12-hours dark. Routine daily observations were performed. Standard laboratory mouse chow and filtered tap water was available ad libitum.
- Exenatide (Byetta®; Eli Lilly Nederland B.V.], CsA (Sandimmun®, Novartis Pharma A.G., Switzerland) and potassium canrenoate (Sigma-Aldrich, Germany) are used as the test articles, either as monotherapies or in double or in triple combined therapy. Dosing solutions of exenatide, CsA and potassium canrenoate were prepared just before the administration to the mice. Normal saline (0.9% NaCl) was used as a control.
- The test/control articles were given intravenously, under general anaesthesia, in order to mimic the expected route of administration in the clinical setting of acute myocardial infarction and primary percutaneous coronary intervention.
- The study followed a predetermined placebo controlled design. In brief, 149 healthy, acclimatized, male mice were randomly assigned to one of twenty (20) study arms. In all groups, mice were subjected to 30 min regional ischemia of the heart (coronary occlusion), followed by 120 min (2 h) reperfusion. In all cases, treatments (intravenous bolus administration of saline or test articles or their combinations) were performed 20 min after the onset of ischemia (10 min before the initiation of reperfusion). The experiments were terminated 2 h post-reperfusion (end of study); irreversible myocardial injury (infarct size by histomorphometry) at this time-point was evaluated, and was the primary-end-point of the study. The study design is summarized in Table 11.
-
TABLE 11 Experimental protocol Study Group (no. of animals) Ischemia Time Reperfusion Time CONTROL 30 min 120 min of placebo (n = 12) (Last 10 min with (saline) saline) EXENATIDE 0.001 μg/Kg 30 min 120 min of exenatide (n = 5) (Last 10 min with exenatide) EXENATIDE 0.005 μg/Kg 30 min 120 min of exenatide (n = 8) (Last 10 min with exenatide) EXENATIDE 0.05 μg/Kg 30 min 120 min of exenatide (n = 8) (Last 10 min with exenatide) EXENATIDE 0.15 μg/Kg 30 min 120 min of exenatide (n = 7) (Last 10 min with exenatide) EXENATIDE 1.5 μg/Kg 30 min 120 min of exenatide (n = 8) (Last 10 min with exenatide) CYCLOSPORINE 0.001 μg/Kg 30 min 120 min of cyclosporine (n = 5) (Last 10 min with cyclosporine) CYCLOSPORINE 0.01 μg/Kg 30 min 120 min of cyclosporine (n = 8) (Last 10 min with cyclosporine) CYCLOSPORINE 0.15 μg/Kg 30 min 120 min of cyclosporine (n = 8) (Last 10 min with cyclosporine) CYCLOSPORINE 0.5 μg/Kg 30 min 120 min of cyclosporine (n = 7) (Last 10 min with cyclosporine) CYCLOSPORINE 2.5 μg/Kg 30 min 120 min of cyclosporine (n = 8) (Last 10 min with cyclosporine) P. CANRENOATE 0.03 μg/Kg 30 min 120 min of potassium (n = 8) (Last 10 min with canrenoate potassium canrenoate) P. CANRENOATE 0.3 μg/Kg 30 min 120 min of potassium (n = 7) (Last 10 min with canrenoate potassium canrenoate) P. CANRENOATE 1 μg/Kg 30 min 120 min of potassium (n = 8) (Last 10 min with canrenoate potassium canrenoate) P. CANRENOATE 10 μg/Kg 30 min 120 min of potassium (n = 8) (Last 10 min with canrenoate potassium canrenoate) EXENATIDE 0.05 μg/Kg + 30 min 120 min of exenatide CYCLOSPORINE 0.15 μg/Kg (Last 10 min with and cyclosporine (n = 5) exenatide and cyclosporine) EXENATIDE 0.05 μg/Kg + 30 min 120 min of exenatide P. CANRENOATE 1 μg/Kg (Last 10 min with and potassium (n = 11) exenatide and canrenoate potassium canrenoate) EXENATIDE 0.05 μg/Kg + 30 min 120 min of exenatide P. CANRENOATE 10 μg/Kg (Last 10 min with and potassium (n = 6) exenatide and canrenoate potassium canrenoate) CYCLOSPORINE 0.15 μg/Kg + 30 min 120 min of cyclosporine P. CANRENOATE 1 μg/Kg (Last 10 min with and potassium (n = 6) cyclosporine and canrenoate potassium canrenoate) EXENATIDE 0.05 μg/Kg + 30 min 120 min of exenatide CYCLOSPORINE 0.15 μg/Kg + (Last 10 min with and cyclosporine P. CANRENOATE 1 μg/Kg exenatide and and potassium (n = 6) cyclosporine and canrenoate potassium canrenoate) - Mice were anaesthetized by intraperitoneal injection (0.01 ml/Kg) with a combination of ketamine, xylazine and atropine (final doses of ketamine, xylazine and atropine were 100, 20 and 0.6 mg/Kg, respectively). Anaesthetic depth was evaluated by loss of pedal reflex to toe-pinch stimulus and breathing rate. A tracheotomy was performed for artificial respiration at 120-150 breaths/min and positive end-expiratory pressure 2.0 (0.2 ml of total tidal volume; Flexivent rodent ventilator, Scireq, Montreal, ON, Canada). A thoracotomy was then performed between the fourth and fifth ribs and the pericardium carefully retracted to visualize the left anterior descending (LAD), which was ligated using an 8-0 prolene monofilament polypropylene suture placed 1 mm below the tip of the left auricle. The heart was allowed to stabilize for 12 min prior to ligation to induce ischemia. After the ischemic period, the ligature was released allowing reperfusion of myocardium. Throughout experiments, body temperature was maintained at 37±0.5° C. by way of a heating pad and monitored via a thermocouple inserted rectally.
- After reperfusion, animals were sacrificed with an intraperitoneal injection of the ketamine (200 mg/Kg) and xylazine (50 mg/Kg) anesthetic mixture (0.02 ml/Kg) hearts were rapidly excided from mice and directly cannulated and washed with 2.5 ml of saline heparin 1% for blood removal. Five ml of 1% TTC phosphate buffer 37° C. were infused into the coronary circulation; the tissue was incubated for 5 min in the same buffer. Evans Blue 1% diluted in distilled water (2.5 ml) was the infused into the heart. Hearts were kept at −20° C. for 24 hours and then sliced in 1 mm sections parallel to the atrioventricular groove, and then fixed in 4% formalin overnight. Slices were then compressed between glass plates 1 mm apart and photographed with a Cannon Powershot A620 Digital Camera through a Zeiss 459300 microscope and measured with the Scion Image program. The areas of myocardial tissue at risk and infarcted were automatically transformed into volumes. Infarct and risk area volumes were expressed in cm3. For each slide, the AAR was expressed as a percentage of the LV area (AAR/LV), and the IF was expressed as a percentage of the AAR (IF/AAR). In all cases, quantitative histomorphometry was performed by personnel blinded to the treatment assignment/study-design.
- All results are presented as mean+SEM. Comparisons of numeric variables among the groups were analyzed using an one-way analysis of variance (ANOVA) model with Bonferroni correction and with Tukey post hoc analysis. Analyses were performed using a Stata 13.1 statistical software package (StataCorp, TX, USA). A calculated P-value of less than 0.05 was considered to be statistically significant.
- The area of the left ventricle (LV) and the ischemic area (AAR) were similar in all animals and did not differ statistically between the study groups. The induction of ischemia (30 min) and reperfusion (120 min) in the control group resulted in significant injury to the myocardium of experimental animals (47.4±1.9%), indicating the sufficient implementation of the model and the reproducibility of the experimental procedure of the study.
- The exenatide monotherapy (0.001 μg/kg-1.5 μg/Kg) caused a dose-response effect with the doses of 0.005 μg/kg and 0.05 μg/kg to cause a reduction of infarct size by 36.9% (29.9±1.8%; P<0.05) and 31.6% (32.4±1.9%; P<0.05), respectively, compared with the control group. The cyclosporine monotherapy (0.001 mg/kg-2.5 mg/Kg) caused a dose-response effect with the doses of 0.01 mg/kg and 0.15 mg/kg to cause a reduction of infarct size by 43.7% (26.7±2.8%; P<0.05) and 49.4% (24±1.9%; P<0.05), respectively, compared with the control group. The potassium canrenoate monotherapy (0.03 mg/kg-10 mg/Kg) caused a dose-response effect with the doses of 1 mg/kg and 10 mg/kg to cause a reduction of infarct size by 30% (33.2±2.4%; P<0.05) and 58.9% (19.5±2.5%; P<0.05), respectively, compared with the control group.
- Double combination of exenatide and cyclosporine caused a reduction in the extent of infarct by 52.5% (22.5±2.3%; P<0.05) compared to the control group. However, this effect was not statistically significant compared to the respective monotherapy doses of exenatide and cyclosporine. The double combination of exenatide and potassium canrenoate caused a reduction in the extent of infarct by 70.9% (13.8±1.3%; P<0.01) compared to the control group. Interestingly, the effect of the combination was also statistically significant (P<0.05) compared to the respective doses of exenatide and potassium canrenoate monotherapies. However, when exenatide was combined with higher dose (10 mg/Kg) of potassium canrenoate reduced infarct size by 52.3% (22.6±2%), which was not statistically significant with the respective monotherapies. Double combination of cyclosporine and potassium canrenoate caused a reduction in the extent of infarct by 61.4% (18.3±2.6%; P<0.05) compared to the control group. However, this effect was not statistically significant compared to the respective monotherapy doses of cyclosporine and potassium canrenoate. Finally, a triple combination of exenatide, cyclosporine and potassium canrenoate caused a reduction in the extent of infarct by 56.7% (20.5±2%; P<0.05) compared to the control group. However, this effect was not statistically significant compared to the respective monotherapy doses of exenatide, cyclosporine and potassium canrenoate.
- Table 12 presents data showing the ratios of area of risk to left ventricular and infarcted area to area of risk for each of group used in this study.
-
TABLE 12 Study histopathology results AAR/LV IF/AAR Different (%) in Significance in Significance in (% (% IF/AAR from IF/AAR versus IF/AAR versus Group mean ± SEM) mean ± SEM) Control Control monotherapies CONTROL 53.1 ± 1.8 47.4 ± 1.9 — — — (n = 12) EXENATIDE 0.001 μg/Kg 56.1 ± 2.5 44.8 ± 3.8 −5.5 ns — (n = 5) EXENATIDE 0.005 μg/Kg 51.4 ± 4.5 29.9 ± 1.8 −36.9 P < 0.05 — (n = 8) EXENATIDE 0.05 μg/Kg 53.1 ± 2.2 32.4 ± 1.9 −31.6 P < 0.05 — (n = 8) EXENATIDE 0.15 μg/Kg 54.5 ± 2 41 ± 3 −13.5 ns — (n = 7) EXENATIDE 1.5 μg/Kg 54.8 ± 2.6 45.4 ± 2.1 −4.2 ns — (n = 8) CYCLOSPORINE 58 ± 5.7 36.6 ± 2.4 −22.8 ns — 0.001 μg/Kg (n = 5) CYCLOSPORINE 48.6 ± 2.82 26.7 ± 2.8 −43.7 P < 0.05 — 0.01 μg/Kg (n = 8) CYCLOSPORINE 50.7 ± 2.9 24 ± 1.9 −49.4 P < 0.05 — 0.15 μg/Kg (n = 8) CYCLOSPORINE 56.4 ± 3.6 33.6 ± 2.5 −29.1 P < 0.05 — 0.5 μg/Kg (n = 7) CYCLOSPORINE 50.4 ± 1.9 30 ± 2.4 −36.7 P < 0.05 — 2.5 μg/Kg (n = 8) P. CANRENOATE 59.4 ± 5.8 46 ± 2.5 −3 ns — 0.03 μg/Kg (n = 8) P. CANRENOATE 55.5 ± 6.1 44 ± 3.2 −7.2 ns — 0.3 μg/Kg (n = 7) P. CANRENOATE 1 μg/Kg 52.4 ± 1.4 33.2 ± 2.4 −30 P < 0.05 — (n = 8) P. CANRENOATE 45.8 ± 1.2 19.5 ± 2.5 −58.9 P < 0.05 — 10 μg/Kg (n = 8) EXENATIDE 0.05 μg/Kg + 54.8 ± 5.6 22.5 ± 2.3 −52.5 P < 0.05 ns CYCLOSPORINE 0.15 μg/Kg (n = 5) EXENATIDE 0.05 μg/Kg + 55.5 ± 2.9 13.8 ± 1.3 −70.9 P < 0.01 P < 0.05 P. CANRENOATE 1 μg/Kg (n = 11) EXENATIDE 0.05 μg/Kg + 53.5 ± 3.1 22.6 ± 2 −52.3 P < 0.05 ns P. CANRENOATE 10 μg/Kg (n = 6) CYCLOSPORINE 56.1 ± 4.4 18.3 ± 2.6 −61.4 P < 0.05 ns 0.15 μg/Kg + P. CANRENOATE 1 μg/Kg (n = 6) EXENATIDE 0.05 μg/Kg + 55.7 ± 3.2 20.5 ± 2 −56.7 P < 0.05 ns CYCLOSPORINE 0.15 μg/Kg + P. CANRENOATE 1 μg/Kg (n = 6) - These results show that in an additional standardized animal (murine) model of acute myocardial ischemia and reperfusion injury, the combined therapy of exenatide, cyclosporine and potassium canrenoate when administrated as an IV bolus at 10 min before the initiation of reperfusion was able to produce a greater reduction in the myocardial infarct size compared to exenatide or CsA or potassium canrenoate monotherapy groups. It is of great interest that the present results provide strong evidence that the combination therapy of potassium canrenoate with exenatide reduced the extent of myocardial injury also in a synergistic manner, since the obtained combination reduction exceeds the sum of the respective monotherapies' reductions. Accordingly, these results demonstrate that in the therapy of myocardial reperfusion injury the combined administration of exenatide and potassium canrenoate provides the greatest cardioprotection effect compared to the respective monotherapies or other double or triple combinations. As such, combined exenatide, and potassium canrenoate is exceptionally useful in methods at preventing and treating ischemia-reperfusion injury in mammalian subjects.
- Various modifications and variations of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in the relevant fields are intended to be covered by the present invention.
- This invention includes all modifications and equivalents of the subject matter recited in the paragraphs appended hereto as permitted by applicable law.
- All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference in their entirety and to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein (to the maximum extent permitted by law).
- The citation and incorporation of patent documents herein is done for convenience only and does not reflect any view of the validity, patentability, and/or enforceability of such patent documents.
- All headings and sub-headings are used herein for convenience only and should not be construed as limiting the invention in any way.
Claims (27)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/201,703 US20190290721A1 (en) | 2015-11-06 | 2018-11-27 | Combination |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GR20150100486 | 2015-11-06 | ||
GR20150100486 | 2015-11-06 | ||
PCT/IB2016/001582 WO2017077378A1 (en) | 2015-11-06 | 2016-11-04 | Combination |
US15/672,841 US10172914B2 (en) | 2015-11-06 | 2017-08-09 | Combination |
US16/201,703 US20190290721A1 (en) | 2015-11-06 | 2018-11-27 | Combination |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/672,841 Continuation US10172914B2 (en) | 2015-11-06 | 2017-08-09 | Combination |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190290721A1 true US20190290721A1 (en) | 2019-09-26 |
Family
ID=57421900
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/672,841 Active US10172914B2 (en) | 2015-11-06 | 2017-08-09 | Combination |
US16/201,703 Pending US20190290721A1 (en) | 2015-11-06 | 2018-11-27 | Combination |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/672,841 Active US10172914B2 (en) | 2015-11-06 | 2017-08-09 | Combination |
Country Status (16)
Country | Link |
---|---|
US (2) | US10172914B2 (en) |
EP (1) | EP3370756B1 (en) |
JP (1) | JP6928611B2 (en) |
CN (1) | CN108472333B (en) |
CY (1) | CY1123041T1 (en) |
DK (1) | DK3370756T3 (en) |
ES (1) | ES2791301T3 (en) |
HR (1) | HRP20200845T1 (en) |
HU (1) | HUE049732T2 (en) |
LT (1) | LT3370756T (en) |
ME (1) | ME03734B (en) |
PL (1) | PL3370756T3 (en) |
PT (1) | PT3370756T (en) |
RS (1) | RS60354B1 (en) |
SI (1) | SI3370756T1 (en) |
WO (1) | WO2017077378A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114423461A (en) * | 2019-07-09 | 2022-04-29 | 杰尼西斯制药有限公司 | Combination of |
WO2023026247A1 (en) | 2021-08-27 | 2023-03-02 | Genesis Pharma Sa | Combination of a nurr1 agonist with at least one of an aldosterone antagonist, an insulin modulator and a sulfonylurea |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050014732A1 (en) * | 2003-03-14 | 2005-01-20 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and an anti-diabetic agent |
US20040214804A1 (en) * | 2003-04-25 | 2004-10-28 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and an anti-obesity agent |
CA2625646A1 (en) * | 2005-10-25 | 2007-05-03 | Merck & Co., Inc. | Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension |
JP2012517977A (en) * | 2009-02-13 | 2012-08-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | An anti-diabetic drug comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other anti-diabetic drugs |
CN101810859A (en) * | 2010-02-09 | 2010-08-25 | 王丽燕 | Medical composition containing aniline derivative |
EP2768856A4 (en) | 2011-10-18 | 2015-05-27 | Prolynx Llc | Peg conjugates of exenatide |
CN103087139B (en) * | 2011-11-08 | 2016-08-03 | 中国科学院上海药物研究所 | A kind of canrenone derivatives class steroidal compounds, its preparation method and the purposes in preparing eplerenone thereof |
-
2016
- 2016-11-04 EP EP16802132.7A patent/EP3370756B1/en active Active
- 2016-11-04 SI SI201630797T patent/SI3370756T1/en unknown
- 2016-11-04 HU HUE16802132A patent/HUE049732T2/en unknown
- 2016-11-04 DK DK16802132.7T patent/DK3370756T3/en active
- 2016-11-04 PT PT168021327T patent/PT3370756T/en unknown
- 2016-11-04 JP JP2018541582A patent/JP6928611B2/en active Active
- 2016-11-04 ES ES16802132T patent/ES2791301T3/en active Active
- 2016-11-04 ME MEP-2020-107A patent/ME03734B/en unknown
- 2016-11-04 CN CN201680078080.XA patent/CN108472333B/en active Active
- 2016-11-04 PL PL16802132T patent/PL3370756T3/en unknown
- 2016-11-04 LT LTEP16802132.7T patent/LT3370756T/en unknown
- 2016-11-04 RS RS20200614A patent/RS60354B1/en unknown
- 2016-11-04 WO PCT/IB2016/001582 patent/WO2017077378A1/en active Application Filing
-
2017
- 2017-08-09 US US15/672,841 patent/US10172914B2/en active Active
-
2018
- 2018-11-27 US US16/201,703 patent/US20190290721A1/en active Pending
-
2020
- 2020-05-26 HR HRP20200845TT patent/HRP20200845T1/en unknown
- 2020-06-05 CY CY20201100511T patent/CY1123041T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2018537522A (en) | 2018-12-20 |
SI3370756T1 (en) | 2020-08-31 |
PL3370756T3 (en) | 2020-10-19 |
CN108472333B (en) | 2023-05-12 |
CY1123041T1 (en) | 2021-10-29 |
JP6928611B2 (en) | 2021-09-01 |
CN108472333A (en) | 2018-08-31 |
US20170333519A1 (en) | 2017-11-23 |
ES2791301T3 (en) | 2020-11-03 |
RS60354B1 (en) | 2020-07-31 |
PT3370756T (en) | 2020-05-18 |
WO2017077378A1 (en) | 2017-05-11 |
EP3370756B1 (en) | 2020-04-08 |
EP3370756A1 (en) | 2018-09-12 |
US10172914B2 (en) | 2019-01-08 |
ME03734B (en) | 2021-01-20 |
HRP20200845T1 (en) | 2020-08-07 |
LT3370756T (en) | 2020-07-10 |
HUE049732T2 (en) | 2020-10-28 |
DK3370756T3 (en) | 2020-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2017501154A (en) | Angiotensin II used alone or in combination for the treatment of hypotension | |
US20100113347A1 (en) | Exenatide and dalargin-based medicinal preparation for treating pancreatic diabetes | |
US10172914B2 (en) | Combination | |
US20220265776A1 (en) | Combination | |
US20120046333A1 (en) | Methods and Compositions of PI-3 Kinase Inhibitors for Treating Fibrosis | |
JP6782932B2 (en) | New Uses of NPR-A Agonists | |
US20110009431A1 (en) | Compositions and methods for treating fibroproliferative disorders | |
KR102606504B1 (en) | Composition for preventing and treating pulmonary hypertension comprising niclosamide | |
KR20230028233A (en) | Renin-angiotensin system (RAS) modulator for treatment of viral infection, pharmaceutical composition containing the same, and treatment method using the same | |
EP4392033A1 (en) | Combination of a nurr1 agonist with at least one of an aldosterone antagonist, an insulin modulator and a sulfonylurea | |
WO2018100403A1 (en) | Combination of parstatin 1-26 and exenatide | |
CN118284417A (en) | Combination of a Nurr1 agonist with at least one of an aldosterone antagonist, an insulin modulator and a sulfonylurea | |
WO2024109652A1 (en) | Use of (-)-epigallocatechin gallate compound | |
US11154561B2 (en) | Preventative or therapeutic agent for pulmonary hypertension including crude drug component | |
US20030220363A1 (en) | Use of propionyl L-carnitine for the preparation of a medicament capable of inducing apoptosis | |
Yifan et al. | Different preventive effects of four cardioprotective agents on mice with adriamycin-induced cardiotoxicity | |
US20060009475A1 (en) | Quinazolinone compounds in combined modalities for improved cancer treatment | |
TW202421112A (en) | Application of (-)-epigallocatechin gallate compound | |
Van De Sandt et al. | Pharmacological CCR1 blockade limits infarct size, preserves cardiac function and attenuates left ventricular remodeling in a murine model of myocardial ischemia/reperfusion | |
JP2007106710A (en) | Preventing and/or treating agent of diabetic nephropathy | |
EP1128823A1 (en) | Use of propionyl l-carnitine for the preparation of a medicament capable of inducing apoptosis | |
US20120095013A1 (en) | Use of kmup-3 for myocardial infarction | |
NZ529345A (en) | The use of a melagatran and inogatran and their derivatives for the manufacture of a medicament for the treatment of idiopathic pulmonary fibrosis (IPF) and pulmonary fibrosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GENESIS PHARMA SA, GREECE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:VOGIATZIS, GEORGE;REEL/FRAME:048168/0934 Effective date: 20170911 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |